

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 7
JULY 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 7

July 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 07
July 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

BD RX INC
(BD RX)

CITRON PHARMA LLC
(CITRON PHARMA LLC)

PROSAM LABS LLC
(PROSAM LABS)

HIKMA MAPLE LTD
(HIKMA MAPLE)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

FRESENIUS KABI USA LLC
(FRESENIUS KABI USA)

CASPER PHARMA LLC
(CASPER PHARMA LLC)

OXFORD PHARMACEUTICALS LLC
(OXFORD PHARMS)

EUROHEALTH INTERNATIONAL SARL
(EUROHLTH INTL SARL)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS	17151	17251	17528		
LISTED SINGLE	2664	2693	2664		
SOURCE	(15.5%)	(15.6%)	(15.2%)		
MULTISOURCE	14487	14558	14864		
	(84.5%)	(84.4%)	(84.8%)		
THERAPEUTICALLY	14366	14434	14731		
EQUIVALENT	(83.8%)	(83.7%)	(84%)		
NOT THERAPEUTICALLY	121	124	133		
EQUIVALENT	(0.7%)	(0.7%)	(0.8%)		
EXCEPTIONS ¹	73	73	73		
	(0.4%)	(0.4%)	(0.4%)		
NEW MOLECULAR	28	9	20		
ENTITIES APPROVED					
NUMBER OF	1011	1007	1023		
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action.

The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

AB	+	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	May CRLD
----	---	-------------------	-------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION; IV (INFUSION)
ACETAMINOPHEN

AP		PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	May NEWA
AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar NEWA
		OFIRMEV					
AP	+	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Mar CFTG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
@ INGENUS PHARMS NJ 325MG; 50MG; 40MG
@ SUN PHARM INDS 325MG; 50MG; 40MG
FIORICET

AA		ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984	May CMFD
----	--	---------------------	-------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
FIORICET W/ CODEINE

>A>	AB	+	ACTAVIS LABS UT INC	325MG; 50MG; 40MG; 30MG	N020232	001	Jul 30, 1992	Jul CAHN
>D>	AB	+	ALLERGAN SALES LLC	325MG; 50MG; 40MG; 30MG	N020232	001	Jul 30, 1992	Jul CAHN
	AB	+		325MG; 50MG; 40MG; 30MG	N020232	001	Jul 30, 1992	Apr CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
>A> @ FRONTIDA BIOPHARM 300MG; 60MG
>D> @ SUN PHARM INDS 300MG; 60MG
@ 300MG; 60MG

A089673	001	Feb 10, 1988	Jul CAHN
A089673	001	Feb 10, 1988	Jul CAHN
A089673	001	Feb 10, 1988	Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
ZYFREL

AA		CYPRESS PHARM INC	325MG/15ML; 7.5MG/15ML	A090468	001	Apr 14, 2016	Apr NEWA
----	--	-------------------	------------------------	---------	-----	--------------	----------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ACTAVIS LABS FL INC	300MG; 5MG	A206470	001	Jun 02, 2016	May NEWA
AA			300MG; 7.5MG	A206470	002	Jun 02, 2016	May NEWA
AA			300MG; 10MG	A206470	003	Jun 02, 2016	May NEWA
		@ ALLERGAN SALES LLC	500MG; 10MG	A040148	002	Feb 14, 1997	Jun CAHN
AA		AMNEAL PHARMS NY	325MG; 7.5MG	A040746	002	May 10, 2016	Apr NEWA
AA		LARKEN LABS INC	325MG; 5MG	A202935	002	Jun 15, 2016	Jun NEWA
AA			325MG; 7.5MG	A202935	003	Jun 15, 2016	Jun NEWA
AA			325MG; 10MG	A202935	004	Jun 15, 2016	Jun NEWA
AA		PAR PHARM	300MG; 5MG	A205001	001	Jul 05, 2016	Jun NEWA
AA			300MG; 7.5MG	A205001	002	Jul 05, 2016	Jun NEWA
AA			300MG; 10MG	A205001	003	Jul 05, 2016	Jun NEWA
AA		RHODES PHARMS	325MG; 5MG	A202991	001	Apr 12, 2016	Mar NEWA
AA			325MG; 7.5MG	A202991	002	Apr 12, 2016	Mar NEWA
AA			325MG; 10MG	A202991	003	Apr 12, 2016	Mar NEWA
AA		TRIS PHARMA INC	300MG; 5MG	A202214	004	Mar 15, 2016	Jun NEWA
AA			300MG; 7.5MG	A202214	005	Mar 15, 2016	Jun NEWA
AA			300MG; 10MG	A202214	006	Mar 15, 2016	Jun NEWA
		NORCO					
AA		ALLERGAN SALES LLC	325MG; 2.5MG	A040148	004	Jul 07, 2014	Jun CAHN
AA	+		325MG; 5MG	A040099	001	Jun 25, 1997	Jun CAHN
AA			325MG; 5MG	A040148	005	Jul 07, 2014	Jun CAHN
AA	+		325MG; 7.5MG	A040148	003	Sep 12, 2000	Jun CAHN
AA	+		325MG; 10MG	A040148	001	Feb 14, 1997	Jun CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL							
OXYCODONE AND ACETAMINOPHEN							
AA	MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006	May	CMFD
TABLET; ORAL							
OXYCODONE AND ACETAMINOPHEN							
AA	ALVOGEN MALTA	325MG; 5MG	A202677	003	Mar 08, 2016	Feb	NEWA
AA		325MG; 7.5MG	A202677	001	Jul 26, 2012	Jan	CAHN
AA		325MG; 10MG	A202677	002	Jul 26, 2012	Jan	CAHN
AA	AMNEAL PHARMS NY	325MG; 7.5MG	A040778	002	Jun 27, 2014	Apr	NEWA
AA	MAYNE PHARMA INC	325MG; 2.5MG	A090177	001	Oct 20, 2008	Feb	CAHN
AA		325MG; 5MG	A090177	002	Oct 20, 2008	Feb	CAHN
AA		325MG; 7.5MG	A090177	003	Oct 20, 2008	Feb	CAHN
AA		325MG; 10MG	A090177	004	Oct 20, 2008	Feb	CAHN
	@	500MG; 7.5MG	A090177	005	Oct 20, 2008	Feb	CAHN
	@	650MG; 10MG	A090177	006	Oct 20, 2008	Feb	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL							
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN							
AB	ATLAS PHARMS LLC	325MG; 37.5MG	A202076	001	Mar 30, 2012	May	CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL							
ACETAZOLAMIDE							
AB	NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar	NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS							
ACETYLCYSTEINE							
AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb	NEWA
TABLET, EFFERVESCENT; ORAL							
CETYLEV							
	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Jan	NEWA
+		2.5GM	N207916	002	Jan 29, 2016	Jan	NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL							
SEMPREX-D							
+	AUXILIUM PHARMS INC	8MG; 60MG	N019806	001	Mar 25, 1994	Mar	CAHN

ACYCLOVIR

CAPSULE; ORAL							
ACYCLOVIR							
	@ RANBAXY	200MG	A074975	001	Sep 30, 1998	Feb	DISC
AB	ZYDUS PHARMS USA INC	200MG	A204313	001	Mar 25, 2016	Mar	NEWA
OINTMENT; TOPICAL							
ACYCLOVIR							
AB	FOUGERA PHARMS INC	5%	A206633	001	May 11, 2016	Apr	NEWA
TABLET; BUCCAL							
SITAVIG							
+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan	CAHN
TABLET; ORAL							
ACYCLOVIR							
	@ SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Feb	DISC
	@	800MG	A074980	002	Sep 30, 1998	Feb	DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION							
ACYCLOVIR SODIUM							
	@ AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Jun	CAHN
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Jun	CAHN
	@ BEDFORD	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Feb	DISC
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	DISC
AP	+	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CTEC
	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Apr	CAHN
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Apr	CAHN
AP	HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb	NEWA
+		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb	CRLD
AP		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb	NEWA

ADAPALENEGEL; TOPICAL
ADAPALENE

AB	TARO	0.3%	A208322	001	Jun 23, 2016	Jun	NEWA
----	------	------	---------	-----	--------------	-----	------

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

AP	EUROHLTH INTL SARL	3MG/ML	A076404	001	Jun 16, 2004	Apr	CAHN
	SOLUTION; IV (INFUSION)						
	ADENOSCAN						
	@ ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Apr	DISC
	@	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Apr	DISC
	ADENOSINE						
AP	+ TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr	CRLD
AP	+	90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr	CRLD

ALBUTEROL SULFATESOLUTION; INHALATION
ALBUTEROL SULFATE

	@ HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar	DISC
	@ LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar	DISC
	@ MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Mar	DISC
AN	+ NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar	CRLD
	@ TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar	DISC
	@ WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar	DISC
	TABLET; ORAL						
	ALBUTEROL SULFATE						
AB	SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar	CAHN
AB		EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION; INHALATION
DUONEB

	@ MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	Jun	DISC
--	----------------	------------------------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET; ORAL

	ALENDRONATE SODIUM						
AB	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	CAHN
AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	CAHN
AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	CAHN
AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	CAHN

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

AB	UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan	NEWA
----	------------------	------	---------	-----	--------------	-----	------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

>A>	AB	INDOCO REMEDIES	100MG	A204467	001	Jul 28, 2016	Jul	NEWA
>A>	AB		300MG	A204467	002	Jul 28, 2016	Jul	NEWA
	AB	SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar	CAHN
		ZYLOPRIM						
	AB	SEBELA IRELAND LTD	100MG	N016084	001		Jan	CAHN
	AB	+	300MG	N016084	002		Jan	CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb	NEWA
AB		EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Feb	NEWA

ALOSETRON HYDROCHLORIDETABLET; ORAL
LOTRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAMTABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

@	ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010	Jan DISC
@		1MG	A077198	002	May 13, 2010	Jan DISC
@		2MG	A077198	003	May 13, 2010	Jan DISC
@		3MG	A077198	004	May 13, 2010	Jan DISC
@	COREPHARMA	0.5MG	A077996	001	Jan 31, 2007	Mar DISC
@		1MG	A077996	002	Jan 31, 2007	Mar DISC
@		2MG	A077996	003	Jan 31, 2007	Mar DISC
@		3MG	A077996	004	Jan 31, 2007	Mar DISC
@	IMPAX LABS	0.5MG	A077968	004	May 24, 2007	Jan DISC
@		1MG	A077968	003	May 24, 2007	Jan DISC
@		2MG	A077968	002	May 24, 2007	Jan DISC
@		3MG	A077968	001	May 24, 2007	Jan DISC

ALPROSTADILINJECTABLE; INJECTION
EDEX

@	AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN

SUPPOSITORY; URETHRAL
MUSE

+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
+		0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
+		0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDECAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA

AMIKACIN SULFATEINJECTABLE; INJECTION
AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
AP		EUROHLTH INTL SARL	EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML;	N020678	011	Mar 26, 1997	Mar CMS1

INJECTABLE;INJECTION

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER							
297MG/100ML;77MG/100ML							
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar	CMS1
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar	CMS1
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar	CMS1
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar	CMS1
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar	CMS1
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar	CMS1
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar	CMS1

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL;TOPICAL

AMELUZ

+	BIOFRONTERA	10%	N208081	001	May 10, 2016	May	NEWA
---	-------------	-----	---------	-----	--------------	-----	------

AMINOPHYLLINE

TABLET;ORAL

AMINOPHYLLINE

	@ IDT AUSTRALIA LTD	100MG	A085261	003		May	CAHN
	@	100MG	A085262	002		May	CAHN
	@	200MG	A085261	002		May	CAHN

AMIODARONE HYDROCHLORIDE

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	May	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@ SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar	DISC
	@	10MG	A089399	002	Jul 14, 1987	Mar	DISC
AB	@	10MG	A089399	002	Jul 14, 1987	Mar	CAHN
	@	25MG	A040816	001	Jun 27, 2008	Mar	DISC
	@	25MG	A089399	001	Jul 14, 1987	Mar	DISC
AB	@	25MG	A089399	001	Jul 14, 1987	Mar	CAHN
	@	50MG	A040816	003	Jun 27, 2008	Mar	DISC
	@	50MG	A089399	003	Jul 14, 1987	Mar	DISC
AB	@	50MG	A089399	003	Jul 14, 1987	Mar	CAHN
	@	75MG	A040816	004	Jun 27, 2008	Mar	DISC
	@	75MG	A089399	004	Jul 14, 1987	Mar	DISC
AB	@	75MG	A089399	004	Jul 14, 1987	Mar	CAHN
	@	100MG	A040816	005	Jun 27, 2008	Mar	DISC
	@	100MG	A089399	005	Jul 14, 1987	Mar	DISC
AB	@	100MG	A089399	005	Jul 14, 1987	Mar	CAHN
	@	150MG	A040816	006	Jun 27, 2008	Mar	DISC
	@	150MG	A089399	006	Jul 14, 1987	Mar	DISC
AB	@	150MG	A089399	006	Jul 14, 1987	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

>A>	@	FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Jul CAHN
>A>	@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Jul CAHN
>D>	@	SUN PHARM INDS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Jul CAHN
	@		EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Mar CAHN
>D>	@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Jul CAHN
	@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	10MG;2MG	A071077	001	Nov 12, 1986	Mar CAHN
@		10MG;4MG	A071078	001	Nov 12, 1986	Mar CAHN
@		25MG;2MG	A070297	001	Nov 12, 1986	Mar CAHN
@		25MG;4MG	A071079	001	Nov 12, 1986	Mar CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB		CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016	May NEWA
AB		INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb CAHN
AB			EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb CAHN
AB			EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb CAHN
AB		POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016	Jun NEWA
AB			EQ 5MG BASE	A207821	002	Jul 11, 2016	Jun NEWA
AB			EQ 10MG BASE	A207821	003	Jul 11, 2016	Jun NEWA
	@	SUN PHARM INDS	EQ 2.5MG BASE	A078081	001	Jan 31, 2008	Mar CAHN
	@		EQ 5MG BASE	A078081	002	Jan 31, 2008	Mar CAHN
	@		EQ 10MG BASE	A078081	003	Jan 31, 2008	Mar CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A206512	001	Apr 22, 2016	Apr NEWA
AB			EQ 5MG BASE;320MG	A206512	002	Apr 22, 2016	Apr NEWA
AB			EQ 10MG BASE;160MG	A206512	003	Apr 22, 2016	Apr NEWA
AB			EQ 10MG BASE;320MG	A206512	004	Apr 22, 2016	Apr NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP		MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan NEWA
AP		MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr CRLD
		LAC-HYDRIN					
	@	RANBAXY	EQ 12% BASE	N020508	001	Aug 29, 1996	Apr DISC

LOTION; TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr CRLD
		LAC-HYDRIN					
	@	RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Apr DISC

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Feb DISC
@		500MG	A065016	002	Apr 08, 1999	Feb DISC

TABLET; ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Feb DISC
@		875MG	A065059	002	Nov 24, 2000	Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Feb DISC
@		250MG	A065021	002	Dec 23, 1999	Feb DISC

TABLET, EXTENDED RELEASE;ORAL
MOXATAG

+ VERNALIS R AND D LTD 775MG N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 875MG;EQ 125MG BASE A065102 001 Sep 17, 2002 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul DISC
>A>		@	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul DISC
>D>	AB		400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul DISC
>A>		@	400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul DISC
		@ SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb DISC
		@	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb DISC
		AUGMENTIN '125'					
>D>		DR REDDYS LABS INC	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Jul DISC
>A>		@	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Jul DISC
			125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Mar CTEC
		AUGMENTIN '250'					
>D>	+	DR REDDYS LABS INC	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Jul DISC
>A>		@	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Jul DISC
	+		250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Mar CRLD

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

NEOS THERAPS

		EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan NEWA
		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan NEWA
		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan NEWA
		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan NEWA
		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan NEWA
+		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	May CRLD
		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION
AMPHOTEC

@ ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
@	100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

ARIPIPIRAZOLE

INJECTABLE;INTRAMUSCULAR
ABILIFY

@ OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun DISC
----------	-------------------------	---------	-----	--------------	----------

SOLUTION;ORAL
ARIPIPIRAZOLE

AA + AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
--------------------	--------	---------	-----	--------------	----------

TABLET;ORAL
ARIPIPIRAZOLE

AB AMNEAL PHARMS	2MG	A204838	001	Jun 17, 2016	Jun NEWA
AB	5MG	A204838	002	Jun 17, 2016	Jun NEWA
AB	10MG	A204838	003	Jun 17, 2016	Jun NEWA
AB	15MG	A204838	004	Jun 17, 2016	Jun NEWA
AB	20MG	A204838	005	Jun 17, 2016	Jun NEWA
AB	30MG	A204838	006	Jun 17, 2016	Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY

@ OTSUKA	10MG	N021729	002	Jun 07, 2006	May DISC
@	15MG	N021729	003	Jun 07, 2006	May DISC

ARIPIPIRAZOLE

+ ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	May CRLD
	15MG	A202102	002	Apr 28, 2015	May CTEC

ARMODAFINIL

TABLET;ORAL
ARMODAFINIL

AB MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Apr CMFD
AB	150MG	A200043	002	Jun 01, 2012	Apr CMFD
AB	250MG	A200043	003	Jun 01, 2012	Apr CMFD

NUVIGIL

AB CEPHALON	50MG	N021875	001	Jun 15, 2007	Apr CTEC
AB	150MG	N021875	003	Jun 15, 2007	Apr CTEC
AB +	250MG	N021875	004	Jun 15, 2007	Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jan CAHN
-----------------------	--	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET;SUBLINGUAL
SAPHRIS

FOREST LABS LLC	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Mar NEWA
-----------------	-------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007	Jan CAHN
--------------------	-----------------	---------	-----	--------------	----------

FIORINAL

AA + ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Apr CAHN
-------------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

FIORINAL

@ ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Apr CAHN
----------------------	-----------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORINAL W/CODEINE

AB + ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Apr CAHN
-------------------------	----------------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	+	HERITAGE PHARMS INC	325MG;200MG	A089594	001	Mar 31, 1989	Jun CRLD
AB		INGENUS PHARMS NJ	325MG;200MG	A040832	001	Jan 07, 2010	Jan CAHN
		SOMA COMPOUND					
		@ MEDA PHARMS	325MG;200MG	N012365	005	Jul 11, 1983	Jun DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar CMFD
		@	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan CAHN
AB	+	SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Mar CTEC
	+		325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan CRLD
		SOMA COMPOUND W/ CODEINE					
		@ MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

		@ AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	Apr DISC
AB			25MG;200MG	A206392	001	Mar 08, 2016	Feb NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

		@ SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998	Mar CAHN
		@	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982	Mar CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB		ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan CAHN
AB			50MG	A072303	001	Jul 15, 1988	Jan CAHN
AB			100MG	A072304	001	Jul 15, 1988	Jan CAHN
		TENORMIN					
AB		ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan CAHN
AB			50MG	N018240	001		Jan CAHN
AB	+		100MG	N018240	002		Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan CAHN
AB			100MG;25MG	A072302	001	May 31, 1990	Jan CAHN
AB		SUN PHARM INDS	100MG;25MG	A073582	001	Apr 29, 1993	Mar CAHN
		TENORETIC 100					
AB	+	ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan CAHN
		TENORETIC 50					
AB		ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB		SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May NEWA
AB			EQ 20MG BASE	A205519	002	May 19, 2016	May NEWA
AB			EQ 40MG BASE	A205519	003	May 19, 2016	May NEWA
AB			EQ 80MG BASE	A205519	004	May 19, 2016	May NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

		@ SUN PHARM INDS	0.025MG;2.5MG	A085506	001		Mar CAHN
--	--	------------------	---------------	---------	-----	--	----------

AURANOFINCAPSULE;ORAL
RIDAURA

+ SEBELA IRELAND LTD 3MG

N018689 001 May 24, 1985 Jan CAHN

AXITINIBTABLET;ORAL
INLYTAPF PRISM CV 1MG
+ 5MGN202324 001 Jan 27, 2012 Apr CAHN
N202324 002 Jan 27, 2012 Apr CAHNAZACITIDINEINJECTABLE;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINEAP MYLAN INSTITUTIONAL 100MG/VIAL
POWDER;IV (INFUSION), SUBCUTANEOUS
AZACITIDINE

A204949 001 Apr 28, 2016 Apr NEWA

ACTAVIS LLC 100MG/VIAL

N208216 001 Apr 29, 2016 Apr NEWA

AZATHIOPRINE

TABLET;ORAL

IMURAN

AB @ SEBELA IRELAND LTD 25MG
+ 50MGN016324 002 Jan CAHN
N016324 001 Jan CAHNAZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

@ SEBELA IRELAND LTD EQ 100MG BASE/VIAL

N017391 001 Jan CAHN

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

ARBOR PHARMS LLC EQ 40MG MEDOXOMIL
+ EQ 80MG MEDOXOMILN200796 001 Feb 25, 2011 Jan CAHN
N200796 002 Feb 25, 2011 Jan CAHNAZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

ARBOR PHARMS LLC EQ 40MG MEDOXOMIL;12.5MG
+ EQ 40MG MEDOXOMIL;25MGN202331 001 Dec 20, 2011 Jan CAHN
N202331 002 Dec 20, 2011 Jan CAHNAZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

BX LUPIN LTD EQ 100MG BASE/5ML
BX EQ 200MG BASE/5MLA065488 001 May 15, 2015 Apr CTEC
A065488 002 May 15, 2015 Apr CTECAZTREONAM

INJECTABLE;INJECTION

AZTREONAM

@ EUROHLTH INTL SARL 1GM/VIAL
@ 2GM/VIALA065286 001 Mar 23, 2011 Mar DISC
A065286 002 Mar 23, 2011 Mar DISCBACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP SINTETICA SA 0.05MG/ML
AP 0.5MG/ML
AP 2MG/MLA091193 001 May 03, 2016 Apr NEWA
A091193 002 May 03, 2016 Apr NEWA
A091193 003 May 03, 2016 Apr NEWA

LIORESAL

AP + SAOL THERAPS RES LTD 0.05MG/ML
AP + 0.5MG/ML
AP + 2MG/MLN020075 003 Nov 07, 1996 May CAHN
N020075 001 Jun 17, 1992 May CAHN
N020075 002 Jun 17, 1992 May CAHN

TABLET;ORAL

BACLOFEN

AB NORTHSTAR HLTHCARE 10MG

A078401 002 Sep 18, 2009 Jan NEWA

BARIUM SULFATEFOR SUSPENSION; ORAL
E-Z-HD

+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan NEWA
SUSPENSION; ORAL						
	READI-CAT 2					
+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan NEWA
	READI-CAT 2 SMOOTHIES					
	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan DISC
@		10MG	A076267	002	Feb 11, 2004	Jan DISC
@		20MG	A076267	003	Feb 11, 2004	Jan DISC
@		40MG	A076267	004	Feb 11, 2004	Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	Jan DISC
@		10MG; 12.5MG	A076342	002	Feb 11, 2004	Jan DISC
@		20MG; 12.5MG	A076342	003	Feb 11, 2004	Jan DISC
@		20MG; 25MG	A076342	004	Feb 11, 2004	Jan DISC
@	IVAX SUB TEVA PHARMS	5MG; 6.25MG	A076348	001	Feb 11, 2004	Mar DISC
@		10MG; 12.5MG	A076348	002	Feb 11, 2004	Mar DISC
@		20MG; 12.5MG	A076348	003	Feb 11, 2004	Mar DISC
@		20MG; 25MG	A076348	004	Feb 11, 2004	Mar DISC
@	SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Mar DISC
@		10MG; 12.5MG	A077483	002	Sep 08, 2005	Mar DISC
@		20MG; 12.5MG	A077483	003	Sep 08, 2005	Mar DISC
@		20MG; 25MG	A077483	004	Sep 08, 2005	Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	May NEWA
AP		100MG/VIAL	A205574	002	May 19, 2016	May NEWA
AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar NEWA
AP	HOSPIRA INC	25MG/VIAL	A204086	001	May 20, 2016	May NEWA
AP		100MG/VIAL	A204086	002	May 20, 2016	May NEWA
AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar NEWA
TREANDA						
AP	+ CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar CFTG
AP	+	100MG/VIAL	N022249	001	Mar 20, 2008	Mar CFTG

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

+	CUTANEA	5%; 3%	N050769	001	Nov 27, 2000	Feb CAHN
---	---------	--------	---------	-----	--------------	----------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@	IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar DISC
---	------------	------	---------	-----	--------------	----------

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

>A>	AA	ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Jul CAHN
>A>	AA		1MG	A204713	002	Apr 14, 2015	Jul CAHN
>A>	AA		2MG	A204713	003	Apr 14, 2015	Jul CAHN

TABLET;ORAL

BENZTROPINE MESYLATE

>A>	@ FRONTIDA BIOPHARM	2MG	A081265	001	Jan 23, 1992	Jul CAHN
>D>	@ MUTUAL PHARM	2MG	A081265	001	Jan 23, 1992	Jul CAHN
>D> AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Jul CAHN
>D> AA		1MG	A204713	002	Apr 14, 2015	Jul CAHN
>D> AA		2MG	A204713	003	Apr 14, 2015	Jul CAHN

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL

SERNIVO

+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb NEWA
---	--------------------	---------------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Mar CAHN
----	-----------------	------------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan CAHN
----	---------------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

@	IMPAX LABS	5MG	A040739	001	Nov 01, 2006	Mar DISC
@		10MG	A040741	001	Nov 01, 2006	Mar DISC
@		25MG	A040740	001	Nov 01, 2006	Mar DISC
@		50MG	A040721	004	Nov 01, 2006	Mar DISC

DUVOID

>A> AA	BI-COASTAL PHARMA	10MG	A086262	001		Jul CAHN
>A> AA		25MG	A086263	001		Jul CAHN
>A> AA		50MG	A085882	003		Jul CAHN
>D> AA	WELLSPRING PHARM	10MG	A086262	001		Jul CAHN
>D> AA		25MG	A086263	001		Jul CAHN
>D> AA		50MG	A085882	003		Jul CAHN

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016	Apr NEWA
----	------------	-------	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

@	SEBELA IRELAND LTD	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N/A, 500MG	N050719	001	Aug 15, 1996	Jan CAHN
---	--------------------	---	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

>A>	@ FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jul CAHN
>A>	@	10MG	A075474	002	Oct 25, 2002	Jul CAHN
>D>	@ SUN PHARM INDS	5MG	A075474	001	Oct 25, 2002	Jul CAHN
	@	5MG	A075474	001	Oct 25, 2002	Mar CAHN
>D>	@	10MG	A075474	002	Oct 25, 2002	Jul CAHN
	@	10MG	A075474	002	Oct 25, 2002	Mar CAHN

BOCEPREVIR

CAPSULE;ORAL

VICTRELIS

@	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Jun DISC
---	-------------------	-------	---------	-----	--------------	----------

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVIACT

+	UBC INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb NEWA
+	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	May CMS1

SOLUTION;ORAL

BRIVIACT

+	UCB INC	10MG/ML	N205838	001	May 12, 2016	May CMS1
---	---------	---------	---------	-----	--------------	----------

SOLUTION;ORAL
BRIVIACT

+ 10MG/ML

N205838 001 Feb 18, 2016 Feb NEWA

TABLET;ORAL
BRIVIACT

UCB INC

10MG

N205836 001 May 12, 2016 May CMS1

10MG

N205836 001 Feb 18, 2016 Feb NEWA

25MG

N205836 002 May 12, 2016 May CMS1

25MG

N205836 002 Feb 18, 2016 Feb NEWA

50MG

N205836 003 May 12, 2016 May CMS1

50MG

N205836 003 Feb 18, 2016 Feb NEWA

75MG

N205836 004 May 12, 2016 May CMS1

75MG

N205836 004 Feb 18, 2016 Feb NEWA

+ 100MG

N205836 005 May 12, 2016 May CMS1

+ 100MG

N205836 005 Feb 18, 2016 Feb NEWA

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMSITE

>D> + INSITE VISION INC EQ 0.075% ACID

N206911 001 Apr 08, 2016 Jul CAHN

+ EQ 0.075% ACID

N206911 001 Apr 08, 2016 Apr NEWA

>A> + SUN PHARMA GLOBAL EQ 0.075% ACID

N206911 001 Apr 08, 2016 Jul CAHN

BROMOCRIPTINE MESYLATECAPSULE;ORAL
BROMOCRIPTINE MESYLATE

AB + MYLAN EQ 5MG BASE

A077226 001 Apr 04, 2005 Jan CRLD

PARLODEL

@ US PHARMS HOLDINGS I EQ 5MG BASE

N017962 002 Mar 01, 1982 Jan DISC

TABLET;ORAL
BROMOCRIPTINE MESYLATE

AB + PADDOCK LLC EQ 2.5MG BASE

A077646 001 Oct 01, 2008 Jan CRLD

AB SANDOZ INC EQ 2.5MG BASE

A074631 001 Jan 13, 1998 Feb CAHN

PARLODEL

AB US PHARMS HOLDINGS I EQ 2.5MG BASE

N017962 001 Apr CMFD

@ EQ 2.5MG BASE

N017962 001 Jan DISC

BUDESONIDECAPSULE;ORAL
BUDESONIDE

AB ACTAVIS ELIZABETH 3MG

A206623 001 Apr 08, 2016 Mar NEWA

ENTOCORT EC

AB + ELAN PHARMA INTL LTD 3MG

N021324 001 Oct 02, 2001 Jan CAHN

AB + PERRIGO PHARMA INTL 3MG

N021324 001 Oct 02, 2001 May CAHN

SUSPENSION;INHALATION
BUDESONIDE

AN APOTEX INC 0.25MG/2ML

A078202 001 Mar 30, 2009 Jun CMFD

AN 0.5MG/2ML

A078202 002 Mar 30, 2009 Jun CMFD

AN TEVA PHARMS USA 1MG/2ML

A204548 001 Mar 08, 2016 Feb NEWA

BUMETANIDEINJECTABLE;INJECTION
BUMETANIDE

AP + AMPHASTAR PHARMS INC 0.25MG/ML

A074441 001 Jan 27, 1995 Jun CAHN

AP + EUROHLTH INTL SARL 0.25MG/ML

A074441 001 Jan 27, 1995 Apr CAHN

BUPIVACAINE HYDROCHLORIDEINJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 0.25%

A207183 001 May 13, 2016 May NEWA

AP 0.5%

A207183 002 May 13, 2016 May NEWA

INJECTABLE;SPINAL
BUPIVACAINE HYDROCHLORIDE

>A> AP CLARIS 0.75%

A207266 001 Jul 25, 2016 Jul NEWA

BUPRENORPHINE HYDROCHLORIDEIMPLANT;IMPLANTATION
PROBUPHINE

+ BRAEBURN PHARMS INC EQ 80MG BASE/IMPLANT

N204442 001 May 26, 2016 Jun CAHN

+ TITAN PHARMS EQ 80MG BASE/IMPLANT

N204442 001 May 26, 2016 May NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan NEWA
AB		EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A>	AB	SUN PHARM INDS LTD	EQ 8MG BASE;EQ 2MG BASE	A201633	002	Aug 05, 2016	Jul NEWA
>A>	AB	SUN PHARM INDS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A201633	001	Aug 05, 2016	Jul NEWA
		ZUBSOLV					
>D>		OREXO AB	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul CAHN
>D>			EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul CAHN
>D>	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul CAHN
>D>			EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul CAHN
>D>			EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul CAHN
>A>		OREXO US INC	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul CAHN
>A>			EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul CAHN
>A>	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul CAHN
>A>			EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul CAHN
>A>			EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
AB1		150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1		200MG	A206674	003	Feb 09, 2016	Jan NEWA
AB1	SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1		150MG	A205794	002	Mar 01, 2016	Feb NEWA
AB1		200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014	Apr CAHN
---	----------	----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
AB		10MG	A204582	002	Sep 18, 2015	Jun CAHN
AB		15MG	A204582	003	Sep 18, 2015	Jun CAHN
AB		30MG	A204582	004	Sep 18, 2015	Jun CAHN

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	---------------------	--------	---------	-----	--------------	----------

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

@	PERRIGO PHARMA INTL	2%	N019881	001	Feb 07, 1997	Jun CAHN
---	---------------------	----	---------	-----	--------------	----------

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

	@	CLARIS	2MG/ML	A075697	001	Oct 23, 2001	Jan CAHN
AP		EUROHLTH INTL SARL	2MG/ML	A075046	001	Aug 12, 1998	Apr CAHN
		BUTORPHANOL TARTRATE PRESERVATIVE FREE					
	@	CLARIS	1MG/ML	A075695	001	Oct 23, 2001	Mar CAHN
	@		2MG/ML	A075695	002	Oct 23, 2001	Mar CAHN
AP		EUROHLTH INTL SARL	1MG/ML	A075045	001	Aug 12, 1998	Apr CAHN
AP			2MG/ML	A075045	002	Aug 12, 1998	Apr CAHN

CABERGOLINETABLET; ORAL
CABERGOLINE

@ IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007	Mar DISC
------------------	-------	---------	-----	--------------	----------

CABOZANTINIB S-MALATETABLET; ORAL
CABOMETYX

EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016	Apr NEWA
	EQ 40MG BASE	N208692	002	Apr 25, 2016	Apr NEWA
+	EQ 60MG BASE	N208692	003	Apr 25, 2016	Apr NEWA

CAFFEINE; ERGOTAMINE TARTRATESUPPOSITORY; RECTAL
MIGERGOT

+ HORIZON PHARMA	100MG; 2MG	A086557	001	Oct 04, 1983	Jan CAHN
------------------	------------	---------	-----	--------------	----------

CALCIFEDIOLCAPSULE, EXTENDED RELEASE; ORAL
RAYALDEE

+ OPKO IRELAND GLOBAL	0.03MG	N208010	001	Jun 17, 2016	Jun NEWA
-----------------------	--------	---------	-----	--------------	----------

CALCIPOTRIENECREAM; TOPICAL
CALCIPOTRIENE

AB GLENMARK PHARMS	0.005%	A205772	001	Jun 09, 2015	Mar CAHN
--------------------	--------	---------	-----	--------------	----------

CALCITRIOLCAPSULE; ORAL
CALCITRIOL

AB BIONPHARMA INC	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
AB	0.5MCG	A091174	002	May 24, 2013	Jan CAHN

INJECTABLE; INJECTION
CALCITRIOL

AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Feb CTEC
@ ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003	Feb DISC

CALCIUM ACETATECAPSULE; ORAL
CALCIUM ACETATE

>A> AB LOTUS PHARM CO LTD	EQ 169MG CALCIUM	A203298	001	Jul 26, 2016	Jul NEWA
---------------------------	------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002		Feb DISC
-------------------	---	---------	-----	--	----------

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003		Feb DISC
-------------------	---	---------	-----	--	----------

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988	Feb DISC
-------------------	---	---------	-----	--------------	----------

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001		Feb DISC
-------------------	--	---------	-----	--	----------

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982	Feb DISC
-------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982	Feb DISC
-------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988	Feb DISC
-------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982	Feb DISC
-------------------	--	---------	-----	--------------	----------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	010	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/10	N017512	011	Nov 18, 1985	Feb CTEC
	0ML;538MG/100ML;448MG/100ML				

CANGRELOR

POWDER;IV (INFUSION)

KENGREAL

>A>	+	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015	Jul CAHN
>D>	+	THE MEDICINES CO	50MG/VIAL	N204958	001	Jun 22, 2015	Jul CAHN

CAPECITABINE

TABLET;ORAL

CAPECITABINE

>A>	AB	ROXANE	150MG	A200483	001	Jul 14, 2016	Jul NEWA
>A>	AB		500MG	A200483	002	Jul 14, 2016	Jul NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

		@ APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar DISC
		@	25MG	A074737	002	Oct 28, 1998	Mar DISC
		@	50MG	A074737	003	Oct 28, 1998	Mar DISC
		@	100MG	A074737	004	Oct 28, 1998	Mar DISC
AB		HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun CAHN
AB			25MG	A074505	002	Feb 13, 1996	Jun CAHN
AB			50MG	A074505	003	Feb 13, 1996	Jun CAHN
AB			100MG	A074505	004	Feb 13, 1996	Jun CAHN
>D>		@ PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jul CMFD
>A>	AB		12.5MG	A074477	001	Feb 13, 1996	Jul CMFD
>D>		@	25MG	A074477	002	Feb 13, 1996	Jul CMFD
>A>	AB		25MG	A074477	002	Feb 13, 1996	Jul CMFD
>D>		@	50MG	A074477	003	Feb 13, 1996	Jul CMFD
>A>	AB		50MG	A074477	003	Feb 13, 1996	Jul CMFD
>D>		@	100MG	A074477	004	Feb 13, 1996	Jul CMFD
>A>	AB		100MG	A074477	004	Feb 13, 1996	Jul CMFD
		@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan DISC
		@	25MG	A074363	002	Nov 09, 1995	Jan DISC
		@	50MG	A074363	003	Nov 09, 1995	Jan DISC
		@	100MG	A074363	004	Nov 09, 1995	Jan DISC
		@ STASON	12.5MG	A074677	004	May 30, 1997	Mar DISC
		@	25MG	A074677	002	May 30, 1997	Mar DISC
		@	50MG	A074677	001	May 30, 1997	Mar DISC
		@	100MG	A074677	003	May 30, 1997	Mar DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan CAHN
AB			200MG	A076697	002	May 20, 2011	Jan CAHN
AB			300MG	A076697	003	May 20, 2011	Jan CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB		EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb NEWA
----	--	-------------------	------	---------	-----	--------------	----------

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

		@ IDT AUSTRALIA LTD	10MG;100MG	A073586	001	Jun 29, 1995	May CAHN
		@	25MG;100MG	A073587	001	Jun 29, 1995	May CAHN
		@	25MG;250MG	A073620	001	Jun 29, 1995	May CAHN

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

		MIKART INC	6MG	A207484	001	May 31, 2016	May NEWA
--	--	------------	-----	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE;IV (INFUSION)
CARBOPLATIN

	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr	DISC
	@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr	DISC
	@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr	DISC
	@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr	DISC
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb	CAHN
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb	CAHN
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb	CAHN
AP	SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	NEWA
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	NEWA
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	NEWA

CARFILZOMIB

POWDER;INTRAVENOUS
KYPROLIS

	ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Jun	NEWA
+		60MG/VIAL	N202714	001	Jul 20, 2012	Feb	CAHN

CARISOPRODOL

TABLET;ORAL
CARISOPRODOL

AA	INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan	CAHN
AB	STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	May	CAHN
AA		350MG	A205513	002	Nov 12, 2015	May	CAHN

CARVEDILOL

TABLET;ORAL
COREG

AB	SMITHKLINE BEECHAM	3.125MG	N020297	004	May 29, 1997	May	CAHN
AB		6.25MG	N020297	003	Sep 14, 1995	May	CAHN
AB	+	12.5MG	N020297	002	Sep 14, 1995	May	CAHN
AB		25MG	N020297	001	Sep 14, 1995	May	CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL
COREG CR

	SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	May	CAHN
		20MG	N022012	002	Oct 20, 2006	May	CAHN
+		40MG	N022012	003	Oct 20, 2006	May	CAHN
		80MG	N022012	004	Oct 20, 2006	May	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL
CEFADROXIL

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb	DISC
@		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb	DISC
@		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb	DISC

CEFAZOLIN SODIUM

INJECTABLE;INJECTION
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan	NEWA
----	-------------	------------------	---------	-----	--------------	-----	------

CEFDITOREN PIVOXIL

TABLET;ORAL
SPECTRACEF

@	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Apr	DISC
@		400MG	N021222	002	Jul 21, 2008	Apr	DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION
CEFEPIME HYDROCHLORIDE

AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	NEWA

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb NEWA
	CLAFORAN					
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN
	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun DISC
	@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun DISC
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan CAHN
	CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan CAHN
	@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan CAHN

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

	@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan CAHN
	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER					
+	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun CMS2
+		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun CMS2

CEFOXITIN SODIUMINJECTABLE; INJECTION
CEFOXITIN

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May CAHN
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May CAHN
AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May CAHN

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

	@ SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb DISC
	@	EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb DISC

TABLET; ORAL

	@ SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb DISC
	@	EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

	@ PERNIX THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun DISC
--	-----------------	---------------	---------	-----	--------------	----------

FOR SUSPENSION; ORAL

CEDAX

	@ PERNIX THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun DISC
	@	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

	@ HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr DISC
	@	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr DISC
	@	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr DISC
	@	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr DISC

ROCEPHIN

	@ HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr DISC
	@	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr DISC

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

	@ BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun DISC
	@	EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun DISC
	@	EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun DISC
	@	EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun DISC
AP	QILU PHARM CO LTD	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jun NEWA
AP		EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jun NEWA
AP		EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jun NEWA
AP		EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jun NEWA

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFTIN

	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb CTEC
+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb CTEC
	CEFUROXIME AXETIL					
	@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb DISC
	@	EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb DISC

TABLET;ORAL

CEFUROXIME AXETIL

	@ SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb DISC
	@	EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb DISC
	@	EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb DISC

CEFUROXIME SODIUM

INJECTABLE;INJECTION

ZINACEF

AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan CAHN

ZINACEF IN PLASTIC CONTAINER

	@ IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan CAHN
+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan CAHN
----	---	--------------	--------------------	---------	-----	--------------	----------

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan NEWA
AB		100MG	A206827	002	Feb 01, 2016	Jan NEWA
AB		200MG	A206827	003	Feb 01, 2016	Jan NEWA
AB		400MG	A206827	004	Feb 01, 2016	Jan NEWA
AB	MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb NEWA
AB		100MG	A204590	002	Mar 16, 2016	Feb NEWA
AB		200MG	A204590	003	Mar 16, 2016	Feb NEWA
AB		400MG	A204590	004	Mar 16, 2016	Feb NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

	@ SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb DISC
	@	EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb DISC

KEFLEX

>A>	AB	PRAGMA PHARMS LLC	EQ 250MG BASE	N050405	002		Jul CAHN
>A>		@	EQ 333MG BASE	N050405	004	May 12, 2006	Jul CAHN
>A>	AB		EQ 500MG BASE	N050405	003		Jul CAHN
>A>	AB	+	EQ 750MG BASE	N050405	005	May 12, 2006	Jul CAHN
>D>	AB	SHIONOGI INC	EQ 250MG BASE	N050405	002		Jul CAHN
>D>		@	EQ 333MG BASE	N050405	004	May 12, 2006	Jul CAHN
>D>	AB		EQ 500MG BASE	N050405	003		Jul CAHN
>D>	AB	+	EQ 750MG BASE	N050405	005	May 12, 2006	Jul CAHN

FOR SUSPENSION;ORAL

KEFLEX

	@ PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N050406	003		Mar CAHN
	@	EQ 125MG BASE/5ML	N050406	001		Mar CAHN
	@	EQ 250MG BASE/5ML	N050406	002		Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN
	@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Apr DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

LIBRAX

>A>	+	VALEANT PHARMS	5MG;2.5MG	N012750	001	Jul NEWA
-----	---	----------------	-----------	---------	-----	----------

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIOGARD

AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan NEWA
----	----------------------	-------	---------	-----	--------------	----------

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

@ IMPAX LABS

EQ 150MG BASE

A080880 001

Mar DISC

@

EQ 300MG BASE

A040516 001 Aug 29, 2003

Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC

4MG

A080961 001

Mar CAHN

@ SUN PHARM INDS

4MG

A080700 001

Jun CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

@ SPRIASO LLC

8MG;54.3MG

N206323 001 Jun 22, 2015

Jun DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Feb CAHN
----	------------------	--------------------------	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC

100MG

A088725 001 Aug 31, 1984

Mar CAHN

@

250MG

A088726 001 Aug 31, 1984

Mar CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	MYLAN	25MG	A086831	002		Jan CTEC
----	-------	------	---------	-----	--	----------

AB	SUN PHARM INDS	25MG	A089286	002	Jul 21, 1986	Jan NEWA
----	----------------	------	---------	-----	--------------	----------

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC

250MG

A089852 001 May 04, 1988

Feb CAHN

@

500MG

A089853 001 May 04, 1988

Feb CAHN

+ MIKART

750MG

A040861 002 Jun 01, 2010

Apr CRLD

+ MIKART INC

250MG

A207483 001 Jun 24, 2016

Jun NEWA

@ SUN PHARM INDS

500MG

A089970 001 Sep 27, 1990

Mar CAHN

>D> AA	WATSON LABS	500MG	A089859	001	May 04, 1988	Jul CRLD
--------	-------------	-------	---------	-----	--------------	----------

>A> AA	+		500MG	A089859	001	May 04, 1988	Jul CRLD
--------	---	--	-------	---------	-----	--------------	----------

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

+ TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008

Jan CRLD

CILASTATIN SODIUM; IMIPENEMPOWDER; INTRAMUSCULAR
PRIMAXIN

@ MERCK	EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990	May DISC
---------	--------------------------------	---------	-----	--------------	----------

CILOSTAZOLTABLET; ORAL
CILOSTAZOL

>A>	@ FRONTIDA BIOPHARM	50MG	A077208	002	Mar 29, 2006	Jul CAHN
>A>	@	100MG	A077208	001	Mar 29, 2006	Jul CAHN
>D>	@ SUN PHARM INDS	50MG	A077208	002	Mar 29, 2006	Jul CAHN
	@	50MG	A077208	002	Mar 29, 2006	Jun CAHN
>D>	@	100MG	A077208	001	Mar 29, 2006	Jul CAHN
	@	100MG	A077208	001	Mar 29, 2006	Jun CAHN
AB	+ TEVA	50MG	A077027	001	Nov 24, 2004	Jun CRLD
AB	+ PLETAL	100MG	A077027	002	Nov 24, 2004	Jun CRLD
	@ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jun DISC
	@	100MG	N020863	002	Jan 15, 1999	Jun DISC

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

>D> AT	IGI LABS INC	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jul CAHN
>A> AT	TELIGENT PHARMA INC	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jul CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ IDT AUSTRALIA LTD	EQ 100MG BASE	A075939	001	Mar 03, 2005	May CAHN
@	EQ 250MG BASE	A075939	002	Jun 09, 2004	May CAHN
@	EQ 500MG BASE	A075939	003	Jun 09, 2004	May CAHN
@	EQ 750MG BASE	A075939	004	Jun 09, 2004	May CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC

OTOVEL

+ LABORATORIOS SALVAT	EQ 0.3% BASE; 0.025%	N208251	001	Apr 29, 2016	Apr NEWA
-----------------------	----------------------	---------	-----	--------------	----------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ ACTAVIS LABS FL INC	212.6MG; EQ 287.5MG BASE	A077417	001	Nov 30, 2010	Jan DISC
@	425.2MG; EQ 574.9MG BASE	A077809	001	Nov 30, 2010	Jan DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ SUN PHARM INDS	EQ 10MG BASE	A077052	001	Jul 03, 2006	Mar CAHN
@	EQ 20MG BASE	A077052	002	Jul 03, 2006	Mar CAHN
@	EQ 40MG BASE	A077052	003	Jul 03, 2006	Mar CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB	ALLIED PHARMA INC	500MG	A203243	001	Feb 29, 2016	Feb NEWA
	@ IDT AUSTRALIA LTD	500MG	A065250	001	Aug 25, 2005	May CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	May NEWA
----	------------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDESSE

+ PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004	Jun CAHN
-----------------------	------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	EUROHLTH INTL SARL	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Apr CAHN
----	--------------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE; TRETINOINGEL;TOPICAL
VELTIN

BX	+	AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010	Jan CAHN
----	---	-----------------	-------------	---------	-----	--------------	----------

CLOBETASOL PROPIONATEOINTMENT;TOPICAL
CLOBETASOL PROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar CRLD
		TEMOVATE					
	@	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Mar DISC

CLOMIPRAMINE HYDROCHLORIDECAPSULE;ORAL
ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan CRLD

CLONIDINE HYDROCHLORIDETABLET;ORAL
CLONIDINE HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb CAHN
	@		0.2MG	A070886	001	Aug 31, 1988	Feb CAHN
	@		0.3MG	A071294	001	Aug 31, 1988	Feb CAHN
>A> AB		FRONTIDA BIOPHARM	0.1MG	A070925	001	Sep 04, 1987	Jul CAHN
>A> AB			0.2MG	A070924	001	Sep 04, 1987	Jul CAHN
>A> AB			0.3MG	A070923	001	Sep 04, 1987	Jul CAHN
>D> AB		SUN PHARM INDS	0.1MG	A070925	001	Sep 04, 1987	Jul CAHN
>D> AB			0.2MG	A070924	001	Sep 04, 1987	Jul CAHN
>D> AB			0.3MG	A070923	001	Sep 04, 1987	Jul CAHN

CLOPIDOGREL BISULFATETABLET;ORAL
CLOPIDOGREL BISULFATE

	@	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Jun DISC
AB		SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar CAHN

CLORAZEPATE DIPOTASSIUMCAPSULE;ORAL
CLORAZEPATE DIPOTASSIUM

@	AUROLIFE PHARMA LLC	3.75MG	A072219	001	Aug 26, 1988	Apr CAHN
@		7.5MG	A072220	001	Aug 26, 1988	Feb CAHN
@		15MG	A072112	001	Aug 26, 1988	Feb CAHN

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@	AUROLIFE PHARMA LLC	3.75MG	A072512	001	May 11, 1990	Mar CAHN
@		7.5MG	A072513	001	May 11, 1990	Mar CAHN
@		15MG	A072514	001	May 11, 1990	Feb CAHN

TRANXENE

@	RECORDATI RARE	3.75MG	N017105	006		Jun DISC
---	----------------	--------	---------	-----	--	----------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDESYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		NOSTRUM LABS INC	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Feb CAHN
----	--	------------------	---------------------	---------	-----	--------------	----------

COLCHICINECAPSULE;ORAL
MITIGARE

+	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Mar CRLD
---	-------------------	-------	---------	-----	--------------	----------

COLCHICINE; PROBENECIDTABLET;ORAL
PROBENECID AND COLCHICINE

AB		INGENUS PHARMS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Jan CAHN
----	--	-------------------	-------------	---------	-----	--------------	----------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS;OTIC
COLY-MYCIN S

+	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001		Feb CAHN
---	-----------------	---	---------	-----	--	----------

CORTICOTROPININJECTABLE;INJECTION
PURIFIED CORTROPHIN GEL

@	ANI PHARMS	40 UNITS/ML	N008975	001		Feb CAHN
@		80 UNITS/ML	N008975	002		Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDEINJECTABLE;INJECTION
CORTROPHIN-ZINC

@	ANI PHARMS	40 UNITS/ML	N009854	001		Feb CAHN
---	------------	-------------	---------	-----	--	----------

CROFELEMERTABLET, DELAYED RELEASE;ORAL
FULYZAQ

+	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Jun CAHN
---	-----------------	-------	---------	-----	--------------	----------

CYANOCOBALAMININJECTABLE;INJECTION
CYANOCOBALAMIN

AP	SOMERSET THERAPS LLC	1MG/ML	A206503	001	Dec 11, 2015	Mar CAHN
----	----------------------	--------	---------	-----	--------------	----------

SPRAY, METERED;NASAL
NASCOBAL

+	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Feb CAHN
---	-----------------	-------------	---------	-----	--------------	----------

CYCLOBENZAPRINE HYDROCHLORIDETABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>A>	AB	FRONTIDA BIOPHARM	5MG	A073541	002	Apr 06, 2006	Jul CAHN
>A>	AB		10MG	A073541	001	May 23, 1995	Jul CAHN
>D>	AB	SUN PHARM INDS	5MG	A073541	002	Apr 06, 2006	Jul CAHN
>D>	AB		10MG	A073541	001	May 23, 1995	Jul CAHN

CYCLOPHOSPHAMIDEINJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

@	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Mar DISC
@		1GM/VIAL	N012142	004	Aug 30, 1982	Mar DISC
@		2GM/VIAL	N012142	005	Aug 30, 1982	Mar DISC

CYPROHEPTADINE HYDROCHLORIDETABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan CAHN
----	-------------------	-----	---------	-----	--------------	----------

CYTARABINEINJECTABLE;INJECTION
CYTARABINE

AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	Mar CAHN
AP		20MG/ML	A200916	001	Dec 13, 2011	Mar CAHN

DACLATASVIR DIHYDROCHLORIDETABLET;ORAL
DAKLINZA

	BRISTOL-MYERS SQUIBB	EQ 90MG BASE	N206843	003	Apr 13, 2016	Apr NEWA
--	----------------------	--------------	---------	-----	--------------	----------

DACTINOMYCININJECTABLE;INJECTION
DACTINOMYCIN

@	EUROHLTH INTL SARL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Feb DISC
---	--------------------	------------	---------	-----	--------------	----------

DALBAVANCIN HYDROCHLORIDEPOWDER; IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL N021883 001 May 23, 2014 Jan CDFR

DANTROLENE SODIUMFOR SUSPENSION; INTRAVENOUS
RYANODEX

+ EAGLE PHARMS 250MG/VIAL N205579 001 Jul 22, 2014 Jun CRLD

INJECTABLE; INJECTION
DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL A205239 001 Feb 18, 2016 Feb NEWA

DAPSONEGEL; TOPICAL
ACZONE

+ ALLERGAN INC 7.5% N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL
DAPSONE

AB ALVOGEN 25MG A205429 001 Jan 07, 2016 Mar CAHN

AB 100MG A205429 002 Jan 07, 2016 Mar CAHN

AB NORTH CREEK PHARMS 25MG A204074 001 May 10, 2016 Apr NEWA

AB 100MG A204074 002 May 10, 2016 Apr NEWA

AB NOSTRUM LABS INC 25MG A203887 001 May 06, 2016 Apr NEWA

AB 100MG A203887 002 May 06, 2016 Apr NEWA

DAPTOMYCINPOWDER; INTRAVENOUS
CUBICIN

AP + CUBIST 500MG/VIAL N021572 002 Sep 12, 2003 Jan CDFR

DAPTOMYCIN

AP CRANE PHARMS LLC 500MG/VIAL A206005 001 Jun 15, 2016 Jun NEWA

AP HOSPIRA INC 500MG/VIAL A202857 001 Sep 12, 2014 Jan CDFR

AP TEVA PARENTERAL 500MG/VIAL A091039 001 Mar 25, 2016 Mar NEWA

POWDER; IV (INFUSION)
CUBICIN

@ CUBIST 250MG/VIAL N021572 001 Sep 12, 2003 Jan CDFR

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
ENABLEX

AB APIL EQ 7.5MG BASE N021513 001 Dec 22, 2004 Jan CAHN

AB + EQ 15MG BASE N021513 002 Dec 22, 2004 Jan CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

>A> TABLET, EXTENDED RELEASE; ORAL

>A> VIEKIRA XR

>A> + ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016 Jul NEWA

DASATINIBTABLET; ORAL
DASATINIB

AB APOTEX INC 20MG A202103 001 Jun 10, 2016 May NEWA

AB 50MG A202103 002 Jun 10, 2016 May NEWA

AB 70MG A202103 003 Jun 10, 2016 May NEWA

AB 100MG A202103 004 Jun 10, 2016 May NEWA

SPRYCEL

AB BRISTOL MYERS SQUIBB 20MG N021986 001 Jun 28, 2006 May CFTG

AB 50MG N021986 002 Jun 28, 2006 May CFTG

AB 70MG N021986 003 Jun 28, 2006 May CFTG

AB + 100MG N021986 004 May 30, 2008 May CFTG

DAUNORUBICIN CITRATEINJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

@ GALEN (UK) EQ 2MG BASE/ML N050704 002 Apr 08, 1996 May DISC

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB	ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB		250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB		500MG	A203560	003	Jan 26, 2016	Jan NEWA
	EXJADE					
AB	NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB		250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+	500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)
DEFITELIO

+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
---	-------------	-----------------------	---------	-----	--------------	----------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DEMECLOCYCLINE HYDROCHLORIDE
@ IMPAX LABS 150MG
@ 300MG

A065094	001	Mar 22, 2004	Mar DISC
A065094	002	Mar 22, 2004	Mar DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
AB	HERITAGE PHARMS INC	10MG	A207433	001	May 05, 2016	Jun CAHN
AB		25MG	A207433	002	May 05, 2016	Jun CAHN
AB		50MG	A207433	003	May 05, 2016	Jun CAHN
AB		75MG	A207433	004	May 05, 2016	Jun CAHN
AB		100MG	A207433	005	May 05, 2016	Jun CAHN
AB		150MG	A207433	006	May 05, 2016	Jun CAHN
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr NEWA
AB		25MG	A207433	002	May 05, 2016	Apr NEWA
AB		50MG	A207433	003	May 05, 2016	Apr NEWA
AB		75MG	A207433	004	May 05, 2016	Apr NEWA
AB		100MG	A207433	005	May 05, 2016	Apr NEWA
AB		150MG	A207433	006	May 05, 2016	Apr NEWA
	NORPRAMIN					
AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
AB		25MG	N014399	001		Jan CAHN
AB		50MG	N014399	003		Jan CAHN
AB		75MG	N014399	004		Jan CAHN
AB	+	100MG	N014399	005		Jan CAHN
AB		150MG	N014399	006		Jan CAHN

DESLORATADINE

SOLUTION; ORAL
DESLORATADINE

AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May NEWA
----	------	----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

TABLET; ORAL
DESMOPRESSIN ACETATE
@ FERRING 0.1MG
@ 0.2MG

N021795	001	May 08, 2008	Jun DISC
N021795	002	May 08, 2008	Jun DISC

DESONIDE

CREAM; TOPICAL
DESONIDE

AB	G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan CAHN
----	------------------	-------	---------	-----	--------------	----------

DESOXIMETASONEOINTMENT; TOPICAL
DESOXIMETASONE

AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr NEWA
AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May CAHN
AB	TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb NEWA

DESVENLAFAXINE SUCCINATETABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

>A>	AB	ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	Jul NEWA
>A>	AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	Jul NEWA
>A>	AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	Jul NEWA
	AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb NEWA
	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb NEWA
		PRISTIQ					
>D>		WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul CFTG
>A>	AB		EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul CFTG

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

@	IDT AUSTRALIA LTD	0.75MG	A080399	001		May CAHN
@	SUN PHARM INDS	0.25MG	A084013	001		Mar CAHN
@		0.25MG	A084764	001		Mar CAHN
@		0.5MG	A084084	001		Mar CAHN
@		0.5MG	A084766	001		Mar CAHN
@		0.75MG	A084081	001		Mar CAHN
@		0.75MG	A084765	001		Mar CAHN
@		1.5MG	A084086	001		Mar CAHN
@		1.5MG	A084763	001		Mar CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar CTNA
----	---	--------------------	----------------------	---------	-----	--------------	----------

DEXLANSOPRAZOLETABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL
DEXILANT SOLUTAB

+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan NEWA
---	-------------------	------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar NEWA
AP		SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May NEWA
		PRECEDEX					
+		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb CAHN
AB			5MG	A201231	002	Sep 24, 2015	Feb CAHN
AB			10MG	A201231	003	Sep 24, 2015	Feb CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

TOTECT

+		CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Mar CAHN
---	--	-------------------	--------------------	---------	-----	--------------	----------

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan NEWA
AB		10MG	A206735	002	Jan 27, 2016	Jan NEWA
AB		15MG	A206735	003	Jan 27, 2016	Jan NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA	NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA		10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA	NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA		10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS 15MG/5ML;6.25MG/5ML

N011265 002 Apr 02, 1984 Feb CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE

5GM/100ML;31MG/100ML;141MG/100ML;2 N017484 001

Feb CMS1

0MG/100ML;12MG/100ML;260MG/100ML

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

5GM/100ML;205MG/100ML;100MG/100ML; N018840 001 Jun 29, 1983 Feb CMS1

120MG/100ML;220MG/100ML

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL

5MG/ML

A070313 001 Dec 16, 1985 Jan CAHN

SOLUTION;ORAL

DIAZEPAM

AA LANNETT HOLDINGS INC 5MG/5ML

A206477 001 Jun 24, 2016 Jun NEWA

AA + ROXANE 5MG/5ML

A070928 001 Apr 03, 1987 Jun CFTG

TABLET;ORAL

DIAZEPAM

DAVA PHARMS INC

2MG

A070228 002 Sep 26, 1985 Jan NEWA

5MG

A070228 003 Sep 26, 1985 Jan NEWA

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB BIONPHARMA INC 25MG

A204648 001 Feb 23, 2016 Feb NEWA

ZIPSOR

AB + DEPOMED INC 25MG

N022202 001 Jun 16, 2009 Feb CFTG

FOR SOLUTION;ORAL

CAMBIA

AB + DEPOMED INC 50MG

N022165 001 Jun 17, 2009 Apr CFTG

DICLOFENAC POTASSIUM

AB PAR FORM 50MG

A202964 001 May 02, 2016 Apr NEWA

TABLET;ORAL

CATAFLAM

@ NOVARTIS

50MG

N020142 002 Nov 24, 1993 Mar DISC

DICLOFENAC POTASSIUM

AB + MYLAN 50MG

A075463 001 Jul 26, 1999 Mar CRLD

@ SUN PHARM INDS

50MG

A075470 001 Feb 21, 2002 Jun CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB AMNEAL PHARMS 1%

A208077 001 Mar 18, 2016 Mar NEWA

AB TARO 3%

A206298 001 Apr 28, 2016 Apr NEWA

VOLTAREN

AB + GLAXOSMITHKLINE CONS 1%

N022122 001 Oct 17, 2007 Mar CFTG

		SOLUTION;TOPICAL													
		DICLOFENAC SODIUM													
AT		TELIGENT PHARMA INC	1.5%			A202769	001	Jul 08, 2015	May	CAHN					
		SOLUTION/DROPS;OPHTHALMIC													
		DICLOFENAC SODIUM													
AT		RISING PHARMS INC	0.1%			A078553	001	Dec 28, 2007	Jan	CAHN					
		TABLET, EXTENDED RELEASE;ORAL													
		DICLOFENAC SODIUM													
AB	+	ACTAVIS ELIZABETH	100MG			A075910	001	Jan 07, 2002	Feb	CRLD					
		VOLTAREN-XR													
		@ NOVARTIS		100MG		N020254	001	Mar 08, 1996	Feb	DISC					
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>															
		TABLET, DELAYED RELEASE;ORAL													
		DICLOFENAC SODIUM AND MISOPROSTOL													
AB		EXELA PHARMA SCS LLC	50MG;0.2MG			A200540	001	Mar 14, 2014	Mar	CAHN					
AB			75MG;0.2MG			A200540	002	Mar 14, 2014	Mar	CAHN					
<u>DICYCLOMINE HYDROCHLORIDE</u>															
		CAPSULE;ORAL													
		DICYCLOMINE HYDROCHLORIDE													
		@ SUN PHARM INDS		10MG		A084505	001	Oct 21, 1986	Mar	CAHN					
		INJECTABLE;INJECTION													
		DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)													
AP		EUROHLTH INTL SARL	10MG/ML			A040465	001	Jun 30, 2003	Mar	CMS1					
		SYRUP;ORAL													
		DICYCLOMINE HYDROCHLORIDE													
	+	MIKART	10MG/5ML			A040169	001	Mar 24, 2005	Jan	CRLD					
		TABLET;ORAL													
		DICYCLOMINE HYDROCHLORIDE													
		@ SUN PHARM INDS		20MG		A084600	001	Jul 29, 1985	Mar	CAHN					
<u>DIENOGEST; ESTRADIOL VALERATE</u>															
		TABLET;ORAL													
		ESTRADIOL VALERATE AND DIENOGEST													
AB		WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A			A202349	001	May 06, 2016	Apr	NEWA					
		NATAZIA													
AB	+	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A			N022252	001	May 06, 2010	Apr	CFTG					
<u>DIETHYLPROPION HYDROCHLORIDE</u>															
		TABLET;ORAL													
		DIETHYLPROPION HYDROCHLORIDE													
		@ COREPHARMA		25MG		A040828	001	Nov 05, 2008	Mar	DISC					
		TENUATE													
AA	+	ACTAVIS LABS UT INC	25MG			N011722	002		Apr	CAHN					
AA	+	ALLERGAN SALES LLC	25MG			N011722	002		Mar	CAHN					
		TABLET, EXTENDED RELEASE;ORAL													
		TENUATE DOSPAN													
AB	+	ACTAVIS LABS UT INC	75MG			N012546	001		Apr	CAHN					
AB	+	ALLERGAN SALES LLC	75MG			N012546	001		Mar	CAHN					
<u>DIFLUNISAL</u>															
		TABLET;ORAL													
		DIFLUNISAL													
		@ IDT AUSTRALIA LTD		500MG		A074604	001	Jun 10, 1996	May	CAHN					
<u>DIGOXIN</u>															
		INJECTABLE;INJECTION													
		LANOXIN													
AP	+	COVIS PHARMA SARL	0.25MG/ML			N009330	002		Jun	CAHN					
		LANOXIN PEDIATRIC													
	+	COVIS PHARMA SARL	0.1MG/ML			N009330	004		Jun	CAHN					
<u>DIHYDROERGOTAMINE MESYLATE</u>															
		INJECTABLE;INJECTION													
		DIHYDROERGOTAMINE MESYLATE													
AP		EUROHLTH INTL SARL	1MG/ML			A040453	001	Jun 09, 2003	Apr	CAHN					

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DILACOR XR

>D>	@	ACTAVIS LABS UT INC	120MG	N020092	001	May 29, 1992	Jul CAHN
>D>	@		180MG	N020092	002	May 29, 1992	Jul CAHN
>D>	@		240MG	N020092	003	May 29, 1992	Jul CAHN
>A>	@	ALLERGAN SALES LLC	120MG	N020092	001	May 29, 1992	Jul CAHN
>A>	@		180MG	N020092	002	May 29, 1992	Jul CAHN
>A>	@		240MG	N020092	003	May 29, 1992	Jul CAHN

DILTIAZEM HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan DISC
	@		180MG	A074852	002	Oct 10, 1997	Jan DISC
	@		240MG	A074852	003	Oct 10, 1997	Jan DISC
AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan CAHN

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074617	001	Feb 28, 1996	Jun CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996	Apr CAHN

DINOPROSTONEINSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan CAHN
---	--------------------	------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

>A>	@	HIKMA INTL PHARMS	50MG	A083567	001		Jul CAHN
>D>	@	HIKMA PHARMS	50MG	A083567	001		Jul CAHN
	@		50MG	A083567	001		Feb CAHN
	@	SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987	Mar CAHN
	@		50MG	A089489	001	Jan 02, 1987	Jun CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074939	001	Apr 13, 1998	Jun CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074939	001	Apr 13, 1998	Apr CAHN

TABLET;ORAL

DIPYRIDAMOLE

	@	IDT AUSTRALIA LTD	25MG	A086944	002	Apr 16, 1991	May CAHN
	@		50MG	A087562	001	Feb 25, 1992	May CAHN
	@		75MG	A087561	001	Feb 25, 1992	May CAHN
>D> AB		PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990	Jul DISC
>A>	@		25MG	A089425	001	Jul 12, 1990	Jul DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

@	AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb CAHN
@		EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb CAHN
@	SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985	Mar CAHN
@		EQ 150MG BASE	A070352	001	Dec 17, 1985	Mar CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan CAHN
----	--	---------------	-------	---------	-----	--------------	----------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

@	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb DISC
@		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

@ TELIGENT PHARMA INC EQ 12.5MG BASE/ML A074098 001 Feb 21, 1995 Jan CAHN

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

HOSPIRA INC 20MG/ML (20MG/ML) N022234 004 Jun 23, 2016 Jun NEWA
80MG/4ML (20MG/ML) N022234 005 Jun 23, 2016 Jun NEWA
120MG/6ML (20MG/ML) N022234 006 Jun 23, 2016 Jun NEWA

SOLUTION; IV (INFUSION)
DOCETAXEL

EAGLE PHARMS 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Jan CAHN
80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Jan CAHN
160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Jan CAHN

DOFETILIDE

CAPSULE; ORAL
DOFETILIDE

AB TIGER PHARMS LLC 0.125MG A207058 001 Jun 06, 2016 May NEWA
AB 0.25MG A207058 002 Jun 06, 2016 May NEWA
AB 0.5MG A207058 003 Jun 06, 2016 May NEWA
TIKOSYN
AB PFIZER 0.125MG N020931 001 Oct 01, 1999 May CFTG
AB 0.25MG N020931 002 Oct 01, 1999 May CFTG
AB + 0.5MG N020931 003 Oct 01, 1999 May CFTG

DOLASETRON MESYLATE

INJECTABLE; INJECTION
ANZEMET

+ US PHARM HOLDINGS 12.5MG/0.625ML (20MG/ML) N020624 002 Sep 11, 1997 Jan CAHN
+ 12.5MG/0.625ML (20MG/ML) N020624 002 Sep 11, 1997 Jan CAHN
+ 100MG/5ML (20MG/ML) N020624 001 Sep 11, 1997 Jan CAHN
@ 500MG/25ML (20MG/ML) N020624 003 Dec 11, 2001 Jun DISC
+ 500MG/25ML (20MG/ML) N020624 003 Dec 11, 2001 Jan CAHN

TABLET; ORAL
ANZEMET

US PHARM HOLDINGS 50MG N020623 001 Sep 11, 1997 Jan CAHN
+ 100MG N020623 002 Sep 11, 1997 Jan CAHN

DOLUTEGRAVIR SODIUM

TABLET; ORAL
TIVICAY

VIIV HLTHCARE EQ 10MG BASE N204790 002 Jun 09, 2016 Jun NEWA
EQ 25MG BASE N204790 003 Jun 09, 2016 Jun NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB DEXCEL PHARMA 23MG A203713 001 Feb 19, 2016 Feb NEWA
AB INDICUS PHARMA 23MG A203419 001 Apr 12, 2016 Mar NEWA
AB OSMOTICA PHARM CORP 23MG A203114 001 Jan 26, 2016 Jan NEWA
AB OSMOTICA PHARM US 23MG A203114 001 Jan 26, 2016 Jun CAHN
AB UNICHEM LABS LTD 5MG A203656 001 Jun 23, 2016 Jun NEWA
AB 10MG A203656 002 Jun 23, 2016 Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
DONEPEZIL HYDROCHLORIDE

@ SUN PHARM INDS 5MG A077975 002 Dec 11, 2009 Mar CAHN
@ 10MG A077975 001 Dec 11, 2009 Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOXAPRAM HYDROCHLORIDE

AP AMPHASTAR PHARMS INC 20MG/ML A076266 001 Jan 10, 2003 Jun CAHN
AP EUROHLTH INTL SARL 20MG/ML A076266 001 Jan 10, 2003 Apr CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar CAHN
@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar CAHN
@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar CAHN
@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

@	SUN PHARM INDS	EQ 25MG BASE	A071502	001	Feb 18, 1988	Mar CAHN
@		EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar CAHN
@		EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar CAHN
@		EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar CAHN

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan NEWA

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar NEWA
	HECTOROL					
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	May CRLD
AP		200MG/100ML	A203622	002	Jun 27, 2014	May CRLD
AP	+ PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	May CRLD
AP	+	200MG/100ML	N050629	002	May 03, 1988	May CRLD

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar CAHN
AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar CAHN
AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb NEWA
AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb NEWA
AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb NEWA

TABLET; ORAL

DOXYCYCLINE

@	SUN PHARM INDS	EQ 50MG BASE	A065471	001	Apr 17, 2009	Jun CAHN
@		EQ 75MG BASE	A065471	002	Apr 17, 2009	Jun CAHN
@		EQ 100MG BASE	A065471	003	Apr 17, 2009	Jun CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

ACTICLATE CAP

+	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Apr NEWA
---	-------------	--------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

AB	AMNEAL PHARMS	EQ 100MG BASE	A207289	001	Jun 27, 2016	Jun NEWA
AB	SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

@	COREPHARMA	EQ 20MG BASE	A065182	001	May 13, 2005	Mar DISC
AB	SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar CAHN
AB		EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar CAHN
@	VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar DISC

TABLET, DELAYED RELEASE; ORAL

DORYX

>A>							
>A>	AB	MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jul CTNA
>D>			EQ 60MG BASE	N050795	007	May 20, 2016	Jul CTNA
			EQ 60MG BASE	N050795	007	May 20, 2016	May NEWA
	AB		EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr CFTG
>D>			EQ 120MG BASE	N050795	008	May 20, 2016	Jul CTNA
			EQ 120MG BASE	N050795	008	May 20, 2016	May NEWA

TABLET, DELAYED RELEASE;ORAL
DORYX

AB	+		EQ 200MG BASE	N050795	005	Apr 11, 2013	May CFTG
>A>		DORYX MPC					
>A>		MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Jul CTNA
>A>			EQ 120MG BASE	N050795	008	May 20, 2016	Jul CTNA
>D>		DOXTERIC					
>D>	AB	MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jul CTNA
	AB		EQ 50MG BASE	N050795	006	Dec 19, 2014	May CFTG
		DOXYCYCLINE HYCLATE					
		@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar DISC
		@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar DISC
	AB	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May NEWA
	AB		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr NEWA
	AB		EQ 200MG BASE	A090431	005	May 19, 2016	May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

AB		NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan NEWA
		TABLET;ORAL-28					
		DROSPIRENONE AND ETHINYL ESTRADIOL					
AB		GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

>A>	AB	HETERO LABS LTD III	EQ 20MG BASE	A204343	001	Aug 03, 2016	Jul NEWA
>A>	AB		EQ 30MG BASE	A204343	002	Aug 03, 2016	Jul NEWA
>A>	AB		EQ 60MG BASE	A204343	003	Aug 03, 2016	Jul NEWA

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB		AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr CAHN
AB		BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan CAHN
AB		INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb NEWA
AB		MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May NEWA
AB		STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar CAHN

DYPHYLLINE

TABLET;ORAL

LUFYLLIN

	@	MEDA PHARMS	200MG	A084566	001		Jun DISC
	@		400MG	A084566	002		Jun DISC

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

>A>	+	EXELTIS SUISSE	1%	N205175	001	Oct 24, 2013	Jul CAHN
>D>	+	VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Jul CAHN

CREAM;TOPICAL

ECONAZOLE NITRATE

AB		TELIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004	May CAHN
		SPECTAZOLE					
>A>	@	ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Jul CAHN
>D>	@	MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jul CAHN

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

TENSILON

	@	TELIGENT PHARMA INC	10MG/ML	N007959	001		Jan CAHN
		TENSILON PRESERVATIVE FREE					
	@	TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan CAHN

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB		MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Feb NEWA
AB		MYLAN PHARMS INC	600MG	A091471	001	Feb 17, 2016	Jun CAHN

TABLET;ORAL									
SUSTIVA									
AB	+	BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb	CFTG	
<u>ELBASVIR; GRAZOPREVR</u>									
TABLET;ORAL									
ZEPATIER									
	+	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016	Jan	NEWA	
<u>ELUXADOLINE</u>									
TABLET;ORAL									
VIBERZI									
		ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015	May	CAHN	
	+		100MG	N206940	002	May 27, 2015	May	CAHN	
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE</u>									
TABLET;ORAL									
ODEFSEY									
	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Apr	CAIN	
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE</u>									
TABLET;ORAL									
ODEFSEY									
	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Mar	NEWA	
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>									
TABLET;ORAL									
DESCOVY									
	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Apr	NEWA	
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>									
TABLET;ORAL									
TRUVADA									
		GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Mar	NEWA	
			133MG;200MG	N021752	003	Mar 10, 2016	Mar	NEWA	
			167MG;250MG	N021752	004	Mar 10, 2016	Mar	NEWA	
<u>ENALAPRILAT</u>									
INJECTABLE;INJECTION									
ENALAPRILAT									
AP	+	AMPHASTAR PHARMS INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jun	CAHN	
AP	+	EUROHLTH INTL SARL	1.25MG/ML	A075634	001	Aug 22, 2000	Apr	CAHN	
<u>EPHEDRINE SULFATE</u>									
SOLUTION;INTRAVENOUS									
AKOAZ									
	+	FLAMEL IRELAND LTD	50MG/ML	N208289	001	Apr 29, 2016	Apr	NEWA	
<u>EPINASTINE HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
EPINASTINE HYDROCHLORIDE									
AT		SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN	
<u>EPINEPHRINE</u>									
INJECTABLE;INJECTION									
SUS-PHRINE SULFITE FREE									
	@	FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999	Mar	CMS1	
	@		5MG/ML	N007942	001		Mar	CMS1	
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS									
AUVI-Q									
BX	+	KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Mar	CAHN	
BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Mar	CAHN	
TWINJECT 0.15									
	@	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May	DISC	
TWINJECT 0.3									
	@	AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May	DISC	
>A>	SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS								
>A>	EPINEPHRINE								
>A>		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul	CAIN	

>D>	<u>EPINEPHRINE HYDROCHLORIDE</u>									
>D>	SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS									
>D>	EPINEPHRINE									
>D>	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul	CAIN			
		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb	CDFR			
<u>ERGOCALCIFEROL</u>										
CAPSULE;ORAL										
DRISDOL										
AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001		Jan	CAHN		
VITAMIN D										
AA		BIONPHARMA INC	50,000 IU	A080704	001		Jan	CAHN		
<u>ERGOLOID MESYLATES</u>										
TABLET;ORAL										
ERGOLOID MESYLATES										
AB		SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar	CAHN		
TABLET;SUBLINGUAL										
ERGOLOID MESYLATES										
	@	SUN PHARM INDS	0.5MG	A087407	001		Jun	CAHN		
	@		1MG	A087552	001		Jun	CAHN		
<u>ERYTHROMYCIN</u>										
SOLUTION;TOPICAL										
C-SOLVE-2										
	@	FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb	DISC		
ERYTHRO-STATIN										
	@	HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb	DISC		
ERYTHROMYCIN										
AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan	CRLD		
AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan	CRLD		
<u>ESCITALOPRAM OXALATE</u>										
SOLUTION;ORAL										
ESCITALOPRAM OXALATE										
AA		MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754	001	Mar 31, 2016	Mar	NEWA		
<u>ESMOLOL HYDROCHLORIDE</u>										
SOLUTION;INTRAVENOUS										
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER										
+	HQ	SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016	Apr	NEWA		
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER										
+	HQ	SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun	CRLD		
			2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Apr	NEWA		
<u>ESOMEPRAZOLE MAGNESIUM</u>										
CAPSULE, DELAYED REL PELLETS;ORAL										
ESOMEPRAZOLE MAGNESIUM										
AB		AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr	NEWA		
AB			EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr	NEWA		
BX		HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr	CTEC		
BX			EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr	CTEC		
<u>ESOMEPRAZOLE SODIUM</u>										
INJECTABLE;INTRAVENOUS										
ESOMEPRAZOLE SODIUM										
>A>	AP	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Jul	NEWA		
>A>	AP		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul	NEWA		
<u>ESTRADIOL</u>										
CREAM;VAGINAL										
ESTRACE										
+		ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr	CAHN		
FILM, EXTENDED RELEASE;TRANSDERMAL										
ALORA										
BX		ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN		
BX			0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN		
BX			0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN		
BX			0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN		

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL
FEMRING

APIL EQ 0.05MG BASE/24HR
+ EQ 0.1MG BASE/24HR

N021367 001 Mar 20, 2003 Jan CAHN
N021367 002 Mar 20, 2003 Jan CAHN

TABLET;ORAL
FEMTRACE

APIL 0.45MG
0.9MG
+ 1.8MG

N021633 001 Aug 20, 2004 Jan CAHN
N021633 002 Aug 20, 2004 Jan CAHN
N021633 003 Aug 20, 2004 Jan CAHN

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL
ESTRASORB

+ EXELTIS USA INC 0.25%

N021371 001 Oct 09, 2003 Jun CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
AMABELZ

AB LUPIN LTD 0.5MG;0.1MG
AB 1MG;0.5MG

A203339 001 Jun 20, 2016 Jun NEWA
A203339 002 Jun 20, 2016 Jun NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL
CENESTIN

@ TEVA BRANDED PHARM 0.3MG
@ 0.45MG
@ 0.625MG
@ 0.9MG
@ 1.25MG

N020992 001 Jun 21, 2002 Jun DISC
N020992 005 Feb 05, 2004 Jun DISC
N020992 002 Mar 24, 1999 Jun DISC
N020992 003 Mar 24, 1999 Jun DISC
N020992 004 Mar 13, 2000 Jun DISC

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL
ENJUVIA

@ TEVA WOMENS 0.625MG

N021443 003 May 10, 2004 Jun DISC

ETHACRYNIC ACID

TABLET;ORAL
EDECIN

AB + ATON 25MG
ETHACRYNIC ACID

N016092 001 Jun CFTG

AB EDENBRIDGE PHARMS 25MG

A205609 001 Jun 30, 2016 Jun NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB JAI PHARMA LTD 0.05MG;1MG

A204704 001 Feb 09, 2016 Jan NEWA

ZOVIA 1/50E-28

AB + WATSON LABS 0.05MG;1MG

A072723 001 Dec 30, 1991 Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL
FAYOSIM

AB LUPIN LTD 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A

A205943 001 Mar 29, 2016 Mar NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A> AB AMNEAL PHARMS 0.03MG;0.15MG

A203871 001 Nov 13, 2015 Jul CAHN

>D> AB HAUPT PHARMA 0.03MG;0.15MG

A203871 001 Nov 13, 2015 Jul CAHN

>D> AB 0.03MG,0.01MG;0.15MG,NA

A203872 001 Dec 22, 2015 Jul CMS1

>A> AB 0.03MG,0.01MG;0.15MG,N/A

A203872 001 Dec 22, 2015 Jul CMS1

QUARTETTE

AB + TEVA BRANDED PHARM 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A

N204061 001 Mar 28, 2013 Mar CFTG

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1 AMNEAL PHARMS 0.02MG;0.1MG

A201108 001 Feb 05, 2014 May CAHN

>A> AB 0.03MG;0.15MG

A201095 001 Dec 08, 2014 Jul CAHN

>D> AB HAUPT PHARMA 0.03MG;0.15MG

A201095 001 Dec 08, 2014 Jul CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21							
BREVICON 21-DAY							
	@ ALLERGAN SALES LLC	0.035MG; 0.5MG	N017566	001		Apr	CAHN
NORINYL 1+35 21-DAY							
AB	ALLERGAN SALES LLC	0.035MG; 1MG	N017565	001		Mar	CAHN
TABLET; ORAL-28							
BREVICON 28-DAY							
AB	ALLERGAN SALES LLC	0.035MG; 0.5MG	N017743	001		Mar	CAHN
NORINYL 1+35 28-DAY							
AB	ALLERGAN SALES LLC	0.035MG; 1MG	N017565	002		Mar	CAHN
TABLET, CHEWABLE; ORAL							
FEMCON FE							
AB	+ APIL	0.035MG; 0.4MG	N021490	001	Nov 14, 2003	Jan	CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+ APIL	0.025MG; 0.8MG	N022573	001	Dec 22, 2010	Jan	CAHN
AB	LUPIN LTD	0.035MG; 0.4MG	A091332	001	Mar 23, 2016	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL							
FEMHRT							
AB	APIL	0.0025MG; 0.5MG	N021065	001	Jan 14, 2005	Jan	CAHN
	@	0.005MG; 1MG	N021065	002	Oct 15, 1999	Jan	CAHN
LERIBANE							
AB	NOVAST LABS LTD	0.0025MG; 0.5MG	A203435	002	Jun 03, 2016	May	NEWA
AB		0.005MG; 1MG	A203435	001	Jun 03, 2016	May	NEWA
LO LOESTRIN FE							
AB	+ APIL	0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010	May	CFTG
	+	0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010	Jan	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	JAI PHARMA LTD	0.01MG, 0.01MG; 1MG, N/A	A205049	001	May 31, 2016	May	NEWA
TABLET; ORAL-21							
ESTROSTEP 21							
	@ APIL	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N020130	001	Oct 09, 1996	Jan	CAHN
LOESTRIN 21 1.5/30							
AB	APIL	0.03MG; 1.5MG	N017875	001		Apr	CAHN
LOESTRIN 21 1/20							
AB	APIL	0.02MG; 1MG	N017876	001		Apr	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	GLENMARK PHARMS LTD	0.02MG; 1MG	A206969	001	Jan 20, 2016	Jan	NEWA
TABLET; ORAL-28							
ESTROSTEP FE							
AB	+ APIL	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N020130	002	Oct 09, 1996	Jan	CAHN
LOESTRIN FE 1.5/30							
AB	+ APIL	0.03MG; 1.5MG	N017355	001		Apr	CAHN
LOESTRIN FE 1/20							
AB	APIL	0.02MG; 1MG	N017354	001		Apr	CAHN
TABLET, CHEWABLE; ORAL							
MIBELAS 24 FE							
AB	LUPIN ATLANTIS	0.02MG; 1MG	A206287	001	May 24, 2016	May	NEWA
MINASTRIN 24 FE							
AB	+ APIL	0.02MG; 1MG	N203667	001	May 08, 2013	May	CFTG
	+	0.02MG; 1MG	N203667	001	May 08, 2013	Jan	CAHN
TABLET, CHEWABLE, TABLET; ORAL							
LO MINASTRIN FE							
	+ APIL	0.01MG, 0.01MG, N/A; 1MG, N/A, N/A	N204654	001	Jul 24, 2013	Jan	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28							
MILI							
AB	AUROBINDO PHARMA LTD	0.035MG; 0.25MG	A205449	001	Jul 07, 2016	Jun	NEWA
NORGESTIMATE AND ETHINYL ESTRADIOL							
AB	AMNEAL PHARMS	0.035MG; 0.25MG	A203865	001	Oct 27, 2015	May	CAHN
AB	GLENMARK PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.2	A204057	001	Feb 23, 2016	Jun	CAHN
		15MG, 0.25MG					
AB	GLENMARK PHARMS LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.2	A204057	001	Feb 23, 2016	Feb	NEWA
		15MG, 0.25MG					
AB	HAUPT PHARMA	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.2	A203873	001	May 12, 2016	May	NEWA
		15MG, 0.25MG					
AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG; 0.18MG,	A201897	001	Jan 27, 2016	Jan	NEWA
		0.215MG, 0.25MG					

TABLET;ORAL-28							
NORGESTIMATE AND ETHINYL ESTRADIOL							
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan	NEWA
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205588	001	Apr 26, 2016	Apr	NEWA
TRI-MILI							
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205441	001	Jul 06, 2016	Jun	NEWA
<u>ETHINYL ESTRADIOL; NORGESTREL</u>							
TABLET;ORAL-21							
LO/OVRAL							
	@ PELAGIUS	0.03MG;0.3MG	N017612	001		Jun	CAHN
TABLET;ORAL-28							
LO/OVRAL-28							
	@ WYETH PHARMS	0.03MG;0.3MG	N017802	001		Jun	DISC
NORGESTREL AND ETHINYL ESTRADIOL							
AB	JAI PHARMA LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Jun	NEWA
<u>ETHOSUXIMIDE</u>							
CAPSULE;ORAL							
ETHOSUXIMIDE							
AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan	CAHN
<u>ETIDRONATE DISODIUM</u>							
TABLET;ORAL							
DIDRONEL							
AB	APIL	200MG	N017831	001		Apr	CAHN
AB	+	400MG	N017831	002		Apr	CAHN
<u>ETODOLAC</u>							
CAPSULE;ORAL							
ETODOLAC							
	@ IDT AUSTRALIA LTD	200MG	A074840	001	Aug 29, 1997	May	CAHN
	@	300MG	A074840	002	Aug 29, 1997	May	CAHN
	@ LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb	CAHN
<u>ETOMIDATE</u>							
INJECTABLE;INJECTION							
ETOMIDATE							
AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996	Apr	CAHN
AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb	NEWA
<u>EXEMESTANE</u>							
TABLET;ORAL							
EXEMESTANE							
AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan	CAHN
<u>EXENATIDE SYNTHETIC</u>							
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS							
BYDUREON PEN							
+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb	NEWA
<u>FAMOTIDINE</u>							
INJECTABLE;INJECTION							
FAMOTIDINE							
AP	AMPHASTAR PHARMS INC	10MG/ML	A075651	001	Apr 16, 2001	Jun	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Jun	CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Apr	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Apr	CAHN
FAMOTIDINE PRESERVATIVE FREE							
AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Jun	CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Jun	CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Apr	CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Apr	CAHN
TABLET;ORAL							
FAMOTIDINE							
	@ SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar	CAHN
	@	40MG	A075639	001	Dec 12, 2001	Mar	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATE

TABLET;ORAL
FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA
AB		145MG	A205118	002	May 05, 2016	Apr NEWA
AB	HETERO LABS LTD III	48MG	A204598	001	Jul 12, 2016	Jun NEWA
AB		145MG	A204598	002	Jul 12, 2016	Jun NEWA
AB	MYLAN	40MG	A204475	001	Jun 23, 2016	Jun NEWA
AB		120MG	A204475	002	Jun 23, 2016	Jun NEWA

	FENOGLIDE					
AB	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Jun CFTG
AB	+	120MG	N022118	002	Aug 10, 2007	Jun CFTG

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

	ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Apr CAHN
+		105MG	N022418	002	Aug 14, 2009	Apr CAHN
	ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009	Jun CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL
FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar CAHN
@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN

TABLET;ORAL

	FENOPROFEN CALCIUM					
@	AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb CAHN
@	SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-12

AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan NEWA
----	-------	------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS
TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Apr NEWA
---	----------------------	-------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

@	ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan DISC
@		8MG	A204827	002	Dec 10, 2015	Jan DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	BARR	60MG;120MG	A076236	001	Apr 14, 2005	Mar DISC
@	IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010	Mar DISC

>A> FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

>A> EMULSION;INTRAVENOUS
>A> SMOFLIPID 20%

>A>	+	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648	001	Jul 13, 2016	Jul NEWA
>A>	+		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648	002	Jul 13, 2016	Jul NEWA
>A>	+		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648	003	Jul 13, 2016	Jul NEWA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003	Mar DISC
----------------	-------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

@ IDT AUSTRALIA LTD	50MG	A076030	001	Oct 28, 2002	May CAHN
@	100MG	A076030	002	Oct 28, 2002	May CAHN
@	150MG	A076030	003	Oct 28, 2002	May CAHN

FLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+ BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May NEWA
--------------	-------------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb DISC
@	200MG/5ML	A076332	002	Jul 29, 2004	Feb DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr CAHN
AP		200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr CAHN
AP		400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr CAHN
	@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan DISC
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan DISC
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CMS1
AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CMS1
AP	EUROHLTH INTL SARL	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun CAHN
AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun CAHN

TABLET; ORAL

FLUCONAZOLE

@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May CAHN
@	100MG	A076086	002	Jul 29, 2004	May CAHN
@	150MG	A076086	003	Jul 29, 2004	May CAHN
@	200MG	A076086	004	Jul 29, 2004	May CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May NEWA
AT		0.01%	A209336	001	May 19, 2016	May NEWA

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr NEWA
----	------	-------	---------	-----	--------------	----------

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE

	@ SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002	Mar CAHN
	@	EQ 20MG BASE	A075787	002	Jan 29, 2002	Mar CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

	+ EDMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar CRLD
	SARAFEM					
AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP

AT	+ AQUA PHARMS	0.05%	N012806	002		Mar CFTG
	FLURANDRENOLIDE					

AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar NEWA
----	---------------------	-------	---------	-----	--------------	----------

TAPE; TOPICAL
CORDRAN

	+ ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001		Apr CAHN
--	----------------------	---------------	---------	-----	--	----------

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
CORDRAN N

	@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001		Mar CMS1
--	---------	------------------------	---------	-----	--	----------

OINTMENT; TOPICAL
CORDRAN N

	@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001		Mar CMS1
--	---------	------------------------	---------	-----	--	----------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb CAHN
	@	30MG	A071717	001	Jul 31, 1991	Feb CAHN
	@ HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986	May CAHN
	@ SUN PHARM INDS	15MG	A070454	001	Aug 04, 1986	Mar CAHN
	@	30MG	A070455	001	Aug 04, 1986	Mar CAHN

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

	@ AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995	Feb CAHN
	@	100MG	A074448	002	Jul 28, 1995	Feb CAHN

FLUTICASONE FUROATE

POWDER; INHALATION
ARNUITY ELLIPTA

	+ GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Mar CRLD
--	-------------------	-----------	---------	-----	--------------	----------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION
Breo ELLIPTA

	+ GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Mar CRLD
--	-----------------	-------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL
FLONASE

	@ GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jun DISC
--	-------------------	--------------	---------	-----	--------------	----------

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL
FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 80MG BASE	A202458	001	Sep 11, 2015	May CPOT
AB	TEVA PHARMS USA	EQ 80MG BASE	A079011	001	Jan 27, 2016	May CPOT
AB		80MG	A079011	001	Jan 27, 2016	Jan NEWA
	LESCOL XL					
AB	+ NOVARTIS	EQ 80MG BASE	N021192	001	Oct 06, 2000	May CPOT

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

@	NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb CAHN
@		50MG	A075900	002	Feb 23, 2006	Feb CAHN
@		100MG	A075900	003	Feb 23, 2006	Feb CAHN
@	SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002	Mar CAHN
@		50MG	A076125	002	Apr 29, 2002	Mar CAHN
@		100MG	A076125	003	Apr 29, 2002	Mar CAHN

FOLIC ACID

INJECTABLE;INJECTION

FOLVITE

@	WYETH PHARMS INC	5MG/ML	N005897	008		May CAHN
---	------------------	--------	---------	-----	--	----------

TABLET;ORAL

FOLIC ACID

@	SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005	Mar CAHN
	FOLVITE					
@	WYETH PHARMS INC	1MG	N005897	004		May CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

FOLLISTIM AQ

@	ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005	Jun DISC
@		150 IU/0.5ML	N021273	002	Aug 26, 2005	Jun DISC

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BEVESPI AEROSPHERE

+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Apr NEWA
---	-------------------	---------------------------	---------	-----	--------------	----------

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

FOSAMPRENAVIR CALCIUM

AB	MYLAN PHARMS INC	EQ 700MG BASE	A204060	001	Apr 15, 2016	Apr NEWA
	LEXIVA					
AB	+ VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr CFTG

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

EMEND

AP	+ MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010	May CFTG
	FOSAPREPITANT DIMEGLUMINE					
AP	FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016	May NEWA

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan DISC
@		20MG	A076620	002	Oct 15, 2004	Jan DISC
@		40MG	A076620	003	Oct 15, 2004	Jan DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan DISC
@		20MG;12.5MG	A076608	002	Dec 03, 2004	Jan DISC
@	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb DISC
@		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

AP EUROHLTH INTL SARL EQ 50MG PHENYTOIN NA/ML A077481 001 Aug 06, 2007 Jun CAHN

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb NEWA
----	---------------------	---------------	---------	-----	--------------	----------

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

>A>	AP	AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul NEWA
	AP	CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May CAHN
	@	EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN
	@	LUITPOLD	10MG/ML	N018579	001	Nov 30, 1983	Feb DISC

TABLET; ORAL
FUROSEMIDE

@ SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar CAHN
@	80MG	A070100	001	Jan 26, 1988	Mar CAHN

LASIX

AB	US PHARM HOLDINGS	20MG	N 016273 002	Jan CAHN
AB		40MG	N 016273 001	Jan CAHN
AB	+	80MG	N 016273 003	Jan CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB	SCIEGEN PHARMS INC	100MG	A 204989	001	Feb 18, 2016	Feb	NEWA
AB		300MG	A 204989	002	Feb 18, 2016	Feb	NEWA
AB		400MG	A 204989	003	Feb 18, 2016	Feb	NEWA
@	SUN PHARM INDS	100MG	A 076537	001	Jun 30, 2005	Mar	CAHN
@		300MG	A 076537	002	Jun 30, 2005	Mar	CAHN
@		400MG	A 076537	003	Jun 30, 2005	Mar	CAHN

SOLUTION; ORAL
GABAPENTIN

AA	TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb NEWA
----	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL
GABAPENTIN

AB	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan NEWA
AB		800MG	A205101	002	Feb 04, 2016	Jan NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL
HORIZONTAL

>A>		ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011	Jul CAHN
>A>	+		600MG	N022399	001	Apr 06, 2011	Jul CAHN
>D>		XENOPORT INC	300MG	N022399	002	Dec 13, 2011	Jul CAHN
>D>	+		600MG	N022399	001	Apr 06, 2011	Jul CAHN

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL
GALANTAMINE HYDROBROMIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895	001	Aug 05, 2016	Jul	NEWA
>A>	AB		EQ 16MG BASE	A204895	002	Aug 05, 2016	Jul	NEWA
>A>	AB		EQ 24MG BASE	A204895	003	Aug 05, 2016	Jul	NEWA
	@	IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC
	@		EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC
	@		EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

+	ROXANE	4MG/ML	A 078185	001	Jan 30, 2009	May CRLD
	RAZADYNE					
@	JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May DISC

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun NEWA
----	---------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar NEWA
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar NEWA
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar NEWA
AP	+ HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar CFTG
AP	+	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar CFTG
AP	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar CFTG

GEMFIBROZILTABLET;ORAL
GEMFIBROZIL

AB	CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun NEWA
----	-------------------	-------	---------	-----	--------------	----------

GLIMEPIRIDETABLET;ORAL
GLIMEPIRIDE

@	ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
@		2MG	A076995	002	Apr 27, 2010	Jan DISC
@		4MG	A076995	003	Apr 27, 2010	Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATETABLET;ORAL
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG;4MG	A078709	001	Apr 01, 2016	Mar NEWA
		2MG;4MG	A078709	002	Apr 01, 2016	Mar NEWA
		2MG;8MG	A078709	004	Apr 01, 2016	Mar NEWA
		4MG;4MG	A078709	003	Apr 01, 2016	Mar NEWA
		4MG;8MG	A078709	005	Apr 01, 2016	Mar NEWA

GLYBURIDETABLET;ORAL
GLYBURIDE

AB1	PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr NEWA
AB1		2.5MG	A203581	002	Apr 14, 2016	Apr NEWA
AB1		5MG	A203581	003	Apr 14, 2016	Apr NEWA
AB1	ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr NEWA
AB1		2.5mg	A206749	002	May 10, 2016	Apr NEWA
AB1		5MG	A206749	003	May 10, 2016	Apr NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET;ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	COREPHARMA	1.25MG;250MG	A076731	001	Nov 19, 2004	Jan DISC
@		2.5MG;500MG	A076731	002	Nov 19, 2004	Jan DISC
@		5MG;500MG	A076731	003	Nov 19, 2004	Jan DISC
AB	ZYDUS PHARMS USA INC	1.25MG;250MG	A206748	001	Feb 29, 2016	Feb NEWA
AB		2.5MG;500MG	A206748	002	Feb 29, 2016	Feb NEWA
AB		5MG;500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATEINJECTABLE;INJECTION
GLYCOPYRROLATE

AP	+ HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
	ROBINUL					
	@ EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb DISC
	TABLET;ORAL					
	GLYCOPYRROLATE					
	@ HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009	May CAHN
	@	2MG	A040836	002	Mar 05, 2009	May CAHN
AA	NATCO PHARMA LTD	1MG	A091413	001	Jun 20, 2016	Jun NEWA
AA		2MG	A091413	002	Jun 20, 2016	Jun NEWA
AA	RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN
AA		2MG	A040821	002	Dec 29, 2008	Jan CAHN

TABLET;ORAL
ROBINUL

AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN
		ROBINUL FORTE					
AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun NEWA
AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@	CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	May CAHN
AP		EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun CAHN
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun CAHN
AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

@	COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
---	------------	-------------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

+	MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
---	----------------------	------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

@	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
@		EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
@		EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
@		EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL

ULTRAVATE

+	SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
>A>	@	FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Jul CAHN
>A>	@		1MG	A071157	001	Jan 02, 1987	Jul CAHN
>A>	@		2MG	A071172	001	Jan 02, 1987	Jul CAHN
>A>	@		5MG	A071212	001	Jan 07, 1988	Jul CAHN
>A>	@		10MG	A071173	001	Jan 07, 1988	Jul CAHN
>D>	@	SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jul CAHN
	@		0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
>D>	@		1MG	A071157	001	Jan 02, 1987	Jul CAHN
	@		1MG	A071157	001	Jan 02, 1987	Jun CAHN
>D>	@		2MG	A071172	001	Jan 02, 1987	Jul CAHN
	@		2MG	A071172	001	Jan 02, 1987	Mar CAHN
>D>	@		5MG	A071212	001	Jan 07, 1988	Jul CAHN
	@		5MG	A071212	001	Jan 07, 1988	Mar CAHN
>D>	@		10MG	A071173	001	Jan 07, 1988	Jul CAHN
	@		10MG	A071173	001	Jan 07, 1988	Mar CAHN
	@		20MG	A071177	001	Jan 07, 1988	Mar CAHN
	@	VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
	@		1MG	A071235	003	Nov 03, 1986	Jan CMS1
	@		5MG	A071235	004	Nov 03, 1986	Jan CMS1
	@		10MG	A071235	005	Jul 20, 1987	Jan CMS1

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

AP FRESENIUS KABI USA 5,000 UNITS/ML A206552 001 Jun 10, 2016 May NEWA

HEXACHLOROPHENE

EMULSION; TOPICAL
PHISOHEX

@ SANOFI AVENTIS US 3% N006882 001 May DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
@ ACTAVIS ELIZABETH 1.5MG; 5MG

A040295 001 Dec 01, 2000 Jan CMS1

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP MYLAN INSTITUTIONAL 20MG/ML A204680 001 Apr 28, 2016 Apr NEWA

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

@ ACTAVIS GRP PTC 10MG A091679 001 Mar 04, 2013 Apr DISC

@ 25MG A091679 002 Mar 04, 2013 Apr DISC

@ 50MG A091679 003 Mar 04, 2013 Apr DISC

@ 100MG A091679 004 Mar 04, 2013 Apr DISC

>A> @ FRONTIDA BIOPHARM 10MG A089359 001 Jul 25, 1986 Jul CAHN

>A> @ 25MG A089258 001 May 05, 1986 Jul CAHN

>A> @ 50MG A089259 001 May 05, 1986 Jul CAHN

>A> @ 100MG A088729 001 Apr 11, 1985 Jul CAHN

>D> @ SUN PHARM INDS 10MG A089359 001 Jul 25, 1986 Jul CAHN

@ 10MG A089359 001 Jul 25, 1986 Mar CAHN

>D> @ 25MG A089258 001 May 05, 1986 Jul CAHN

@ 25MG A089258 001 May 05, 1986 Mar CAHN

>D> @ 50MG A089259 001 May 05, 1986 Jul CAHN

@ 50MG A089259 001 May 05, 1986 Mar CAHN

>D> @ 100MG A088729 001 Apr 11, 1985 Jul CAHN

@ 100MG A088729 001 Apr 11, 1985 Jun CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDRALAZINE AND HYDROCHLOROTHIAZIDE
@ WATSON LABS 25MG; 15MG

A085827 001 Feb CMS1

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
@ SUN PHARM INDS 25MG; 15MG; 0.1MG

A088570 001 Apr 10, 1984 Mar CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
MICROZIDE

AB + ALLERGAN SALES LLC 12.5MG N020504 001 Dec 27, 1996 Apr CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@ AUROLIFE PHARMA LLC 25MG A083899 001 Feb CAHN

@ 50MG A085219 001 Feb CAHN

@ HIKMA INTL PHARMS 25MG A084878 002 Jul 12, 2006 May CAHN

AB 50MG A084878 001 May CAHN

@ SUN PHARM INDS 25MG A083972 001 Mar CAHN

@ 50MG A083972 002 Mar CAHN

@ 100MG A083972 003 Mar CAHN

ORETIC

@ ABBVIE 50MG N011971 002 Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB AUROBINDO PHARMA LTD 25MG; 300MG A203630 003 Mar 31, 2016 Mar NEWA

AB INTL SPECLT CHEMS 12.5MG; 150MG A203036 001 Jan 15, 2016 Jan NEWA

AB 12.5MG; 300MG A203036 002 Jan 15, 2016 Jan NEWA

AB 25MG; 300MG A203036 003 Jan 15, 2016 Mar CTEC

TABLET;ORAL					
IRBESARTAN AND HYDROCHLOROTHIAZIDE					
	25MG;300MG	A203036	003	Jan 15, 2016	Jan NEWA
>A> AB	MYLAN PHARMS INC 25MG;300MG	A077969	003	Jul 20, 2016	Jul NEWA
<u>HYDROCHLOROTHIAZIDE; LISINOPRIL</u>					
TABLET;ORAL					
ZESTORETIC					
AB	ALVOGEN MALTA 12.5MG;10MG	N019888	003	Nov 18, 1993	Jan CAHN
AB	+ 12.5MG;20MG	N019888	001	Sep 20, 1990	Jan CAHN
AB	+ 25MG;20MG	N019888	002	Jul 20, 1989	Jan CAHN
<u>HYDROCHLOROTHIAZIDE; SPIRONOLACTONE</u>					
TABLET;ORAL					
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE					
AB	SUN PHARM INDS 25MG;25MG	A089534	001	Jul 02, 1987	Mar CAHN
<u>HYDROCHLOROTHIAZIDE; VALSARTAN</u>					
TABLET;ORAL					
VALSARTAN AND HYDROCHLOROTHIAZIDE					
AB	PRINSTON INC 12.5MG;80MG	A206083	001	Feb 08, 2016	Jan NEWA
AB	12.5MG;160MG	A206083	002	Feb 08, 2016	Jan NEWA
AB	12.5MG;320MG	A206083	003	Feb 08, 2016	Jan NEWA
AB	25MG;160MG	A206083	004	Feb 08, 2016	Jan NEWA
AB	25MG;320MG	A206083	005	Feb 08, 2016	Jan NEWA
<u>HYDROCODONE BITARTRATE; IBUPROFEN</u>					
TABLET;ORAL					
HYDROCODONE BITARTRATE AND IBUPROFEN					
	@ ACTAVIS LABS FL INC 5MG;200MG	A077454	001	Jun 23, 2010	Jan DISC
AB	AUROLIFE PHARMA LLC 7.5MG;200MG	A204575	001	Jun 02, 2016	May NEWA
<u>HYDROCORTISONE</u>					
TABLET;ORAL					
HYDROCORTISONE					
AB	PHARMACEUTICS INTL 5MG	A207029	001	Apr 26, 2016	Apr NEWA
AB	10MG	A207029	002	Apr 26, 2016	Apr NEWA
AB	20MG	A207029	003	Apr 26, 2016	Apr NEWA
<u>HYDROCORTISONE VALERATE</u>					
CREAM;TOPICAL					
WESTCORT					
>A>	@ RANBAXY LABS LTD 0.2%	N017950	001		Jul CAHN
>D>	@ SUN PHARM INDS LTD 0.2%	N017950	001		Jul CAHN
	@ 0.2%	N017950	001		Jun CAHN
<u>HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>					
SUSPENSION/DROPS;OTIC					
PEDIOTIC					
	@ MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Jan DISC
<u>HYDROMORPHONE HYDROCHLORIDE</u>					
TABLET;ORAL					
HYDROMORPHONE HYDROCHLORIDE					
AB	AUROLIFE PHARMA LLC 2MG	A205814	001	May 13, 2016	May NEWA
AB	4MG	A205814	002	May 13, 2016	May NEWA
AB	8MG	A205814	003	May 13, 2016	May NEWA
TABLET, EXTENDED RELEASE;ORAL					
EXALGO					
AB	+ MALLINCKRODT INC 32MG	N021217	004	Aug 24, 2012	Jun CFTG
HYDROMORPHONE HYDROCHLORIDE					
AB	ACTAVIS LABS FL INC 32MG	A202144	004	Jun 30, 2016	Jun NEWA
AB	OSMOTICA 8MG	A205629	001	Jul 07, 2016	Jun NEWA
AB	12MG	A205629	002	Jul 07, 2016	Jun NEWA
AB	16MG	A205629	003	Jul 07, 2016	Jun NEWA
AB	32MG	A205629	004	Jul 07, 2016	Jun NEWA

HYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT@ SERB SA 2.5GM/VIAL (5GM/KIT)
+ 5GM/VIAL (5GM/KIT)N022041 002 Dec 15, 2006 Jan CAHN
N022041 001 Apr 08, 2011 Jan CAHNHYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE
AB WATSON LABS 200MG

A040133 001 Nov 30, 1995 Feb CMFD

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

>D> @ ACTAVIS LABS UT INC 125MG/ML
>D> @ 250MG/ML
>A> @ ALLERGAN SALES LLC 125MG/ML
>A> @ 250MG/ML
+ ASPEN GLOBAL INC 250MG/ML
SOLUTION; INTRAMUSCULAR
MAKENA
+ AMAG PHARMA USA 250MG/ML (250MG/ML)
+ 1250MG/5ML (250MG/ML)
+ LUMARA HEALTH INC 250MG/ML (250MG/ML)
>A> MAKENA PRESERVATIVE FREE
>A> + AMAG PHARMA USA 250MG/ML (250MG/ML)N017439 001 Jul CAHN
N017439 002 Jul CAHN
N017439 001 Jul CAHN
N017439 002 Jul CAHN
A200271 001 Aug 24, 2015 Jan CAHN
N021945 002 Feb 19, 2016 Jun CAHN
N021945 001 Feb 03, 2011 Jun CAHN
N021945 002 Feb 19, 2016 Feb NEWA
N021945 003 Jul 15, 2016 Jul NEWAHYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 10MG
@ 25MG
@ 50MG
AB ECI PHARMS LLC 10MG
AB 25MG
AB 50MG
AB ELITE LABS INC 10MG
AB 25MG
@ SUN PHARM INDS 10MG
@ 25MG
@ 50MG
@ 100MGA087869 001 Dec 20, 1982 Feb CAHN
A087870 001 Dec 20, 1982 Feb CAHN
A087871 001 Dec 20, 1982 Feb CAHN
A040804 001 Jun 30, 2008 May CAHN
A040804 002 Jun 30, 2008 May CAHN
A040804 003 Jun 30, 2008 May CAHN
A040604 002 Dec 28, 2004 Jun NEWA
A040604 003 Dec 28, 2004 Jun NEWA
A089381 001 May 19, 1986 Mar CAHN
A089382 001 May 19, 1986 Mar CAHN
A089383 001 May 19, 1986 Mar CAHN
A087862 001 Apr 18, 1983 Mar CAHNIBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

AP ACCORD HLTHCARE EQ 3MG BASE/3ML

A206058 001 Feb 05, 2016 Jan NEWA

TABLET; ORAL

IBANDRONATE SODIUM

AB AUROBINDO PHARMA LTD EQ 150MG BASE
AB SUN PHARM INDS EQ 150MG BASEA204502 001 Mar 11, 2016 Feb NEWA
A078996 001 Aug 15, 2012 Mar CAHNIBUPROFEN

TABLET; ORAL

IBUPROFEN

@ AUROLIFE PHARMA LLC 300MG
@ 400MG
@ 600MG
@ 800MG
>A> @ J AND J CONSUMER INC 400MG
>D> @ MCNEIL 400MG
AB STRIDES PHARMA 400MG
AB 600MG
AB 800MG
@ SUN PHARM INDS 400MG
@ 600MG
@ 800MGA070734 001 Jun 12, 1986 Feb CAHN
A070735 001 Jun 12, 1986 Feb CAHN
A070736 001 Jun 12, 1986 Feb CAHN
A071938 001 Jan 14, 1988 Mar CAHN
A070081 001 Jun 16, 1986 Jul CAHN
A070081 001 Jun 16, 1986 Jul CAHN
A078329 001 Feb 05, 2009 May CAHN
A078329 002 Feb 05, 2009 May CAHN
A078329 003 Feb 05, 2009 May CAHN
A070079 001 Jul 24, 1985 Mar CAHN
A070080 001 Jul 24, 1985 Mar CAHN
A071448 001 Feb 18, 1987 Mar CAHN

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS
IBUPROFEN LYSINE

AP		EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar NEWA
AP	+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar CFTG

IMATINIB MESYLATE

TABLET;ORAL
IMATINIB MESYLATE

>A>	AB	APOTEX INC	EQ 100MG BASE	A079179	001	Aug 05, 2016	Jul NEWA
>A>	AB		EQ 400MG BASE	A079179	002	Aug 05, 2016	Jul NEWA
>A>	AB	TEVA PHARMS USA	EQ 100MG BASE	A204285	001	Aug 04, 2016	Jul NEWA
>A>	AB		EQ 400MG BASE	A204285	002	Aug 04, 2016	Jul NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

AB		SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar CAHN
AB			25MG	A081049	001	Jun 05, 1990	Mar CAHN
AB			50MG	A081050	001	Jun 05, 1990	Mar CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL
IMIPRAMINE PAMOATE

AB	+	ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb CRLD
		TOFRANIL-PM					
		@ MALLINCKRODT INC	EQ 75MG HCL	N017090	001		Feb DISC
		@	EQ 100MG HCL	N017090	004		Feb DISC
		@	EQ 125MG HCL	N017090	003		Feb DISC
		@	EQ 150MG HCL	N017090	002		Feb DISC

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION
INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN
---	---------------------	------------	---------	-----	--------------	----------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar CMS1
---	---------------	---------	---------	-----	--------------	----------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION
OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
---	---------------------	---------	---------	-----	--------------	----------

INDOCYANINE GREEN

INJECTABLE;INJECTION
INDOCYANINE GREEN

AP		DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan CAHN
----	--	------------------	-----------	---------	-----	--------------	----------

INDOMETHACIN SODIUM

INJECTABLE;INJECTION
INDOMETHACIN SODIUM

AP		HOSPIRA INC	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Apr NEWA
----	--	-------------	------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN

@	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb DISC
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS
HUMULIN R

+	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan CAIN
+	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan NEWA

INSULIN RECOMBINANT HUMANPOWDER; INHALATION
AFREZZA

	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar CAHN
+		8 UNITS/INH	N022472	002	Jun 27, 2014	Mar CAHN
		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar CAHN

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

@ GUERBET	62%	N020316	001	Dec 21, 1995	Jun DISC
-----------	-----	---------	-----	--------------	----------

OXILAN-350

@ GUERBET	73%	N020316	002	Dec 21, 1995	Jun DISC
-----------	-----	---------	-----	--------------	----------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D> AN	+	MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Jul DISC
>A>		@	0.02%	A074755	001	Jan 10, 1997	Jul DISC
>D> AN		RTEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul CRLD
>A> AN	+		0.02%	A075693	001	Jan 26, 2001	Jul CRLD

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB	HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May NEWA
AB		150MG	A206194	002	Jun 14, 2016	May NEWA
AB		300MG	A206194	003	Jun 14, 2016	May NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

AP	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr CTEC
		IRINOTECAN HYDROCHLORIDE					
AP		EUROHLTH INTL SARL	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun CAHN
AP			100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun CAHN
AP		QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr NEWA
AP			100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr NEWA
AP			300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr NEWA
AP		SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan CAHN
AP			100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan CAHN

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP	+	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr CAHN
----	---	--------------------	-----------------	---------	-----	--	----------

ISONIAZID

TABLET; ORAL

ISONIAZID

AA		MIKART	100MG	A040090	001	Jun 26, 1997	Jun CMFD
AA			300MG	A040090	002	Jun 26, 1997	Jun CMFD
		@ SUN PHARM INDS	100MG	A080136	001		Mar CAHN
		@	300MG	A083633	001		Mar CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

>D>	+	AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Jul CAHN
	+		40MG	N019790	001	Sep 02, 1988	Mar CAHN
>A>	+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Jul CAHN

TABLET; ORAL

ISOSORBIDE DINITRATE

@ SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar CAHN
@	10MG	A086169	001	Sep 19, 1986	Jun CAHN
@	20MG	A086167	001	Sep 19, 1986	Jun CAHN
@	30MG	A087564	001	Sep 18, 1986	Jun CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun CAHN
@	5MG	A086168	001	Sep 18, 1986	Jun CAHN

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

@ 10MG

A087545 001 Sep 18, 1986 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

@ COREPHARMA 40MG

A040723 001 Mar 17, 2008 Mar DISC

+ SUN PHARM INDS INC 40MG

A040009 001 Dec 30, 1998 Mar CTEC

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

AP AUROBINDO PHARMA LTD 1%

A206831 001 Feb 02, 2016 Jan NEWA

AP + MYLAN INSTITUTIONAL 1%

A090874 001 Jul 20, 2010 Jan CTEC

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA

>D> BX RANBAXY 10MG

N021951 001 May 25, 2012 Jul CAHN

>D> BX 20MG

N021951 002 May 25, 2012 Jul CAHN

>D> 25MG

N021951 005 Aug 15, 2014 Jul CAHN

>D> BX 30MG

N021951 003 May 25, 2012 Jul CAHN

>D> 35MG

N021951 006 Aug 15, 2014 Jul CAHN

>D> BX + 40MG

N021951 004 May 25, 2012 Jul CAHN

>A> BX RANBAXY LABS LTD 10MG

N021951 001 May 25, 2012 Jul CAHN

>A> BX 20MG

N021951 002 May 25, 2012 Jul CAHN

>A> 25MG

N021951 005 Aug 15, 2014 Jul CAHN

>A> BX 30MG

N021951 003 May 25, 2012 Jul CAHN

>A> 35MG

N021951 006 Aug 15, 2014 Jul CAHN

>A> BX + 40MG

N021951 004 May 25, 2012 Jul CAHN

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

AB ACCORD HLTHCARE 100MG

A205991 001 May 26, 2016 May NEWA

SOLUTION;ORAL

ITRACONAZOLE

@ AMNEAL PHARMS 10MG/ML

A205573 001 Oct 30, 2015 Apr DISC

SPORANOX

+ JANSSEN PHARMS 10MG/ML

N020657 001 Feb 21, 1997 Apr CTEC

IVERMECTIN

LOTION;TOPICAL

SKLICE

+ ARBOR PHARMS LLC 0.5%

N202736 001 Feb 07, 2012 May CAHN

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE

@ SUN PHARM INDS 200MG

A075314 001 Jun 15, 1999 Jan CAHN

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

@ AUROLIFE PHARMA LLC 50MG

A074024 001 Dec 29, 1995 Feb CAHN

@ 75MG

A074024 002 Dec 29, 1995 Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

@ EUROHLTH INTL SARL 15MG/ML

A075222 001 Apr 26, 1999 Apr CAHN

@ 30MG/ML

A075222 002 Apr 26, 1999 Apr CAHN

@ 30MG/ML

A075228 001 Apr 26, 1999 May CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP SAGENT STRIDES 5MG/ML

A079134 001 Feb 03, 2010 Jan CTNA

TRANDATE

@ SEBELA IRELAND LTD 5MG/ML

N019425 001 Dec 31, 1985 Jan CAHN

TABLET;ORAL					
LABETALOL HYDROCHLORIDE					
AB	NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999 Jan CAHN
AB		200MG	A075215	002	Jul 29, 1999 Jan CAHN
AB		300MG	A075215	003	Jul 29, 1999 Jan CAHN
<u>LACOSAMIDE</u>					
SOLUTION;ORAL					
LACOSAMIDE					
AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016 Apr NEWA
VIMPAT					
AA	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010 Apr CFTG
TABLET;ORAL					
LACOSAMIDE					
AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016 Apr NEWA
AB		100MG	A204855	002	Apr 28, 2016 Apr NEWA
AB		150MG	A204855	003	Apr 28, 2016 Apr NEWA
AB		200MG	A204855	004	Apr 28, 2016 Apr NEWA
AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016 Apr NEWA
AB		100MG	A204974	002	Apr 28, 2016 Apr NEWA
AB		150MG	A204974	003	Apr 28, 2016 Apr NEWA
AB		200MG	A204974	004	Apr 28, 2016 Apr NEWA
AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016 Apr NEWA
AB		100MG	A204994	002	Apr 28, 2016 Apr NEWA
AB		150MG	A204994	003	Apr 28, 2016 Apr NEWA
AB		200MG	A204994	004	Apr 28, 2016 Apr NEWA
AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016 Apr NEWA
AB		100MG	A204921	002	Apr 28, 2016 Apr NEWA
AB		150MG	A204921	003	Apr 28, 2016 Apr NEWA
AB		200MG	A204921	004	Apr 28, 2016 Apr NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016 Apr NEWA
AB		100MG	A205026	002	Apr 28, 2016 Apr NEWA
AB		150MG	A205026	003	Apr 28, 2016 Apr NEWA
AB		200MG	A205026	004	Apr 28, 2016 Apr NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016 Apr NEWA
AB		100MG	A205031	002	Apr 28, 2016 Apr NEWA
AB		150MG	A205031	003	Apr 28, 2016 Apr NEWA
AB		200MG	A205031	004	Apr 28, 2016 Apr NEWA
VIMPAT					
AB	UCB INC	50MG	N022253	001	Oct 28, 2008 Apr CFTG
AB		100MG	N022253	002	Oct 28, 2008 Apr CFTG
AB		150MG	N022253	003	Oct 28, 2008 Apr CFTG
AB	+	200MG	N022253	004	Oct 28, 2008 Apr CFTG
<u>LAMIVUDINE</u>					
TABLET;ORAL					
LAMIVUDINE					
AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016 Feb NEWA
AB		300MG	A204528	002	Mar 04, 2016 Feb NEWA
<u>LAMOTRIGINE</u>					
TABLET;ORAL					
LAMOTRIGINE					
AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009 Jun CAHN
AB		100MG	A079132	002	Jan 27, 2009 Jun CAHN
AB		150MG	A079132	003	Jan 27, 2009 Jun CAHN
AB		200MG	A079132	004	Jan 27, 2009 Jun CAHN
TABLET, EXTENDED RELEASE;ORAL					
LAMICTAL XR					
AB	+ GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009 Jan CRLD
TABLET, ORALLY DISINTEGRATING;ORAL					
LAMOTRIGINE					
AB	SCIEGEN PHARMS INC	25MG	A206382	001	Jun 17, 2016 Jun NEWA
AB		50MG	A206382	002	Jun 17, 2016 Jun NEWA
AB		100MG	A206382	003	Jun 17, 2016 Jun NEWA
AB		200MG	A206382	004	Jun 17, 2016 Jun NEWA

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

>A>	AB	ANCHEN PHARMS	15MG	A203203	001	Jul 25, 2016	Jul NEWA
>A>	AB		30MG	A203203	002	Jul 25, 2016	Jul NEWA

LATANOPROSTSOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT	FDC LTD	0.005%	A202442	001	Apr 22, 2016	Apr NEWA
----	---------	--------	---------	-----	--------------	----------

LETROZOLETABLET;ORAL
LETROZOLE

AB	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016	May NEWA
AB	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan CAHN

LEUCOVORIN CALCIUM

TABLET;ORAL

LEUCOVORIN CALCIUM

@	IDT AUSTRALIA LTD	EQ 15MG BASE	A075327	001	Mar 24, 1999	May CAHN
	ROXANE	EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun CTEC

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar NEWA
AN		EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar NEWA
AN		EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan NEWA
AP	JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb NEWA
AB		750MG	A204511	002	Feb 23, 2016	Feb NEWA
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May NEWA
AB		750MG	A202095	001	Jun 06, 2016	May NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar CAHN
AB		750MG	A091285	002	Sep 12, 2011	Mar CAHN

TABLET, FOR SUSPENSION;ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb CDFR
		500MG	N207958	002	Jul 31, 2015	Feb CDFR
		750MG	N207958	003	Jul 31, 2015	Feb CDFR
+		1GM	N207958	004	Jul 31, 2015	Mar CRLD
		1GM	N207958	004	Jul 31, 2015	Feb CDFR

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

>A>	AT	ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Jul CAHN
>D>	AT	FALCON PHARMS	0.25%	A074851	001	Oct 28, 1996	Jul CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun DISC
@		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun DISC
@		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+	RISEING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan CAHN
----	---	--------------------	------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUMPOWDER; IV (INFUSION)
FUSILEV

AP	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun CFTG
		LEVOLEUCOVORIN CALCIUM					
AP		EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jun NEWA

LEVONORGESTRELTABLET; ORAL
LEVONORGESTREL

	+	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Apr CRLD
	@	WATSON LABS	0.75MG	A078665	001	Aug 28, 2009	Apr DISC
		PLAN B					
	@	TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	Apr DISC

LEVOTHYROXINE SODIUMPOWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

AP		FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun NEWA
AP			500MCG/VIAL	A206163	002	Jun 29, 2016	Jun NEWA
AP	+	FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun CFTG
AP	+		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun CFTG

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOLET

>A>	@	LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Jul CAHN
>A>	@		0.05MG	N021137	002	Jun 06, 2003	Jul CAHN
>A>	@		0.075MG	N021137	003	Jun 06, 2003	Jul CAHN
>A>	@		0.088MG	N021137	004	Jun 06, 2003	Jul CAHN
>A>	@		0.1MG	N021137	005	Jun 06, 2003	Jul CAHN
>A>	@		0.112MG	N021137	006	Jun 06, 2003	Jul CAHN
>A>	@		0.125MG	N021137	007	Jun 06, 2003	Jul CAHN
>A>	@		0.137MG	N021137	008	Jun 06, 2003	Jul CAHN
>A>	@		0.15MG	N021137	009	Jun 06, 2003	Jul CAHN
>A>	@		0.175MG	N021137	010	Jun 06, 2003	Jul CAHN
>A>	@		0.2MG	N021137	011	Jun 06, 2003	Jul CAHN
>A>	@		0.3MG	N021137	012	Jun 06, 2003	Jul CAHN
>D>	@	VINTAGE	0.025MG	N021137	001	Jun 06, 2003	Jul CAHN
>D>	@		0.05MG	N021137	002	Jun 06, 2003	Jul CAHN
>D>	@		0.075MG	N021137	003	Jun 06, 2003	Jul CAHN
>D>	@		0.088MG	N021137	004	Jun 06, 2003	Jul CAHN
>D>	@		0.1MG	N021137	005	Jun 06, 2003	Jul CAHN
>D>	@		0.112MG	N021137	006	Jun 06, 2003	Jul CAHN
>D>	@		0.125MG	N021137	007	Jun 06, 2003	Jul CAHN
>D>	@		0.137MG	N021137	008	Jun 06, 2003	Jul CAHN
>D>	@		0.15MG	N021137	009	Jun 06, 2003	Jul CAHN
>D>	@		0.175MG	N021137	010	Jun 06, 2003	Jul CAHN
>D>	@		0.2MG	N021137	011	Jun 06, 2003	Jul CAHN
>D>	@		0.3MG	N021137	012	Jun 06, 2003	Jul CAHN

LEVOTHROID

@ LLOYD

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

AB1,	MYLAN	0.3MG	A076187	011	Jun 05, 2002	May CRLD
AB2,						
AB3,						
AB4	+					

LIDOCAINEOINTMENT; TOPICAL
LIDOCAINE

AT	SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun CAHN
AT	TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	400MG/100ML	N018388	002			Feb DISC
-----------	-------------	---------	-----	--	--	----------

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982		Feb DISC
-----------	-------------	---------	-----	--------------	--	----------

JELLY; TOPICAL

ANESTACON

@ BIONPHARMA INC	2%	A080429	001			Jan CAHN
------------------	----	---------	-----	--	--	----------

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	TELIGENT PHARMA INC	4%	A204494	001	Mar 12, 2014	May CAHN
----	---------------------	----	---------	-----	--------------	----------

>A> LIFITEGRAST

>A> SOLUTION/DROPS; OPHTHALMIC

>A> XIIDRA

>A>	+	SHIRE DEV LLC	5%	N208073	001	Jul 11, 2016	Jul NEWA
-----	---	---------------	----	---------	-----	--------------	----------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

JENTADUETO XR

BOEHRINGER INGELHEIM 2.5MG; 1GM

N208026	001	May 27, 2016	May NEWA
---------	-----	--------------	----------

+ 5MG; 1GM

N208026	002	May 27, 2016	May NEWA
---------	-----	--------------	----------

LINEZOLID

SOLUTION; IV (INFUSION)

LINEZOLID

>A>	AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	Jul NEWA
-----	----	----------------------	----------------------	---------	-----	--------------	----------

AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	Feb NEWA
----	--------------------	----------------------	---------	-----	--------------	----------

TABLET; ORAL

LINEZOLID

AB	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Jan NEWA
----	-------------	-------	---------	-----	--------------	----------

AB	GLENMARK PHARMS	600MG	A078987	001	Dec 21, 2015	Mar CAHN
----	-----------------	-------	---------	-----	--------------	----------

LIOETHYRONINE SODIUM

TABLET; ORAL

LIOETHYRONINE SODIUM

AB	MAYNE PHARMA INC	EQ 0.005MG BASE	A090097	001	Mar 20, 2009	Mar CAHN
----	------------------	-----------------	---------	-----	--------------	----------

AB		EQ 0.025MG BASE	A090097	002	Mar 20, 2009	Mar CAHN
----	--	-----------------	---------	-----	--------------	----------

AB		EQ 0.05MG BASE	A090097	003	Mar 20, 2009	Mar CAHN
----	--	----------------	---------	-----	--------------	----------

AB	SUN PHARM INDS LTD	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Apr NEWA
----	--------------------	-----------------	---------	-----	--------------	----------

AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Apr NEWA
----	--	-----------------	---------	-----	--------------	----------

AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Apr NEWA
----	--	----------------	---------	-----	--------------	----------

LISINOPRIL

>A> SOLUTION; ORAL

>A> QBRELIS

>A>	+	SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016	Jul NEWA
-----	---	-------------------	--------	---------	-----	--------------	----------

TABLET; ORAL

ZESTRIL

AB	ALVOGEN MALTA	2.5MG	N019777	005	Apr 29, 1993	Jan CAHN
----	---------------	-------	---------	-----	--------------	----------

AB		5MG	N019777	001	May 19, 1988	Jan CAHN
----	--	-----	---------	-----	--------------	----------

AB		10MG	N019777	002	May 19, 1988	Jan CAHN
----	--	------	---------	-----	--------------	----------

AB		20MG	N019777	003	May 19, 1988	Jan CAHN
----	--	------	---------	-----	--------------	----------

AB		30MG	N019777	006	Jan 20, 1999	Jan CAHN
----	--	------	---------	-----	--------------	----------

AB	+	40MG	N019777	004	May 19, 1988	Jan CAHN
----	---	------	---------	-----	--------------	----------

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Feb CAHN
----	-------------------	-------	---------	-----	--------------	----------

AB		300MG	A076243	001	Jun 27, 2002	Feb CAHN
----	--	-------	---------	-----	--------------	----------

AB		600MG	A078763	001	Apr 15, 2008	Feb CAHN
----	--	-------	---------	-----	--------------	----------

AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan CMFD
----	--------------	-------	---------	-----	--------------	----------

<u>LIXISENATIDE</u>									
>A>	SOLUTION;SUBCUTANEOUS								
>A>	ADLYXIN								
>A>	+	SANOFI-AVENTIS US	0.05MG/ML	N208471	001	Jul 27, 2016	Jul	NEWA	
>A>	+		0.1MG/ML	N208471	002	Jul 27, 2016	Jul	NEWA	
<u>LOMITAPIDE MESYLATE</u>									
CAPSULE;ORAL									
JUXTAPID									
		AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CRLD	
	+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CRLD	
<u>LOPERAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
IMODIUM									
		@ J AND J CONSUMER INC	2MG	N017694	001		Feb	DISC	
		LOPERAMIDE HYDROCHLORIDE							
AB	+	MYLAN	2MG	A072741	001	Sep 18, 1991	Feb	CRLD	
<u>LORAZEPAM</u>									
TABLET;ORAL									
LORAZEPAM									
>A>		@ FRONTIDA BIOPHARM	2MG	A072555	001	Mar 29, 1991	Jul	CAHN	
>D>		@ MUTUAL PHARM	2MG	A072555	001	Mar 29, 1991	Jul	CAHN	
<u>LORCASERIN HYDROCHLORIDE</u>									
>A>	TABLET, EXTENDED RELEASE;ORAL								
>A>	BELVIQ XR								
>A>	+	EISAI INC	20MG	N208524	001	Jul 15, 2016	Jul	NEWA	
<u>LOSARTAN POTASSIUM</u>									
TABLET;ORAL									
LOSARTAN POTASSIUM									
BX		HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr	CTEC	
BX			50MG	A203835	002	Aug 12, 2015	Apr	CTEC	
BX			100MG	A203835	003	Aug 12, 2015	Apr	CTEC	
BX		LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Apr	CTEC	
BX			50MG	A078232	002	Oct 06, 2010	Apr	CTEC	
BX			100MG	A078232	003	Oct 06, 2010	Apr	CTEC	
<u>LOVASTATIN</u>									
TABLET;ORAL									
LOVASTATIN									
AB		SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar	CAHN	
AB			20MG	A077520	002	Apr 14, 2006	Mar	CAHN	
AB			40MG	A077520	003	Apr 14, 2006	Mar	CAHN	
<u>LOXAPINE</u>									
POWDER;INHALATION									
ADASUVE									
	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb	CAHN	
<u>MAGNESIUM SULFATE</u>									
INJECTABLE;INJECTION									
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER									
AP		FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb	NEWA	
AP	+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb	CFTG	
AP		HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb	NEWA	
MAGNESIUM SULFATE IN PLASTIC CONTAINER									
AP		FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb	NEWA	
AP			4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb	NEWA	
AP			2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar	NEWA	
AP			20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar	NEWA	
AP			40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar	NEWA	
AP		HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar	CFTG	
AP	+		4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb	CFTG	
AP	+		4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb	CFTG	
AP			20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar	CFTG	
AP			40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar	CFTG	

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@	RISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan CAHN
@		25MG	A040179	002	Jan 30, 1997	Jan CAHN

TABLET, CHEWABLE;ORAL

ANTIVERT

@	CASPER PHARMA LLC	25MG	N010721	005		Jun DISC
---	-------------------	------	---------	-----	--	----------

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

@	HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010	May CAHN
---	-------------------	-------	---------	-----	--------------	----------

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	Feb CAHN
----	---	-----------------	----------	---------	-----	--------------	----------

MELOXICAM

TABLET;ORAL

MELOXICAM

>A>	@	FRONTIDA BIOPHARM	7.5MG	A077935	001	Jul 19, 2006	Jul CAHN
>A>	@		15MG	A077935	002	Jul 19, 2006	Jul CAHN
>D>	@	SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jul CAHN
	@		7.5MG	A077935	001	Jul 19, 2006	Jan CAHN
>D>	@		15MG	A077935	002	Jul 19, 2006	Jul CAHN
	@		15MG	A077935	002	Jul 19, 2006	Jan CAHN

MELPHALAN

TABLET;ORAL

ALKERAN

+	APOTEX INC	2MG	N014691	002		Jan CAHN
---	------------	-----	---------	-----	--	----------

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan CAHN
----	---	------------	-------------------	---------	-----	--------------	----------

POWDER; IV (INFUSION)

EVOMELA

		SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar NEWA
--	--	-----------------	-------------------	---------	-----	--------------	----------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

@	US PHARM HOLDINGS	25MG/ML	N005010	007		Jan CAHN
@		50MG/ML	N005010	002		Jan CAHN
@		75MG/ML	N005010	009		Jan CAHN
@		100MG/ML	N005010	003		Jan CAHN

SYRUP;ORAL

DEMEROL

@	US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan CAHN
---	-------------------	----------	---------	-----	--	----------

TABLET;ORAL

DEMEROL

AA	+	US PHARM HOLDINGS	50MG	N005010	001		Jan CAHN
AA	+		100MG	N005010	004		Jan CAHN

MEPERIDINE HYDROCHLORIDE

@	SUN PHARM INDS	50MG	A080448	001		Mar CAHN
@		100MG	A080448	002		Mar CAHN

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

@	AUROLIFE PHARMA LLC	400MG	A080655	001		Feb CAHN
@	SUN PHARM INDS	200MG	A080699	001		Mar CAHN
@		400MG	A080699	002		Mar CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB	DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Apr CAHN
	PURINETHOL					
	@ STASON PHARMS	50MG	N009053	002		Jan CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar NEWA
AP		1GM/VIAL	A205883	002	Apr 12, 2016	Mar NEWA
AP	GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016	May NEWA
AP		1GM/VIAL	A206141	002	Jun 08, 2016	May NEWA
AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	May NEWA
AP		1GM/VIAL	A204139	002	Jun 09, 2016	May NEWA
AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+	APIL	400MG	N204412	001	Feb 01, 2013	Jan CAHN
	TABLET, DELAYED RELEASE; ORAL					
	ASACOL					
	@ APIL	400MG	N019651	001	Jan 31, 1992	Jan CAHN
	ASACOL HD					
+	APIL	800MG	N021830	001	May 29, 2008	Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	CSPC OUYI PHARM CO	500MG	A205096	001	Jul 11, 2016	Jun NEWA
AB		850MG	A205096	002	Jul 11, 2016	Jun NEWA
AB		1GM	A205096	003	Jul 11, 2016	Jun NEWA
AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar CAHN
AB		850MG	A076038	002	Feb 21, 2002	Mar CAHN
AB		1GM	A076038	003	Feb 21, 2002	Mar CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	GLUMETZA					
AB3	SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan CTEC
AB3	+	1GM	N021748	002	Jun 03, 2005	Jan CTEC
	METFORMIN HYDROCHLORIDE					
>A> AB3	ACTAVIS LABS FL INC	500MG	A203755	001	Aug 01, 2016	Jul NEWA
>A> AB3		1GM	A203755	002	Aug 01, 2016	Jul NEWA
	@ IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar DISC
	@	750MG	A076985	001	Sep 13, 2005	Mar DISC
AB1	MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr NEWA
AB		750MG	A090295	002	Apr 29, 2016	Apr NEWA
	@ SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar CAHN
>A> AB3	SUN PHARMA GLOBAL	500MG	A202917	001	Aug 01, 2016	Jul NEWA
>A> AB3		1GM	A202917	002	Aug 01, 2016	Jul NEWA

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

AB	+	US PHARM HOLDINGS	1GM	N017681	001	Jan CAHN
	METHENAMINE HIPPURATE					
AB	AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

>D> AB	CEDAR PHARMS	5MG	A040547	001	Feb 18, 2005	Jul CAHN
>D> AB		10MG	A040547	002	Feb 18, 2005	Jul CAHN
>D>	@	20MG	A040547	004	Feb 18, 2005	Jul CAHN
>A> AB	ECI PHARMS LLC	5MG	A040547	001	Feb 18, 2005	Jul CAHN
>A> AB		10MG	A040547	002	Feb 18, 2005	Jul CAHN
>A>	@	20MG	A040547	004	Feb 18, 2005	Jul CAHN
AB	RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan CAHN
AB		10MG	A202068	002	Mar 07, 2012	Jan CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP		AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May NEWA
----	--	----------------------	---------------------	---------	-----	--------------	----------

TABLET; ORAL

METHOCARBAMOL

@ SANDOZ

500MG

A084616

001

Feb DISC

@

750MG

A084615

001

Feb DISC

@ SUN PHARM INDS

500MG

A084488

001

Mar CAHN

@

750MG

A084486

001

Mar CAHN

ROBAXIN

>D>	AA	+	AUXILIUM PHARMS INC	500MG	N011011	004		Jul CAHN
-----	----	---	---------------------	-------	---------	-----	--	----------

	AA	+		500MG	N011011	004		Mar CAHN
--	----	---	--	-------	---------	-----	--	----------

>A>	AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004		Jul CAHN
-----	----	---	---------------------	-------	---------	-----	--	----------

ROBAXIN-750

>D>	AA	+	AUXILIUM PHARMS INC	750MG	N011011	006		Jul CAHN
-----	----	---	---------------------	-------	---------	-----	--	----------

	AA	+		750MG	N011011	006		Mar CAHN
--	----	---	--	-------	---------	-----	--	----------

>A>	AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Jul CAHN
-----	----	---	---------------------	-------	---------	-----	--	----------

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

@ PAR STERILE PRODUCTS 200MG/VIAL

N011559	004	Dec 21, 2012	Jun DISC
---------	-----	--------------	----------

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

ANTARES PHARMA INC

12.5MG/0.4ML (12.5MG/0.4ML)

N204824	006	Mar 24, 2016	May NEWA
---------	-----	--------------	----------

17.5MG/0.4ML (17.5MG/0.4ML)

N204824	007	Mar 24, 2016	May NEWA
---------	-----	--------------	----------

22.5MG/0.4ML (22.5MG/0.4ML)

N204824	008	Mar 24, 2016	May NEWA
---------	-----	--------------	----------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP		SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan CAHN
----	--	------------	------------------------------------	---------	-----	--------------	----------

AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan CAHN
----	--	--	--------------------------------------	---------	-----	--------------	----------

AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan CAHN
----	--	--	------------------------------------	---------	-----	--------------	----------

METHOXSALEN

INJECTABLE; INJECTION

UVADEX

+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr CAHN
---	-------------------	-----------	---------	-----	--------------	----------

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@ SUN PHARM INDS

125MG

A070073	001	Oct 09, 1986	Mar CAHN
---------	-----	--------------	----------

@

250MG

A070060	001	Oct 09, 1986	Mar CAHN
---------	-----	--------------	----------

@

500MG

A070074	001	Oct 09, 1986	Mar CAHN
---------	-----	--------------	----------

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr NEWA
---	----------------	--------------------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

@ EDISON THERAPS LLC

0.2MG

N006035	003		Jan DISC
---------	-----	--	----------

METHYLERGONOVINE MALEATE

+	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan CRLD
---	----------------	-------	---------	-----	--------------	----------

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

RELISTOR

>D>		SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Jul CRLD
-----	--	--------------	-----------------------	---------	-----	--------------	----------

>A>	+		8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Jul CRLD
-----	---	--	-----------------------	---------	-----	--------------	----------

>A>	TABLET;ORAL						
>A>	RELISTOR						
>A>	+ SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016	Jul	NEWA
<u>METHYLPHENIDATE HYDROCHLORIDE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
>A>	AB2 COREPHARMA	10MG	A205105	001	Jul 28, 2016	Jul	NEWA
>A>	AB2	20MG	A205105	002	Jul 28, 2016	Jul	NEWA
>A>	AB2	30MG	A205105	003	Jul 28, 2016	Jul	NEWA
>A>	AB2	40MG	A205105	004	Jul 28, 2016	Jul	NEWA
>A>	AB2	50MG	A205105	005	Jul 28, 2016	Jul	NEWA
>A>	AB2	60MG	A205105	006	Jul 28, 2016	Jul	NEWA
	AB1 WATSON LABS INC	60MG	A078458	004	Jun 23, 2016	Jun	NEWA
	RITALIN LA						
	AB1 + NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun	CFTG
	SOLUTION;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb	CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb	NEWA
AB		20MG	A204772	002	Feb 29, 2016	Feb	NEWA
<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>							
	INJECTABLE;INJECTION						
	METHYLPREDNISOLONE SODIUM SUCCINATE						
AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb	NEWA
AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb	NEWA
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan	CAHN
AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan	CAHN
<u>METHYLTESTOSTERONE</u>							
	TABLET;ORAL						
	ANDROID 10						
	@ VALEANT PHARM INTL	10MG	A086450	001		Apr	DISC
	METHYLTESTOSTERONE						
	@ IMPAX LABS	25MG	A084310	001		Mar	DISC
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>							
	TABLET;ORAL						
	METOCLOPRAMIDE HYDROCHLORIDE						
AB	SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar	CAHN
	@	EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar	CAHN
<u>METOPROLOL TARTRATE</u>							
	INJECTABLE;INJECTION						
	METOPROLOL TARTRATE						
AP	EUROHLTH INTL SARL	1MG/ML	A076495	001	Jul 07, 2003	Apr	CAHN
	TABLET;ORAL						
	METOPROLOL TARTRATE						
	@ SANDOZ	50MG	A073288	001	Mar 25, 1994	May	DISC
	@	100MG	A073289	001	Mar 25, 1994	May	DISC
AB	SUN PHARM INDS	25MG	A073654	002	Jul 15, 2009	Mar	CAHN
AB		100MG	A073654	001	Dec 21, 1993	Mar	CAHN
<u>METRONIDAZOLE</u>							
	GEL;VAGINAL						
	NUVESSA						
	+ ALLERGAN SALES LLC	1.3%	N205223	001	Mar 24, 2014	Apr	CAHN
	TABLET;ORAL						
	METRONIDAZOLE						
AB	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	May	NEWA
AB		500MG	A207309	002	May 16, 2016	May	NEWA
AB	NOSTRUM LABS INC	250MG	A070772	001	Jul 16, 1986	Jan	CAHN
AB		500MG	A070773	001	Jul 16, 1986	Jan	CAHN
AB	STRIDES PHARMA	250MG	A208162	001	May 25, 2016	May	NEWA
AB		500MG	A208162	002	May 25, 2016	May	NEWA

TABLET;ORAL							
METRONIDAZOLE							
AB	VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	May	CMFD
AB		500MG	A070039	001	Jan 29, 1985	May	CMFD
<u>MICONAZOLE</u>							
TABLET;BUCCAL							
ORAVIG							
+	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan	CAHN
<u>MIDAZOLAM HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
MIDAZOLAM HYDROCHLORIDE							
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	May	CAHN
AP		EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr	CAHN
AP		EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	May	CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr	CAHN
<u>MIGLITOL</u>							
TABLET;ORAL							
GLYSET							
AB	+ PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb	CRLD
AB		100MG	N020682	003	Dec 18, 1996	Feb	CRLD
<u>MILNACIPRAN HYDROCHLORIDE</u>							
TABLET;ORAL							
MILNACIPRAN HYDROCHLORIDE							
AB	AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Apr	NEWA
AB		25MG	A205081	002	Apr 22, 2016	Apr	NEWA
AB		50MG	A205081	003	Apr 22, 2016	Apr	NEWA
AB		100MG	A205081	004	Apr 22, 2016	Apr	NEWA
	@ LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan	DISC
		12.5MG	A205071	001	Jan 27, 2016	Jan	NEWA
	@	25MG	A205071	002	Jan 27, 2016	Jan	DISC
		25MG	A205071	002	Jan 27, 2016	Jan	NEWA
	@	50MG	A205071	003	Jan 27, 2016	Jan	DISC
		50MG	A205071	003	Jan 27, 2016	Jan	NEWA
	@	100MG	A205071	004	Jan 27, 2016	Jan	DISC
		100MG	A205071	004	Jan 27, 2016	Jan	NEWA
SAVELLA							
AB	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr	CFTG
AB		25MG	N022256	002	Jan 14, 2009	Apr	CFTG
AB	+	50MG	N022256	003	Jan 14, 2009	Apr	CFTG
AB		100MG	N022256	004	Jan 14, 2009	Apr	CFTG
<u>MILRINONE LACTATE</u>							
INJECTABLE;INJECTION							
MILRINONE LACTATE							
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Apr	CAHN
MILRINONE LACTATE IN DEXTROSE 5%							
AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar	CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar	CAHN
AP	EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun	CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun	CAHN
<u>MINOCYCLINE HYDROCHLORIDE</u>							
TABLET;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan	NEWA
AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan	NEWA
AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan	NEWA
TABLET, EXTENDED RELEASE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May	NEWA
AB		EQ 105MG BASE	A202261	007	Jun 13, 2016	May	NEWA
	@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar	DISC
	@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar	DISC
	@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar	DISC

MINOXIDILTABLET;ORAL
MINOXIDIL

AB	SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar CAHN
----	----------------	------	---------	-----	--------------	----------

MIPOMERSEN SODIUMSOLUTION;SUBCUTANEOUS
KYNAMRO

+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun CAHN
---	--------------------	---------------------	---------	-----	--------------	----------

MIRTAZAPINETABLET;ORAL
MIRTAZAPINE

@	ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan DISC
@		30MG	A076336	002	Jun 20, 2003	Jan DISC
@		45MG	A076336	003	Jun 20, 2003	Jan DISC

MITOMYCININJECTABLE;INJECTION
MITOMYCIN

AP	EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MODAFINILTABLET;ORAL
MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOMETASONE FUROATESPRAY, METERED;NASAL
MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA	
AB	+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB			20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB			30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB			40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB			50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB			60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB			70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB			80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+		100MG	N020616	003	Jul 03, 1996	Feb CTEC
AB	+		200MG	N020616	007	Feb 27, 2007	Feb CTEC
AB	+	ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB			20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB			30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB			40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB			50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB			60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB			70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB			80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+		100MG	N020616	003	Jul 03, 1996	Apr CAHN
AB			130MG	N020616	011	Jul 09, 2012	Apr CAHN
AB			150MG	N020616	012	Jul 09, 2012	Apr CAHN
AB	+		200MG	N020616	007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB		30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB		50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB		60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB		80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC

CAPSULE, EXTENDED RELEASE;ORAL							
MORPHINE SULFATE							
AB		30MG	A200812	002	Nov 10, 2011	Feb	CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb	CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb	CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb	CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb	CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb	CTEC
AB		30MG	A202718	002	Dec 29, 2014	Feb	CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb	CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb	CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb	CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb	CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb	CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb	CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb	CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb	CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb	CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb	CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb	CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb	CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb	CTEC
SOLUTION;ORAL							
MORPHINE SULFATE							
AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar	CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar	CAHN
AA	RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun	NEWA
AA	TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May	NEWA
TABLET, EXTENDED RELEASE;ORAL							
MORPHINE SULFATE							
AB	COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun	NEWA
AB		30MG	A091357	002	Jun 23, 2016	Jun	NEWA
AB		60MG	A091357	003	Jun 23, 2016	Jun	NEWA
AB		100MG	A091357	004	Jun 23, 2016	Jun	NEWA
AB		200MG	A091357	005	Jun 23, 2016	Jun	NEWA
<u>MOXIFLOXACIN HYDROCHLORIDE</u>							
TABLET;ORAL							
MOXIFLOXACIN HYDROCHLORIDE							
AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan	NEWA
<u>MYCOPHENOLATE MOFETIL</u>							
CAPSULE;ORAL							
MYCOPHENOLATE MOFETIL							
AB	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Jun	CAHN
TABLET;ORAL							
MYCOPHENOLATE MOFETIL							
AB	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Jun	CAHN
<u>NALIDIXIC ACID</u>							
TABLET;ORAL							
NALIDIXIC ACID							
	@ SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988	Mar	CAHN
	@	500MG	A070271	001	Jun 29, 1988	Jun	CAHN
	@	1GM	A070272	001	Jun 29, 1988	Mar	CAHN
<u>NALOXONE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
NALOXONE HYDROCHLORIDE							
AP	MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016	Jun	NEWA
<u>NAPROXEN</u>							
SUSPENSION;ORAL							
NAPROSYN							
AB	+ ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun	CAHN
TABLET;ORAL							
NAPROSYN							
AB	ATNAHS PHARMA US	250MG	N017581	002		Feb	CAHN
AB		375MG	N017581	003		Feb	CAHN
AB	+	500MG	N017581	004	Apr 15, 1982	Feb	CAHN
NAPROXEN							
	@ SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb	DISC

TABLET;ORAL									
NAPROXEN									
	@	375MG		A074140	002	Dec 21, 1993		Feb	DISC
	@	500MG		A074140	003	Dec 21, 1993		Feb	DISC
TABLET, DELAYED RELEASE;ORAL									
EC-NAPROSYN									
AB	+ ATNAHS PHARMA US	375MG		N020067	002	Oct 14, 1994		Feb	CAHN
AB	+ NAPROXEN	500MG		N020067	003	Oct 14, 1994		Feb	CAHN
	@ SANDOZ	375MG		A075061	001	Feb 18, 1998		Feb	DISC
	@	500MG		A075061	002	Feb 18, 1998		Feb	DISC
<u>NAPROXEN SODIUM</u>									
TABLET;ORAL									
ANAPROX									
AB	ATNAHS PHARMA US	EQ 250MG BASE		N018164	001			Feb	CAHN
	ANAPROX DS								
AB	+ ATNAHS PHARMA US	EQ 500MG BASE		N018164	003	Sep 30, 1987		Feb	CAHN
<u>NATEGLINIDE</u>									
TABLET;ORAL									
NATEGLINIDE									
AB	ZYDUS PHARMS USA INC	60MG		A205248	001	Jul 06, 2016		Jun	NEWA
AB		120MG		A205248	002	Jul 06, 2016		Jun	NEWA
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN</u>									
TABLET;ORAL									
BYVALSON									
	FOREST LABS LLC	EQ 5MG BASE;80MG		N206302	001	Jun 03, 2016		Jun	NEWA
<u>NEFAZODONE HYDROCHLORIDE</u>									
TABLET;ORAL									
NEFAZODONE HYDROCHLORIDE									
	@ SUN PHARM INDS LTD	50MG		A076409	001	Sep 16, 2003		Feb	DISC
	@	100MG		A076409	002	Sep 16, 2003		Feb	DISC
	@	150MG		A076409	003	Sep 16, 2003		Feb	DISC
	@	200MG		A076409	004	Sep 16, 2003		Feb	DISC
	@	250MG		A076409	005	Sep 16, 2003		Feb	DISC
<u>NEOMYCIN SULFATE</u>									
TABLET;ORAL									
NEOMYCIN SULFATE									
AA	LANNETT HOLDINGS INC	500MG		A204435	001	Jun 10, 2016		May	NEWA
<u>NICARDIPINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
CARDENE									
	@ CHIESI USA INC	20MG		N019488	001	Dec 21, 1988		May	DISC
	@	30MG		N019488	002	Dec 21, 1988		May	DISC
NICARDIPINE HYDROCHLORIDE									
AB	+ MYLAN	30MG		A074642	002	Jul 18, 1996		May	CRLD
INJECTABLE;INJECTION									
NICARDIPINE HYDROCHLORIDE									
AP	EUROHLTH INTL SARL	25MG/10ML (2.5MG/ML)		A078714	001	Dec 28, 2009		Jun	CAHN
<u>NIFEDIPINE</u>									
CAPSULE;ORAL									
NIFEDIPINE									
>D>	@ VALIDUS PHARMS	10MG		A073250	001	Oct 08, 1991		Jul	CMFD
>A> AB		10MG		A073250	001	Oct 08, 1991		Jul	CMFD
	@	10MG		A073250	001	Oct 08, 1991		Mar	CAHN
>D>	@	20MG		A074045	001	Apr 30, 1992		Jul	CMFD
>A> AB		20MG		A074045	001	Apr 30, 1992		Jul	CMFD
	@	20MG		A074045	001	Apr 30, 1992		Mar	CAHN
TABLET, EXTENDED RELEASE;ORAL									
ADALAT CC									
AB1	ALVOGEN	30MG		N020198	001	Apr 21, 1993		Feb	CAHN
AB1	+	60MG		N020198	002	Apr 21, 1993		Feb	CAHN
AB1	+	90MG		N020198	003	Apr 21, 1993		Feb	CAHN
NIFEDIPINE									
AB2	OSMOTICA PHARM US	30MG		A077127	001	Nov 21, 2005		Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

AB2		60MG	A077127	002	Nov 21, 2005	Jun CAHN
AB1	VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000	Jan CAHN
AB1		60MG	A075269	002	Dec 04, 2000	Jan CAHN
AB1		90MG	A076070	001	Aug 16, 2002	Jan CAHN

NILUTAMIDE

TABLET;ORAL
NILANDRON

>D>	+	CONCORDIA PHARMS INC	150MG	N020169	002	Apr 30, 1999	Jul CFTG
>A>	AB	+	150MG	N020169	002	Apr 30, 1999	Jul CFTG
>A>		NILUTAMIDE					
>A>	AB	ANI PHARMS INC	150MG	A207631	001	Jul 15, 2016	Jul NEWA

NIMODIPINE

CAPSULE;ORAL
NIMODIPINE

AB	+	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan CAHN
----	---	----------------	------	---------	-----	--------------	----------

NITISINONE

CAPSULE;ORAL
ORFADIN

+	SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Jun NEWA
---	----------------	------	---------	-----	--------------	----------

SUSPENSION;ORAL
ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016	Apr NEWA
---	----------------	--------	---------	-----	--------------	----------

NITRIC OXIDE

GAS;INHALATION
INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan CAHN
---	-------------------	--------	---------	-----	--------------	----------

NITROFURANTOIN

SUSPENSION;ORAL
FURADANTIN

AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun CAHN
----	---	-------------------	----------	---------	-----	--	----------

NITROFURANTOIN

AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr NEWA
AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb NEWA
AB			50MG	A201722	002	Feb 16, 2016	Feb NEWA
AB			100MG	A201722	003	Feb 16, 2016	Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
MACROBID

AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan CAHN
----	---	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May CAHN
-----	--	----------------------	----------	---------	-----	--------------	----------

POWDER;SUBLINGUAL
GONITRO

+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun NEWA
---	--------------	--------------	---------	-----	--------------	----------

NIZATIDINE

SOLUTION;ORAL
NIZATIDINE

+	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Feb CRLD
---	---------------	---------	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

AP	CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Apr CAHN

NORETHINDRONE

TABLET; ORAL-28
NOR-QD

AB1	+	APIL	0.35MG	N017060	001	Jan CAHN
-----	---	------	--------	---------	-----	----------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
@	EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
@	EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
@	EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN
@ IDT AUSTRALIA LTD	EQ 10MG BASE	A074054	001	Dec 31, 1992	May CAHN
@	EQ 25MG BASE	A074054	002	Dec 31, 1992	May CAHN
@	EQ 50MG BASE	A074054	003	Dec 31, 1992	May CAHN
@	EQ 75MG BASE	A074054	004	Dec 31, 1992	May CAHN

NYSTATIN

TABLET; ORAL
NYSTATIN

AA	SUN PHARM INDS	500,000 UNITS	A062838	001	Dec 22, 1988	Mar CAHN
----	----------------	---------------	---------	-----	--------------	----------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
NYSTATIN TRIAMCINOLONE ACETONIDE

@ PHARMADERM	100,000 UNITS/GM; 0.1%	A062596	001	Oct 08, 1985	Mar CMS1
--------------	------------------------	---------	-----	--------------	----------

OINTMENT; TOPICAL
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM; 0.1%	A062733	001	Mar 06, 1987	May CMS1
AT	NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	GLENMARK PHARMS LTD	100,000 UNITS/GM; 0.1%	A208300	001	Jun 23, 2016	Jun NEWA

OBETICHOLIC ACID

TABLET; ORAL
OCALIVA

INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May NEWA
+	10MG	N207999	002	May 27, 2016	May NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE

@ WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan DISC
@	EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan DISC
OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan DISC
@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan DISC
@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan DISC
OCTREOTIDE ACETATE PRESERVATIVE FREE					
@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb CMS1
@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb CMS1
@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb CMS1

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

AT	ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Mar CAHN
----	---------	------	---------	-----	--------------	----------

SOLUTION/DROPS; OTIC
FLOXIN OTIC

@ DAIICHI	0.3%	N020799	001	Dec 16, 1997	Feb DISC
OFLOXACIN					

AT	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Mar CAHN	
AT	+	BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb CRLD

OLANZAPINETABLET; ORAL
OLANZAPINE

AB	INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb NEWA
AB		5MG	A203333	002	Mar 15, 2016	Feb NEWA
AB		7.5MG	A203333	003	Mar 15, 2016	Feb NEWA
AB		10MG	A203333	004	Mar 15, 2016	Feb NEWA
AB		15MG	A203333	005	Mar 15, 2016	Feb NEWA
AB		20MG	A203333	006	Mar 15, 2016	Feb NEWA
AB	QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan NEWA
AB		5MG	A204319	002	Jan 27, 2016	Jan NEWA
AB		7.5MG	A204319	003	Jan 27, 2016	Jan NEWA
AB		10MG	A204319	004	Jan 27, 2016	Jan NEWA
AB		15MG	A204319	005	Jan 27, 2016	Jan NEWA
AB		20MG	A204319	006	Jan 27, 2016	Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB	INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb NEWA
AB		10MG	A203456	002	Mar 16, 2016	Feb NEWA
AB		15MG	A203456	003	Mar 16, 2016	Feb NEWA
AB		20MG	A203456	004	Mar 16, 2016	Feb NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar CAHN
----	----------------------	--------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERSCAPSULE; ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1
----	---------------	--	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE; ORAL
OMTRYG

+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Mar CAIN
---	-------	--	---------	-----	--------------	----------

OMEPRAZOLECAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD
		PRILOSEC					
	@	ASTRAZENECA PHARMS	10MG	N019810	003	Oct 05, 1995	Jun DISC
	@		20MG	N019810	001	Sep 14, 1989	Jun DISC
	@		40MG	N019810	002	Jan 15, 1998	Jun DISC

OMEPRAZOLE; SODIUM BICARBONATECAPSULE; ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

>A>	AB	AJANTA PHARMA LTD	20MG; 1.1GM	A204228	001	Jul 15, 2016	Jul NEWA
>A>	AB		40MG; 1.1GM	A204228	002	Jul 15, 2016	Jul NEWA
>A>	AB	DR REDDYS LABS LTD	20MG; 1.1GM	A204068	001	Jul 15, 2016	Jul NEWA
>A>	AB		40MG; 1.1GM	A204068	002	Jul 15, 2016	Jul NEWA

FOR SUSPENSION; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>A>	AA	AJANTA PHARMA LTD	20MG/PACKET; 1.68GM/PACKET	A205545	001	Jul 27, 2016	Jul NEWA
>A>	AA		40MG/PACKET; 1.68GM/PACKET	A205545	002	Jul 27, 2016	Jul NEWA
		ZEGERID					
>D>		SANTARUS INC	20MG/PACKET; 1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul CTEC
>A>	AA		20MG/PACKET; 1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul CTEC
>D>	+		40MG/PACKET; 1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul CTEC
>A>	AA	+	40MG/PACKET; 1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul CTEC

ONDANSETRONFILM;ORAL
ZUPLENZ

	MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	Jun CAHN
+		8MG	N022524	002	Jul 02, 2010	Jun CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr CAHN
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
@		EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
@		EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

>A> OSELTAMIVIR PHOSPHATE

>A> AB	NATCO PHARMA LTD	EQ 30MG BASE	A202595	001	Aug 03, 2016	Jul NEWA
>A> AB		EQ 45MG BASE	A202595	002	Aug 03, 2016	Jul NEWA
>A> AB		EQ 75MG BASE	A202595	003	Aug 03, 2016	Jul NEWA

TAMIFLU

>D>	ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul CFTG
>A> AB		EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul CFTG
>D>		EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul CFTG
>A> AB		EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul CFTG
>D>	+	EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul CFTG
>A> AB	+	EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul CFTG

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

AP	@ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun DISC
	+	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May CFTG

OXALIPLATIN

AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May NEWA
AP		50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May NEWA
AP		100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
	+	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun CRLD
AP		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May NEWA
AP	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Jan CAHN
AP		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Jan CAHN

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

@	SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Mar CAHN
@		15MG	A071026	003	Aug 10, 1987	Mar CAHN
@		30MG	A071026	001	Aug 10, 1987	Mar CAHN

TABLET;ORAL

OXAZEPAM

>A>	@ FRONTIDA BIOPHARM	15MG	A070683	001	Jan 16, 1987	Jul CAHN
>D>	@ SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jul CAHN
	@	15MG	A070683	001	Jan 16, 1987	Jun CAHN

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

AB	ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jun CMFD
AB		300MG	A078005	002	Dec 11, 2007	Jun CMFD
AB		600MG	A078005	003	Dec 11, 2007	Jun CMFD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXICONAZOLE NITRATE

AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb NEWA
AB	OXISTAT					
AB	+ FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

AB	+ ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr CAHN
	GEL, METERED; TRANSDERMAL					
	GELNIQUE 3%					
	+ ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Apr CAHN

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

	+ ALLERGAN SALES LLC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Apr CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	OXYBUTYNIN CHLORIDE					
AB	ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb NEWA
AB		10MG	A207138	002	Feb 29, 2016	Feb NEWA
AB		15MG	A207138	003	Feb 29, 2016	Feb NEWA
AB	OSMOTICA PHARM US	5MG	A078503	001	Feb 04, 2009	Jun CAHN
AB		10MG	A078503	002	Feb 04, 2009	Jun CAHN
AB		15MG	A078503	003	Feb 04, 2009	Jun CAHN
AB	UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	May NEWA
AB		10MG	A206121	002	May 27, 2016	May NEWA
AB		15MG	A206121	003	May 27, 2016	May NEWA

OXYCODONE

CAPSULE, EXTENDED RELEASE; ORAL

XTAMPZA ER

	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016	May CAIN
		13.5MG	N208090	002	Apr 26, 2016	May CAIN
		18MG	N208090	003	Apr 26, 2016	May CAIN
		27MG	N208090	004	Apr 26, 2016	May CAIN
	+	36MG	N208090	005	Apr 26, 2016	May CAIN

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar NEWA
	CAPSULE, EXTENDED RELEASE; ORAL					
	XTAMPZA ER					
	COLLEGIUM PHARM INC	EQ 9MG BASE	N208090	001	Apr 26, 2016	Apr NEWA
		EQ 13.5MG BASE	N208090	002	Apr 26, 2016	Apr NEWA
		EQ 18MG BASE	N208090	003	Apr 26, 2016	Apr NEWA
		EQ 27MG BASE	N208090	004	Apr 26, 2016	Apr NEWA
	+	EQ 36MG BASE	N208090	005	Apr 26, 2016	May CRLD
		EQ 36MG BASE	N208090	005	Apr 26, 2016	Apr NEWA
	TABLET; ORAL					
	OXYCODONE HYDROCHLORIDE					
AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan CAHN
AB		15MG	A202116	002	Dec 30, 2011	Jan CAHN
AB		30MG	A202116	003	Dec 30, 2011	Jan CAHN
AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar NEWA
AB		10MG	A207119	002	Apr 12, 2016	Mar NEWA
AB		15MG	A207119	003	Apr 12, 2016	Mar NEWA
AB		20MG	A207119	004	Apr 12, 2016	Mar NEWA
AB		30MG	A207119	005	Apr 12, 2016	Mar NEWA

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED; NASAL

KOVANAZE

	+ ST RENATUS	0.1MG/SPRAY; 6MG/SPRAY	N208032	001	Jun 29, 2016	Jun NEWA
--	--------------	------------------------	---------	-----	--------------	----------

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr NEWA
AB		10MG	A204459	002	Apr 26, 2016	Apr NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan CAHN
----	------------	--------	---------	-----	--------------	----------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

	JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar CRLD
+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr NEWA

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar NEWA
		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan CAHN

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar NEWA
----	----------------------	-------------------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan NEWA
AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan NEWA

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN
AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb NEWA
AB		2MCG	A206710	002	Feb 24, 2016	Feb NEWA
AB		4MCG	A206710	003	Feb 24, 2016	Feb NEWA

SOLUTION; INTRAVENOUS

PARICALCITOL

AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb NEWA
AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb NEWA
AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	KREMERS URBAN PHARMS	EQ 12.5MG BASE	A204744	001	Jun 10, 2016	May NEWA
AB		EQ 25MG BASE	A204744	002	Jun 10, 2016	May NEWA
AB		EQ 37.5MG BASE	A204744	003	Jun 10, 2016	May NEWA

PENCICLOVIRCREAM;TOPICAL
DENA VIR

+	DENCO ASSET	1%	N020629	001	Sep 24, 1996	Apr	CAIN
---	-------------	----	---------	-----	--------------	-----	------

PENTETATE CALCIUM TRISODIUMSOLUTION;INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Apr	CMFD
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb	CAHN

PENTETATE ZINC TRISODIUMSOLUTION;INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Apr	CMFD
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb	CAHN

PENTOBARBITAL SODIUMINJECTABLE;INJECTION
NEMBUTAL SODIUM

AP	+	OAK PHARMS	50MG/ML	A083246	001		May	CTEC
AP		PENTOBARBITAL SODIUM						
AP		MYLAN INSTITUTIONAL	50MG/ML	A206404	001	May 23, 2016	May	NEWA

PENTOXIFYLLINETABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar	CRLD
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar	DISC
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar	DISC
		TRENTAL						
	@	US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan	CAHN

PERAMPANELSUSPENSION;ORAL
FYCOMPA

+	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016	Apr	NEWA
---	-----------	----------	---------	-----	--------------	-----	------

PERPHENAZINETABLET;ORAL
PERPHENAZINE

AB		WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan	CAHN
AB			4MG	A205973	002	Dec 17, 2015	Jan	CAHN
AB			8MG	A205973	003	Dec 17, 2015	Jan	CAHN
AB			16MG	A205973	004	Dec 17, 2015	Jan	CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIMTABLET;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@	ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105	001	Jun 26, 2001	Jan	CMS1
---	------	-------------------------------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDECAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA		SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar	CAHN
	@		37.5MG	A040527	001	Oct 23, 2003	Mar	CAHN

TABLET;ORAL
PHENTERMINE HYDROCHLORIDE

AA		INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan	CAHN
AA		SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
SUPRENZA

@	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun	DISC
@		30MG	N202088	002	Jun 13, 2011	Jun	DISC
@		37.5MG	N202088	003	Mar 27, 2012	Jun	DISC

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

@ SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985	Mar CAHN
------------------	-------	---------	-----	--------------	----------

TABLET; ORAL

PHENYLBUTAZONE

@ SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985	Mar CAHN
------------------	-------	---------	-----	--------------	----------

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

@ TELIGENT PHARMA INC	1MG/0.5ML	N012223	002		Jan CAHN
-----------------------	-----------	---------	-----	--	----------

@	10MG/ML	N012223	001		Jan CAHN
---	---------	---------	-----	--	----------

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+ ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Apr NEWA
---------------------	--------------	---------	-----	--------------	----------

PINDOLOL

TABLET; ORAL

PINDOLOL

@ IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May CAHN
---------------------	-----	---------	-----	--------------	----------

@	10MG	A073609	001	Mar 29, 1993	May CAHN
---	------	---------	-----	--------------	----------

AB SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	Mar CAHN
-------------------	-----	---------	-----	--------------	----------

AB	10MG	A074063	002	Jan 27, 1994	Mar CAHN
----	------	---------	-----	--------------	----------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@ SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993	Mar CAHN
------------------	------	---------	-----	--------------	----------

PODOFILOX

GEL; TOPICAL

CONDYLOX

+ ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997	Mar CAHN
----------------------	------	---------	-----	--------------	----------

SOLUTION; TOPICAL

CONDYLOX

AT + ALLERGAN SALES LLC	0.5%	N019795	001	Dec 13, 1990	Mar CAHN
-------------------------	------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

@ MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	May DISC
---------------	---	---------	-----	--------------	----------

COLYTE WITH FLAVOR PACKS

>D> MEDA PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC
-----------------	--	---------	-----	--------------	----------

>A> AA	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC
--------	--	---------	-----	--------------	----------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE

AP AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar NEWA
-------------------------	----------------------------	---------	-----	--------------	----------

AP GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr NEWA
---------------------	----------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan NEWA
------------------------	-------	---------	-----	--------------	----------

AB KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar NEWA
-------------------------	------	---------	-----	--------------	----------

AB	10MEQ	A204210	002	Mar 28, 2016	Mar NEWA
----	-------	---------	-----	--------------	----------

AB TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb NEWA
--------------------	------	---------	-----	--------------	----------

AB	10MEQ	A201944	002	Mar 04, 2016	Feb NEWA
----	-------	---------	-----	--------------	----------

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

>D> PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Jul CRLD
-------------------------	-------	---------	-----	--------------	----------

>A> +	20MEQ	N208019	001	Aug 19, 2015	Jul CRLD
-------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

>A>	AB1	GLENMARK PHARMS LTD	10MEQ	A203562	001	Jul 26, 2016	Jul NEWA
>A>	AB1		20MEQ	A203562	002	Jul 26, 2016	Jul NEWA
>A>	AB2	NOVEL LABS INC	8MEQ	A206759	001	Aug 09, 2016	Jul NEWA
	AB1		10MEQ	A206347	001	Jan 21, 2016	Jan NEWA
>A>	AB2		10MEQ	A206759	002	Aug 09, 2016	Jul NEWA
	AB1		20MEQ	A206347	002	Jan 21, 2016	Jan NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

>D>	TABLET, DELAYED RELEASE;ORAL						
>D>	PRAMIPEXOLE DIHYDROCHLORIDE						
>D>	AB	SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul CDFR
>D>	AB		0.75MG	A202353	002	Dec 04, 2014	Jul CDFR
>D>	AB		1.5MG	A202353	003	Dec 04, 2014	Jul CDFR
>D>	AB		3MG	A202353	004	Dec 04, 2014	Jul CDFR
>D>	AB		4.5MG	A202353	005	Dec 04, 2014	Jul CDFR

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

	AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr NEWA
	AB		0.75MG	A201963	002	Apr 21, 2016	Apr NEWA
	AB		1.5MG	A201963	003	Apr 21, 2016	Apr NEWA
	AB		3MG	A201963	004	Apr 21, 2016	Apr NEWA
	AB		4.5MG	A201963	005	Apr 21, 2016	Apr NEWA
	AB	MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun NEWA
	AB		0.75MG	A206156	002	Jun 24, 2016	Jun NEWA
	AB		1.5MG	A206156	003	Jun 24, 2016	Jun NEWA
	AB		2.25MG	A206156	004	Jun 24, 2016	Jun NEWA
	AB		3MG	A206156	005	Jun 24, 2016	Jun NEWA
	AB		4.5MG	A206156	007	Jun 24, 2016	Jun NEWA
>A>	AB	SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul CDFR
>A>	AB		0.75MG	A202353	002	Dec 04, 2014	Jul CDFR
>A>	AB		1.5MG	A202353	003	Dec 04, 2014	Jul CDFR
>A>	AB		3MG	A202353	004	Dec 04, 2014	Jul CDFR
>A>	AB		4.5MG	A202353	005	Dec 04, 2014	Jul CDFR

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

AB		CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
	@	MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
	@		20MG	A077013	002	Oct 23, 2006	Mar DISC
	@		40MG	A077013	003	Oct 23, 2006	Mar DISC
	@		80MG	A077013	004	Dec 28, 2007	Mar DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May CAHN
@		EQ 2MG BASE	A072577	001	May 16, 1989	May CAHN
@		EQ 5MG BASE	A072578	001	May 16, 1989	May CAHN

PREDNISOLONE

TABLET;ORAL
PREDNISOLONE

@	AUROLIFE PHARMA LLC	5MG	A084773	001		Feb CAHN
---	---------------------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL
ORAPRED

@	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	Mar DISC
AA	+ WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD

PREDNISONE

TABLET;ORAL
PREDNISONE

@	AUROLIFE PHARMA LLC	5MG	A084774	001		Mar CAHN
@		10MG	A089983	001	Jan 12, 1989	Mar CAHN
@		20MG	A085813	001		Mar CAHN
@		50MG	A089984	001	Jan 12, 1989	Mar CAHN
AB	DELCOR ASSET CORP	5MG	A080292	001		Mar CAHN

TABLET;ORAL
PREDNISONE

AB		10MG	A088832	001	Dec 04, 1985	Mar CAHN
AB		20MG	A083677	001		Mar CAHN
AB	SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar CAHN
	@	50MG	A086596	001		Jun CAHN

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE PHOSPHATE

AB	INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016	Jun NEWA
----	-------------------	--------------	---------	-----	--------------	----------

PRIMIDONE

TABLET;ORAL
PRIMIDONE

>A>	AB	FRONTIDA BIOPHARM	50MG	A040626	001	Sep 29, 2005	Jul CAHN
>A>	AB		250MG	A040626	002	Sep 29, 2005	Jul CAHN
>A>		@ HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006	Jul CAHN
>A>	AB		250MG	A040667	002	Jul 27, 2006	Jul CAHN
>D>		@ HIKMA PHARMS LLC	50MG	A040667	001	Jul 27, 2006	Jul CAHN
>D>	AB		250MG	A040667	002	Jul 27, 2006	Jul CAHN
		@ IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar DISC
		@	250MG	A040717	002	Feb 12, 2008	Mar DISC
>D>	AB	SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Jul CAHN
	AB		50MG	A040626	001	Sep 29, 2005	Mar CAHN
>D>	AB		250MG	A040626	002	Sep 29, 2005	Jul CAHN
	AB		250MG	A040626	002	Sep 29, 2005	Mar CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL
PROCAINAMIDE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	375MG	A089220	001	Jul 01, 1986	May CAHN
--	---------------------	-------	---------	-----	--------------	----------

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan CAHN
AB	PROMETRIUM					
AB	VIRTUS PHARMS	100MG	N019781	001	May 14, 1998	Jun CAHN
AB	+	200MG	N019781	002	Oct 15, 1999	Jun CAHN
	@	300MG	N019781	003	Oct 15, 1999	Jun CAHN

GEL;VAGINAL
CRINONE

+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997	Apr CAHN
+		8%	N020701	002	Jul 31, 1997	Apr CAHN

INJECTABLE;INJECTION
PROGESTERONE

AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002		Apr CAHN
----	---	--------------------	---------	---------	-----	--	----------

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Feb CAHN
----	------------------	------------	---------	-----	--------------	----------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

	@ IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008	Mar DISC
	@	25MG	A040724	002	Feb 12, 2008	Mar DISC
	@	50MG	A040791	001	May 20, 2008	Mar DISC
	@ SUN PHARM INDS	12.5MG	A084555	001		Mar CAHN
	@	25MG	A084554	001		Mar CAHN
	@	50MG	A084557	001		Jan CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB	MYLAN PHARMS INC	225MG	A203803	001	Apr 29, 2016	Apr NEWA
AB		325MG	A203803	002	Apr 29, 2016	Apr NEWA
AB		425MG	A203803	003	Apr 29, 2016	Apr NEWA

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB	ORION CORP ORION	150MG	A202445	001	May 11, 2016	Apr	NEWA
AB		225MG	A202445	002	May 11, 2016	Apr	NEWA
AB		300MG	A202445	003	May 11, 2016	Apr	NEWA
AB	SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001	Mar	CAHN
AB		225MG	A075998	002	Nov 29, 2001	Mar	CAHN
AB		300MG	A075998	003	Nov 29, 2001	Mar	CAHN

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
INDERAL LA

AB	ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987	Apr	CAHN
AB		80MG	N018553	002	Apr 19, 1983	Apr	CAHN
AB		120MG	N018553	003	Apr 19, 1983	Apr	CAHN
AB	+	160MG	N018553	001	Apr 19, 1983	Apr	CAHN

PROPRANOLOL HYDROCHLORIDE

BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Jun	CMFD
	@	60MG	A078311	001	Mar 06, 2009	May	DISC
BX		60MG	A078311	001	Mar 06, 2009	Mar	CTEC
BX		80MG	A078311	002	Mar 06, 2009	Jun	CMFD
	@	80MG	A078311	002	Mar 06, 2009	May	DISC
BX		80MG	A078311	002	Mar 06, 2009	Mar	CTEC
BX		120MG	A078311	003	Mar 06, 2009	Jun	CMFD
	@	120MG	A078311	003	Mar 06, 2009	May	DISC
BX		120MG	A078311	003	Mar 06, 2009	Mar	CTEC
BX		160MG	A078311	004	Mar 06, 2009	Jun	CMFD
	@	160MG	A078311	004	Mar 06, 2009	May	DISC
BX		160MG	A078311	004	Mar 06, 2009	Mar	CTEC

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000	Jun	CAHN
AP	EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Apr	CAHN
	@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar	DISC

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	@ FRONTIDA BIOPHARM	10MG	A070319	001	Oct 22, 1985	Jul	CAHN
>A>	@	20MG	A070320	001	Oct 22, 1985	Jul	CAHN
>A>	@	40MG	A070103	001	Oct 22, 1985	Jul	CAHN
>A>	@	60MG	A070321	001	Sep 24, 1986	Jul	CAHN
>A>	@	80MG	A070322	001	Aug 04, 1986	Jul	CAHN
>D>	@ SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Jul	CAHN
	@	10MG	A070319	001	Oct 22, 1985	Mar	CAHN
>D>	@	20MG	A070320	001	Oct 22, 1985	Jul	CAHN
	@	20MG	A070320	001	Oct 22, 1985	Mar	CAHN
>D>	@	40MG	A070103	001	Oct 22, 1985	Jul	CAHN
	@	40MG	A070103	001	Oct 22, 1985	Mar	CAHN
>D>	@	60MG	A070321	001	Sep 24, 1986	Jul	CAHN
	@	60MG	A070321	001	Sep 24, 1986	Jun	CAHN
>D>	@	80MG	A070322	001	Aug 04, 1986	Jul	CAHN
	@	80MG	A070322	001	Aug 04, 1986	Mar	CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

>A>	@ HIKMA INTL PHARMS	50MG	A080154	001		Jul	CAHN
>D>	@ HIKMA PHARMS LLC	50MG	A080154	001		Jul	CAHN
	@ SUN PHARM INDS	50MG	A083982	001		Mar	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

>D>	+	FRESENIUS KABI USA	100MG/ML	A080618	001		Jul	CTEC
>A>	AP	+	100MG/ML	A080618	001		Jul	CTEC
>A>	AP	MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016	Jul	NEWA

QUAZEPAM

TABLET; ORAL

DORAL

@ CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar CAHN
+	15MG	N018708	001	Dec 27, 1985	Apr CMFD
@	15MG	N018708	001	Dec 27, 1985	Mar CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

@ ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr DISC
@	EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr DISC
@	EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr DISC
@	EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr DISC
@	EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr DISC
@	EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr DISC
@	EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr DISC
AB MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May NEWA
AB	EQ 50MG BASE	A203359	002	May 17, 2016	May NEWA
AB	EQ 100MG BASE	A203359	003	May 17, 2016	May NEWA
AB	EQ 200MG BASE	A203359	004	May 17, 2016	May NEWA
AB	EQ 300MG BASE	A203359	005	May 17, 2016	May NEWA
AB	EQ 400MG BASE	A203359	006	May 17, 2016	May NEWA
AB UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb NEWA
AB	EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb NEWA
AB	EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb NEWA
AB	EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb NEWA
AB	EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb NEWA
AB	EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@ ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan DISC
@	EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan DISC
@	EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan DISC
@	EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

@ AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar CAHN
BX + SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar CAHN

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@ SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun CAHN
AB	200MG	A081030	001	Apr 14, 1989	Mar CAHN
AB	300MG	A081031	001	Apr 14, 1989	Mar CAHN

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

AB + SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun CAHN
---------------------	-------	---------	-----	--------------	----------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun CAHN
+	10MG	N204736	002	Mar 26, 2013	Jun CAHN

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

RALOXIFENE HYDROCHLORIDE

AB AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar NEWA
AB GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP	MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May NEWA
AP	ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May CPOT
	ZANTAC					
AP	+ IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
	ZANTAC IN PLASTIC CONTAINER					
	@ IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan CAHN
	@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan CAHN
	SYRUP;ORAL					
	RANITIDINE HYDROCHLORIDE					
AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar CAHN
	@ WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr DISC
	@	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB	ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb NEWA
AB		EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb NEWA

RESERPINE

TABLET;ORAL

RESERPINE

	@ HIKMA INTL PHARMS	0.1MG	A080975	001		Feb CAHN
	@	0.25MG	A080975	002		Feb CAHN
	@	1MG	A080975	003		Feb CAHN

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

	+ AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan CAHN
--	-------------------	----	---------	-----	--------------	----------

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS;OPHTHALMIC

PHOTREXA

	+ AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr NEWA
	PHOTREXA VISCOUS IN DEXTRAN 20%					
	+ AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun CMS1
	PHOTREXA VISCOUS IN DEXTROSE 20%					
	+ AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Apr NEWA

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

AP	EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Apr CAHN
AP	HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb NEWA
AP	WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan NEWA

RILUZOLE

TABLET;ORAL

RILUZOLE

AB	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar NEWA
----	----------------	------	---------	-----	--------------	----------

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

	@ ALCON	1%	N020474	001	Dec 30, 1994	Jun DISC
--	---------	----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

AB	APIL	5MG	N020835	002	Apr 14, 2000	Jan CAHN
AB		30MG	N020835	001	Mar 27, 1998	Jan CAHN
AB	+	35MG	N020835	003	May 25, 2002	Jan CAHN
	@	75MG	N020835	004	Apr 16, 2007	Jan CAHN
AB	+	150MG	N020835	005	Apr 22, 2008	Jan CAHN

TABLET, DELAYED RELEASE;ORAL							
ATELVIA							
AB	+	APIL	35MG	N022560	001	Oct 08, 2010	Jan CAHN
<u>RISPERIDONE</u>							
SOLUTION;ORAL							
RISPERIDONE							
	@	WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009	Apr DISC
<u>RIVASTIGMINE</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
RIVASTIGMINE							
AB		ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN
<u>RIVASTIGMINE TARTRATE</u>							
CAPSULE;ORAL							
EXELON							
AB	+	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
RIVASTIGMINE TARTRATE							
AB		AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB			EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB			EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB			EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA
<u>RIZATRIPTAN BENZOATE</u>							
TABLET;ORAL							
RIZATRIPTAN BENZOATE							
AB		ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB			EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB		NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN
<u>ROPIVACAINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
ROPIVACAINE HYDROCHLORIDE							
AP		AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar NEWA
SOLUTION;INJECTION							
NAROPIN							
	@	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May DISC
			50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May NEWA
AP			20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May CMS1
AP			20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar CDFR
AP			40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar NEWA
	@		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr DISC
			75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr NEWA
AP			100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun CFTG
			100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May CMS1
			100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar CDFR
AP			100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar NEWA
AP			150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar CDFR
AP			150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar NEWA
AP			200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun CFTG
			200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar NEWA
AP	+		200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar NEWA
			400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar NEWA
			500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr CMS1
			500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar NEWA
			1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr CMS1
			1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar NEWA
ROPIVACAINE HYDROCHLORIDE							
AP		AUROBINDO PHARMA LTD	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun NEWA
AP			100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun NEWA
AP			100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun NEWA
AP			150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun NEWA
AP			150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun NEWA
AP			200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun NEWA
AP			200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun NEWA
AP		HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar CDFR
AP			40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar NEWA
AP			100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar CDFR

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar CDFR

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr CFTG

ROSUVASTATIN CALCIUM

>A>	AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jul NEWA
>A>	AB		10MG	A079145	002	Jul 19, 2016	Jul NEWA
>A>	AB		20MG	A079145	003	Jul 19, 2016	Jul NEWA
>A>	AB		40MG	A079145	004	Jul 19, 2016	Jul NEWA
>A>	AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Jul NEWA
>A>	AB		10MG	A079170	002	Jul 19, 2016	Jul NEWA
>A>	AB		20MG	A079170	003	Jul 19, 2016	Jul NEWA
>A>	AB		40MG	A079170	004	Jul 19, 2016	Jul NEWA
>A>	AB	GLENMARK PHARMS LTD	5MG	A079172	001	Jul 19, 2016	Jul NEWA
>A>	AB		10MG	A079172	002	Jul 19, 2016	Jul NEWA
>A>	AB		20MG	A079172	003	Jul 19, 2016	Jul NEWA
>A>	AB		40MG	A079172	004	Jul 19, 2016	Jul NEWA
>A>	AB	MYLAN PHARMS INC	5MG	A079161	001	Jul 19, 2016	Jul NEWA
>A>	AB		10MG	A079161	002	Jul 19, 2016	Jul NEWA
>A>	AB		20MG	A079161	003	Jul 19, 2016	Jul NEWA
>A>	AB		40MG	A079161	004	Jul 19, 2016	Jul NEWA
>A>	AB	PAR PHARM INC	5MG	A079168	001	Jul 19, 2016	Jul NEWA
>A>	AB		10MG	A079168	002	Jul 19, 2016	Jul NEWA
>A>	AB		20MG	A079168	003	Jul 19, 2016	Jul NEWA
>A>	AB		40MG	A079168	004	Jul 19, 2016	Jul NEWA
>A>	AB	SANDOZ INC	5MG	A079171	001	Jul 19, 2016	Jul NEWA
>A>	AB		10MG	A079171	002	Jul 19, 2016	Jul NEWA
>A>	AB		20MG	A079171	003	Jul 19, 2016	Jul NEWA
>A>	AB		40MG	A079171	004	Jul 19, 2016	Jul NEWA
>A>	AB	SUN PHARMA GLOBAL	5MG	A079169	001	Jul 19, 2016	Jul NEWA
>A>	AB		10MG	A079169	002	Jul 19, 2016	Jul NEWA
>A>	AB		20MG	A079169	003	Jul 19, 2016	Jul NEWA
>A>	AB		40MG	A079169	004	Jul 19, 2016	Jul NEWA
>A>	AB	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul NEWA
>A>	AB		10MG	A079166	002	Jul 19, 2016	Jul NEWA
>A>	AB		20MG	A079166	003	Jul 19, 2016	Jul NEWA
>A>	AB		40MG	A079166	004	Jul 19, 2016	Jul NEWA
AB		WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr NEWA
AB			10MG	A079167	002	Apr 29, 2016	Apr NEWA
AB			20MG	A079167	003	Apr 29, 2016	Apr NEWA
AB			40MG	A079167	004	Apr 29, 2016	Apr NEWA

RUFINAMIDE

TABLET;ORAL

BANZEL

AB	EISAI INC	200MG	N021911	002	Nov 14, 2008	May CFTG
AB	+	400MG	N021911	003	Nov 14, 2008	May CFTG

RUFINAMIDE

AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May NEWA
AB		400MG	A205075	002	May 16, 2016	May NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May NEWA
AB		400MG	A205095	002	May 16, 2016	May NEWA
AB	ROXANE	200MG	A204988	001	May 16, 2016	May NEWA
AB		400MG	A204988	002	May 16, 2016	May NEWA

SCOPOLAMINEFILM, EXTENDED RELEASE;TRANSDERMAL
TRANSDERM SCOP

AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001		May	CAHN
----	---	---------------------	----------	---------	-----	--	-----	------

SERTRALINE HYDROCHLORIDETABLET;ORAL
SERTRALINE HYDROCHLORIDE

>A>	@	FRONTIDA BIOPHARM	EQ 25MG BASE	A077818	001	Feb 06, 2007	Jul	CAHN
>A>	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Jul	CAHN
>A>	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Jul	CAHN
>D>	@	SUN PHARM INDS	EQ 25MG BASE	A077818	001	Feb 06, 2007	Jul	CAHN
	@		EQ 25MG BASE	A077818	001	Feb 06, 2007	Mar	CAHN
>D>	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Jul	CAHN
	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Mar	CAHN
>D>	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Jul	CAHN
	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Mar	CAHN

SILDENAFIL CITRATETABLET;ORAL
SILDENAFIL CITRATE

	@	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	DISC
AB		RUBICON RES PVT LTD	EQ 20MG BASE	A204883	001	Jun 20, 2016	Jun	NEWA
	@	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	DISC
			EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	NEWA
	@		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	DISC
			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	NEWA
	@		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	DISC
			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	NEWA

SILODOSINCAPSULE;ORAL
RAPAFLO

	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr	CAHN
			8MG	N022206	002	Oct 08, 2008	Apr	CAHN

SIMVASTATINSUSPENSION;ORAL
SIMVASTATIN

		ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr	NEWA
+			40MG/5ML	N206679	002	Apr 21, 2016	Apr	NEWA

TABLET;ORAL
SIMVASTATIN

@	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb	DISC
@		10MG	A076285	002	Dec 20, 2006	Feb	DISC
@		20MG	A076285	003	Dec 20, 2006	Feb	DISC
@		40MG	A076285	004	Dec 20, 2006	Feb	DISC
@		80MG	A076285	005	Jun 23, 2006	Feb	DISC

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION;IV (INFUSION)
AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb	CFTG
		SODIUM PHENYLACETATE AND SODIUM BENZOATE						
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb	NEWA
>A> AP		NAVINTA LLC	10%;10% (5GM/50ML; 5GM/50ML)	A205880	001	Aug 04, 2016	Jul	NEWA

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb	NEWA
--	--	-------------	-----------	---------	-----	--------------	-----	------

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May	NEWA
----	--	----------------------	--------	---------	-----	--------------	-----	------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP	KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May NEWA
AP	ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

JUBILANT DRAXIMAGE 0.009-0.1mCi
@ 2-200mCi

N021305	006	May 19, 2005	Mar CMS1
N021305	004	Nov 18, 2004	Mar CMS1

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB	+ HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CAHN
	SODIUM PHENYLBUTYRATE					

AB	PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun NEWA
----	-----------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

BUPHENYL

AB	+ HORIZON PHARMA INC	500MG	N020572	001	May 13, 1996	Mar CAHN
	SODIUM PHENYLBUTYRATE					

AB	PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr NEWA
----	-----------	-------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb NEWA
AA	INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb NEWA

SOFOBUVIR; VELPATASVIR

TABLET;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016	Jun NEWA
---	---------------------	-------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

@	IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar DISC
@		120MG	A075663	002	Nov 07, 2000	Mar DISC
@		160MG	A075663	003	Nov 07, 2000	Mar DISC
@		240MG	A075663	004	Nov 07, 2000	Mar DISC
@	SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar CAHN
@		80MG	A076576	001	Apr 08, 2004	Mar CAHN
@		120MG	A075515	004	Oct 15, 2001	Mar CAHN
@		120MG	A076576	002	Apr 08, 2004	Mar CAHN
@		160MG	A075515	002	Oct 15, 2001	Mar CAHN
@		160MG	A076576	003	Apr 08, 2004	Mar CAHN
@		240MG	A075515	003	Oct 15, 2001	Mar CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB	SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar CAHN
AB		50MG	A089424	002	Aug 11, 1999	Mar CAHN
AB		100MG	A089424	003	Aug 11, 1999	Mar CAHN

SUCRALFATE

TABLET;ORAL

SUCRALFATE

AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan CAHN
----	-------------------	-----	---------	-----	--------------	----------

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan CPOT
+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan CPOT

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@ AUROLIFE PHARMA LLC	500MG	A085844	001		Feb CAHN
-----------------------	-------	---------	-----	--	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM

@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	001		Jun CAHN
------------------	---------------------	---------	-----	--	----------

BACTRIM PEDIATRIC

@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	002		Jun CAHN
------------------	---------------------	---------	-----	--	----------

TABLET; ORAL

BACTRIM

AB	SUN PHARM INDS	400MG; 80MG	N017377	001		Mar CAHN
----	----------------	-------------	---------	-----	--	----------

BACTRIM DS

AB	+	SUN PHARM INDS	800MG; 160MG	N017377	002		Mar CAHN
----	---	----------------	--------------	---------	-----	--	----------

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		SUN PHARM INDS	800MG; 160MG	A071017	001	Aug 25, 1986	Mar CAHN
----	--	----------------	--------------	---------	-----	--------------	----------

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

@ SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987	Mar CAHN
------------------	-------	---------	-----	--------------	----------

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ AUROLIFE PHARMA LLC	500MG	A085628	001		Feb CAHN
-----------------------	-------	---------	-----	--	----------

SULINDAC

TABLET; ORAL

SULINDAC

AB		SUN PHARM INDS	150MG	A072050	001	Apr 17, 1991	Mar CAHN
----	--	----------------	-------	---------	-----	--------------	----------

AB			200MG	A072051	001	Apr 17, 1991	Mar CAHN
----	--	--	-------	---------	-----	--------------	----------

SUMATRIPTAN

SPRAY; NASAL

IMITREX

AB	+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997	Feb CFTG
----	---	-----------------	-----------	---------	-----	--------------	----------

AB	+		20MG/SPRAY	N020626	003	Aug 26, 1997	Feb CFTG
----	---	--	------------	---------	-----	--------------	----------

SUMATRIPTAN

AB		LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016	Feb NEWA
----	--	---------	-----------	---------	-----	--------------	----------

AB			20MG/SPRAY	A204841	002	Feb 19, 2016	Feb NEWA
----	--	--	------------	---------	-----	--------------	----------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP		EUROHLTH INTL SARL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jun CAHN
----	--	--------------------	-------------------------------------	---------	-----	--------------	----------

POWDER; INHALATION

ONZETRA XSAIL

+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan NEWA
---	---------------	--------------	---------	-----	--------------	----------

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

	DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan NEWA
--	--------------------	---------------------------------------	---------	-----	--------------	----------

TACROLIMUS

OINTMENT; TOPICAL

PROTOPIC

AB	+	LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun CAHN
----	---	---------------	-------	---------	-----	--------------	----------

AB	+		0.1%	N050777	002	Dec 08, 2000	Jun CAHN
----	---	--	------	---------	-----	--------------	----------

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

	MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005	Jan CAHN
--	--------------------	------------------	---------	-----	--------------	----------

TABLET; ORAL

TAMOXIFEN CITRATE

@ ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003	Jan DISC
-----------------------	--------------	---------	-----	--------------	----------

TABLET;ORAL

TAMOXIFEN CITRATE

@

EQ 20MG BASE

A076179 002 Feb 20, 2003 Jan DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

ULTRA-TECHNEKOW FM

+ MALLINKRODT NUCLEAR

1-19 CI/GENERATOR

N017243 003 Feb 18, 2014 Jan CAHN

@

0.25-3 CI/GENERATOR

N017243 002 Jan CAHN

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

@ US WORLDMEDS LLC

EQ 2MG BASE

N021200 001 Jul 24, 2002 Jan CAHN

@

EQ 6MG BASE

N021200 002 Jul 24, 2002 Jan CAHN

TELITHROMYCIN

TABLET;ORAL

KETEK

@ SANOFI AVENTIS US

300MG

N021144 002 Feb 09, 2005 Mar DISC

@

400MG

N021144 001 Apr 01, 2004 Mar DISC

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB HETERO LABS LTD V

20MG

A205901 001 Apr 22, 2016 Apr NEWA

AB

40MG

A205901 002 Apr 22, 2016 Apr NEWA

AB

80MG

A205901 003 Apr 22, 2016 Apr NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB AMNEAL PHARMS

7.5MG

A203482 001 May 23, 2016 May NEWA

AB

15MG

A203482 002 May 23, 2016 May NEWA

AB

22.5MG

A203482 003 May 23, 2016 May NEWA

AB

30MG

A203482 004 May 23, 2016 May NEWA

AB SUN PHARM INDS

7.5MG

A078581 001 Sep 08, 2009 Mar CAHN

@

15MG

A071174 001 Jul 10, 1986 Mar CAHN

AB

22.5MG

A071175 002 Sep 14, 2009 Mar CAHN

@

30MG

A071175 001 Jul 10, 1986 Mar CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>A> AB AMERIGEN PHARMS LTD

5MG

A203490 001 Jul 13, 2016 Jul NEWA

>A> AB

20MG

A203490 002 Jul 13, 2016 Jul NEWA

>A> AB

100MG

A203490 003 Jul 13, 2016 Jul NEWA

>A> AB

140MG

A203490 004 Jul 13, 2016 Jul NEWA

>A> AB

180MG

A203490 005 Jul 13, 2016 Jul NEWA

>A> AB

250MG

A203490 006 Jul 13, 2016 Jul NEWA

AB IDT AUSTRALIA LTD

5MG

A206413 001 Apr 12, 2016 Mar NEWA

AB

20MG

A206413 002 Apr 12, 2016 Mar NEWA

AB

100MG

A206413 003 Apr 12, 2016 Mar NEWA

AB

140MG

A206413 004 Apr 12, 2016 Mar NEWA

AB

180MG

A206413 005 Apr 12, 2016 Mar NEWA

AB

250MG

A206413 006 Apr 12, 2016 Mar NEWA

AB KREMERS URBAN PHARMS

5MG

A203898 001 Feb 10, 2016 Jan NEWA

AB

20MG

A203898 002 Feb 10, 2016 Jan NEWA

AB

100MG

A203898 003 Feb 10, 2016 Jan NEWA

AB

140MG

A203898 004 Feb 10, 2016 Jan NEWA

AB

180MG

A203898 005 Feb 10, 2016 Jan NEWA

AB

250MG

A203898 006 Feb 10, 2016 Jan NEWA

AB LOTUS PHARM CO LTD

5MG

A206309 001 Apr 27, 2016 Apr NEWA

AB

20MG

A206309 002 Apr 27, 2016 Apr NEWA

AB

100MG

A206309 003 Apr 27, 2016 Apr NEWA

AB

140MG

A206309 004 Apr 27, 2016 Apr NEWA

AB

180MG

A206309 005 Apr 27, 2016 Apr NEWA

AB

250MG

A206309 006 Apr 27, 2016 Apr NEWA

AB MYLAN PHARMS INC

5MG

A205227 001 Jun 29, 2016 Jun NEWA

AB

20MG

A205227 002 Jun 29, 2016 Jun NEWA

AB

100MG

A205227 003 Jun 29, 2016 Jun NEWA

AB

140MG

A205227 004 Jun 29, 2016 Jun NEWA

AB

180MG

A205227 005 Jun 29, 2016 Jun NEWA

CAPSULE;ORAL							
TEMOZOLOMIDE							
AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA
<u>TERBUTALINE SULFATE</u>							
INJECTABLE;INJECTION							
TERBUTALINE SULFATE							
AP	+	AMPHASTAR PHARMS INC 1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
AP	+	EUROHLTH INTL SARL 1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN
TABLET;ORAL							
TERBUTALINE SULFATE							
	@	IMPAX LABS 2.5MG	A075877	001	Jun 26, 2001	Mar	DISC
	@	5MG	A075877	002	Jun 26, 2001	Mar	DISC
		LANNETT 2.5MG	A077152	001	Mar 25, 2005	Mar	CTEC
		5MG	A077152	002	Mar 25, 2005	Mar	CTEC
<u>TESTOSTERONE</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
ANDRODERM							
	+	ALLERGAN SALES LLC 2MG/24HR	N020489	003	Oct 20, 2011	Mar	CAHN
	@	2.5MG/24HR	N020489	001	Sep 29, 1995	Mar	CAHN
	+	4MG/24HR	N020489	004	Oct 20, 2011	Mar	CAHN
	@	5MG/24HR	N020489	002	May 02, 1997	Mar	CAHN
GEL, METERED;NASAL							
NATESTO							
		AYTU BIOSCIENCE INC 5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	CAHN
PELLET;IMPLANTATION							
TESTOPEL							
	+	AUXILIUM PHARMS INC 75MG	A080911	001		Mar	CAHN
TABLET, EXTENDED RELEASE;BUCCAL							
STRIANT							
	+	AUXILIUM PHARMS INC 30MG	N021543	001	Jun 19, 2003	Mar	CAHN
<u>TESTOSTERONE CYPIONATE</u>							
INJECTABLE;INJECTION							
TESTOSTERONE CYPIONATE							
AO		EUROHLTH INTL SARL 100MG/ML	A090387	001	Jul 15, 2010	Jun	CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jun	CAHN
<u>TETRABENAZINE</u>							
TABLET;ORAL							
TETRABENAZINE							
AB		HETERO LABS LTD V 12.5MG	A204574	001	Feb 03, 2016	Jan	NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan	NEWA
<u>TETRACAINE HYDROCHLORIDE</u>							
SOLUTION;OPHTHALMIC							
TETRACAINE HYDROCHLORIDE							
	+	ALCON RES LTD 0.5%	N208135	001	Feb 29, 2016	Feb	NEWA
<u>TETRACYCLINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
TETRACYCLINE HYDROCHLORIDE							
AB		CHARTWELL CIENCA 250MG	A062752	001	Aug 12, 1988	Apr	CMFD
AB		500MG	A062752	002	Aug 12, 1988	Apr	CMFD
	@	SUN PHARM INDS 250MG	A060736	001		Mar	CAHN
	@	500MG	A060736	002		Mar	CAHN
<u>THEOPHYLLINE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
THEO-24							
>D>		AUXILIUM PHARMS INC 200MG	A087943	001	Aug 22, 1983	Jul	CAHN
		200MG	A087943	001	Aug 22, 1983	Mar	CAHN
>D>		300MG	A087944	001	Aug 22, 1983	Jul	CAHN
		300MG	A087944	001	Aug 22, 1983	Mar	CAHN
	+	400MG	A081034	001	Feb 28, 1992	Mar	CAHN
>A>		AUXILIUM PHARMS LLC 200MG	A087943	001	Aug 22, 1983	Jul	CAHN
>A>		300MG	A087944	001	Aug 22, 1983	Jul	CAHN
SOLUTION, ELIXIR;ORAL							
ELIXOPHYLLIN							
	+	NOSTRUM LABS INC 80MG/15ML	A085186	001		Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL						
THEOCHRON						
AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jan CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jan CAHN
THEOPHYLLINE						
AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	Jan CAHN
<u>THIORIDAZINE HYDROCHLORIDE</u>						
TABLET;ORAL						
THIORIDAZINE HYDROCHLORIDE						
AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar CAHN
	@	15MG	A088461	001	Nov 18, 1983	Mar CAHN
AB		25MG	A089953	003	Aug 01, 1986	Mar CAHN
AB		50MG	A089953	002	Aug 01, 1986	Mar CAHN
AB		100MG	A089953	001	Oct 07, 1988	Mar CAHN
	@	150MG	A088737	001	Sep 26, 1984	Mar CAHN
	@	200MG	A088738	001	Oct 16, 1984	Mar CAHN
<u>THIOTHIXENE</u>						
CAPSULE;ORAL						
THIOTHIXENE						
	@ SANDOZ	1MG	A071610	001	Jun 24, 1987	Mar DISC
	@	2MG	A071570	001	Jun 24, 1987	Mar DISC
	@	5MG	A071529	001	Jun 24, 1987	Mar DISC
	@	10MG	A071530	001	Jun 24, 1987	Mar DISC
<u>TINIDAZOLE</u>						
TABLET;ORAL						
TINIDAZOLE						
BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr CTEC
BX		500MG	A202489	002	Oct 09, 2013	Apr CTEC
<u>TOBRAMYCIN SULFATE</u>						
INJECTABLE;INJECTION						
TOBRAMYCIN SULFATE						
AP	CLARIS	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Jun NEWA
<u>TOFACITINIB CITRATE</u>						
TABLET, EXTENDED RELEASE;ORAL						
XELJANZ XR						
+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb NEWA
<u>TOLAZAMIDE</u>						
TABLET;ORAL						
TOLAZAMIDE						
	@ SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar CAHN
	@	250MG	A071358	001	Jul 16, 1987	Mar CAHN
	@	500MG	A071359	001	Jul 16, 1987	Mar CAHN
<u>TOLMETIN SODIUM</u>						
CAPSULE;ORAL						
TOLMETIN SODIUM						
	@ SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar CAHN
TABLET;ORAL						
TOLMETIN SODIUM						
AB	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar CAHN
<u>TOPIRAMATE</u>						
TABLET;ORAL						
TOPIRAMATE						
	@ ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Apr DISC
AB		25MG	A078637	001	Feb 27, 2013	Jan CAHN
	@	50MG	A078637	002	Feb 27, 2013	Apr DISC
AB		50MG	A078637	002	Feb 27, 2013	Jan CAHN
	@	100MG	A078637	003	Feb 27, 2013	Apr DISC
AB		100MG	A078637	003	Feb 27, 2013	Jan CAHN
	@	200MG	A078637	004	Feb 27, 2013	Apr DISC
AB		200MG	A078637	004	Feb 27, 2013	Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar CAHN
AB	SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

ULTRAM ER

AB1	+ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar CAHN
AB1		200MG	N021692	002	Sep 08, 2005	Mar CAHN
AB1		300MG	N021692	003	Sep 08, 2005	Mar CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	AKORN	100MG/ML	A206634	001	Jun 09, 2016	May NEWA
AP	AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan NEWA
AP	NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb NEWA

TABLET; ORAL

TRANEXAMIC ACID

>A>	@ AMERIGEN PHARMS LTD	650MG	A203256	001	Jul 25, 2016	Jul DISC
>A> AB		650MG	A203256	001	Jul 25, 2016	Jul NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb CAHN
AB	SUN PHARM INDS	50MG	A073137	002	Mar 24, 1993	Mar CAHN
AB		100MG	A073137	001	Mar 24, 1993	Mar CAHN
AB		150MG	A073137	003	Dec 22, 1995	Mar CAHN

TRETINOIN

CREAM; TOPICAL

TRETINOIN

>A>	+ ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Jul CAHN
>A>		0.075%	A202209	001	Oct 11, 2012	Jul CAHN
>D> AB	ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Jul CAHN
AB		0.025%	A075264	001	Dec 24, 1998	Feb CAHN
>D> AB1		0.05%	A075265	001	Dec 24, 1998	Jul CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Feb CAHN
>D> AB		0.1%	A075213	001	Dec 24, 1998	Jul CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Feb CAHN
>A> AB	PERRIGO PHARMA INTL	0.025%	A075264	001	Dec 24, 1998	Jul CAHN
>A> AB1		0.05%	A075265	001	Dec 24, 1998	Jul CAHN
>A> AB		0.1%	A075213	001	Dec 24, 1998	Jul CAHN
>D>	+ WATSON LABS INC	0.0375%	A090098	001	Mar 22, 2010	Jul CAHN
>D>		0.075%	A202209	001	Oct 11, 2012	Jul CAHN

GEL; TOPICAL

TRETINOIN

>D> AB	ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Jul CAHN
AB		0.01%	A075589	001	Jun 11, 2002	Feb CAHN
>D> AB		0.025%	A075529	001	Feb 22, 2000	Jul CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Feb CAHN
>A> AB	PERRIGO PHARMA INTL	0.01%	A075589	001	Jun 11, 2002	Jul CAHN
>A> AB		0.025%	A075529	001	Feb 22, 2000	Jul CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul NEWA
--------	---------------------	------	---------	-----	--------------	----------

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	TELIGENT PHARMA INC	0.025%	A204608	001	Jul 07, 2016	Jun NEWA
AT		0.1%	A204606	001	Jul 07, 2016	Jun NEWA

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT	GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul NEWA
AT	TELIGENT PHARMA INC	0.1%	A205373	001	May 13, 2016	May NEWA

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

>A> AT	VERSAPHARM INC	0.1%	A206312	001	Aug 11, 2016	Jul NEWA
--------	----------------	------	---------	-----	--------------	----------

		SPRAY; TOPICAL							
		KENALOG							
>A>	AT	+	RANBAXY LABS LTD	0.147MG/GM	N012104	001		Jul	CAHN
>D>	AT	+	SUN PHARM INDS LTD	0.147MG/GM	N012104	001		Jul	CAHN
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>									
		CAPSULE; ORAL							
		TRIMETHOBENZAMIDE HYDROCHLORIDE							
AB			SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar	CAHN
<u>TRIMETHOPRIM</u>									
		TABLET; ORAL							
		TRIMETHOPRIM							
		@	SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun	CAHN
		@		200MG	A070495	001	Sep 24, 1986	Mar	CAHN
<u>TRIMETHOPRIM HYDROCHLORIDE</u>									
		SOLUTION; ORAL							
		PRIMSOL							
		+	AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun	CAHN
		@	AYTU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun	CMS2
		@		EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jan	CAHN
		+		EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan	CAHN
<u>TRIMIPRAMINE MALEATE</u>									
		CAPSULE; ORAL							
		TRIMIPRAMINE MALEATE							
AB			CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr	NEWA
AB				EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr	NEWA
AB				EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr	NEWA
<u>TRIPTORELIN PAMOATE</u>									
		INJECTABLE; INTRAMUSCULAR							
		TRELSTAR							
		+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr	CAHN
		+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr	CAHN
		+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr	CAHN
<u>TROSPIMUM CHLORIDE</u>									
		CAPSULE, EXTENDED RELEASE; ORAL							
		TROSPIMUM CHLORIDE							
		@	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	DISC
<u>UNOPROSTONE ISOPROPYL</u>									
		SOLUTION/DROPS; OPHTHALMIC							
		RESCULA							
		@	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	Mar	DISC
		@	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Mar	CAHN
<u>URSODIOL</u>									
		CAPSULE; ORAL							
		ACTIGALL							
		@	ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
AB		+		300MG	N019594	002	Dec 31, 1987	Mar	CAHN
<u>VALGANCICLOVIR HYDROCHLORIDE</u>									
		FOR SOLUTION; ORAL							
		VALCYTE							
>D>		+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	Jul	CFTG
>A>	AB	+		50MG/ML	N022257	001	Aug 28, 2009	Jul	CFTG
>A>			VALGANCICLOVIR HYDROCHLORIDE						
>A>	AB		ACTAVIS LABS FL INC	50MG/ML	A205220	001	Jul 18, 2016	Jul	NEWA
		TABLET; ORAL							
		VALGANCICLOVIR HYDROCHLORIDE							
AB			AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar	NEWA
AB			HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar	NEWA

VALPROATE SODIUMINJECTABLE; INJECTION
VALPROATE SODIUM

AP	AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun CAHN
AP	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACIDCAPSULE; ORAL
VALPROIC ACID

AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

SYRUP; ORAL

VALPROIC ACID

AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
----	------------------	-----------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar NEWA
AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar NEWA
AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar NEWA
AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar NEWA
>A> AP	CFT PHARMS LLC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015	Jul CAHN
>A> AP		EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015	Jul CAHN
>A> AP		EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Jul CAHN
>A> AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Jul CAHN
>D> AP	CUSTOPHARM INC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015	Jul CAHN
>D> AP		EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015	Jul CAHN
>D> AP		EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Jul CAHN
>D> AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Jul CAHN
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan NEWA
AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan NEWA

VANDETANIBTABLET; ORAL
CAPRELSA

GENZYME CORP

+

100MG
300MG

N022405	001	Apr 06, 2011	Jun CAHN
N022405	002	Apr 06, 2011	Jun CAHN

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

AP	EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Apr CAHN
AP		20MG/VIAL	A075549	002	Jun 13, 2000	Apr CAHN
AP	GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May NEWA
AP		20MG/VIAL	A205390	002	May 26, 2016	May NEWA
AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan CAHN
AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan CAHN

VENETOCLAXTABLET; ORAL
VENCLEXTA

ABBVIE INC

+

10MG
50MG
100MG

N208573	001	Apr 11, 2016	Apr NEWA
N208573	002	Apr 11, 2016	Apr NEWA
N208573	003	Apr 11, 2016	Apr NEWA

VERAPAMIL HYDROCHLORIDESOLUTION; INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr CMFD
----	----------------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

@ SUN PHARM INDS

@

80MG
120MG

A071489	002	Jan 13, 1988	Jun CAHN
A071489	001	Jan 13, 1988	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

@ PFIZER

180MG

N019152	002	Dec 15, 1989	Feb DISC
---------	-----	--------------	----------

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr CAHN
----	--------------------	-----------------	---------	-----	--------------	----------

VORICONAZOLE

FOR SUSPENSION; ORAL
VORICONAZOLE

AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar NEWA
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May NEWA

INJECTABLE; IV (INFUSION)
VORICONAZOLE

AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar NEWA
----	-------------	------------	---------	-----	--------------	----------

TABLET; ORAL

VORICONAZOLE

AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May NEWA
AB		200MG	A206181	002	May 24, 2016	May NEWA
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May NEWA
AB		200MG	A206762	002	May 24, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan NEWA
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May NEWA
AB		200MG	A207371	002	May 24, 2016	May NEWA
>A> AB	PRINSTON INC	50MG	A206654	001	Aug 08, 2016	Jul NEWA
>A> AB		200MG	A206654	002	Aug 08, 2016	Jul NEWA
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May NEWA
AB		200MG	A206747	002	May 24, 2016	May NEWA

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

TAKEDA PHARMS USA

EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun CTNA
EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun CTNA
EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun CTNA
+	N204447	004	Sep 30, 2013	Jun CTNA

XENON XE-133

GAS; INHALATION

XENON XE 133

LANTHEUS MEDCL

MALLINKRODT NUCLEAR

20mCi/VIAL	N017284	002		Feb CTEC
10mCi/VIAL	N018327	001	Mar 09, 1982	Feb CMFD
20mCi/VIAL	N018327	002	Mar 09, 1982	Feb CMFD

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	2.5MG	A204041	001	May 20, 2016	May NEWA
AB		5MG	A204041	002	May 20, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr NEWA
AB		5MG	A207021	002	May 11, 2016	Apr NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ SUN PHARM INDS

@

5MG	A077288	001	Apr 23, 2007	Mar CAHN
10MG	A077288	002	Apr 23, 2007	Mar CAHN

TABLET; SUBLINGUAL

EDLUAR

>D>	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009	Jul CFTG
>A> AB		5MG	N021997	001	Mar 13, 2009	Jul CFTG
>D>	+	10MG	N021997	002	Mar 13, 2009	Jul CFTG
>A> AB	+	10MG	N021997	002	Mar 13, 2009	Jul CFTG

ZOLPIDEM TARTRATE

>A> AB	MYLAN PHARMS INC	5MG	A202657	001	Aug 08, 2016	Jul NEWA
>A> AB		10MG	A202657	002	Aug 08, 2016	Jul NEWA
>A> AB	PAR FORM	5MG	A201509	001	Aug 01, 2016	Jul NEWA
>A> AB		10MG	A201509	002	Aug 01, 2016	Jul NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb CAHN
	ZONISAMIDE					
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN
	@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar CAHN
	@	50MG	A077635	002	Dec 22, 2005	Mar CAHN
	@	100MG	A077635	003	Dec 22, 2005	Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

+	GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998	Feb CAHN
---	----------------------	------------------	---------	-----	--------------	----------

BUDESONIDE

SPRAY, METERED;NASAL

BUDESONIDE

	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015	Apr NEWA
--	------------	---------------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009	Jan CAHN
--	----------------	-----	---------	-----	--------------	----------

+		10MG	N022429	004	Jul 23, 2009	Jan CAHN
---	--	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009	Jan CAHN
--	----------------	-----	---------	-----	--------------	----------

+		10MG	N022429	002	Jul 23, 2009	Jan CAHN
---	--	------	---------	-----	--------------	----------

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Apr DISC
---	---------------	---------	---------	-----	--------------	----------

	NOSTRUM LABS INC	5MG/5ML	A091327	001	Oct 17, 2011	Mar CAHN
--	------------------	---------	---------	-----	--------------	----------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Apr DISC
---	---------------	---------	---------	-----	--------------	----------

	NOSTRUM LABS INC	5MG/5ML	A091327	002	Oct 17, 2011	Mar CAHN
--	------------------	---------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016	Feb NEWA
--	----------------	-----	---------	-----	--------------	----------

		10MG	A206793	002	Mar 08, 2016	Feb NEWA
--	--	------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE

SPONGE;TOPICAL

CHLORHEXIDINE GLUCONATE

+	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989	Jun CRLD
---	------------------	----	---------	-----	--------------	----------

PHARMASEAL SCRUB CARE

@	CAREFUSION	4%	N019793	001	Dec 02, 1988	Jun DISC
---	------------	----	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000	May CAHN
---	---------------------	--------------	---------	-----	--------------	----------

+		2%;70% (10.5ML)	N020832	004	Aug 20, 2003	May CAHN
---	--	-----------------	---------	-----	--------------	----------

+		2%;70% (26ML)	N020832	006	Nov 21, 2006	May CAHN
---	--	---------------	---------	-----	--------------	----------

CHLORAPREP ONE-STEP FREPP

+	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002	May CAHN
---	---------------------	----------------	---------	-----	--------------	----------

CHLORAPREP WITH TINT

+	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005	May CAHN
---	---------------------	---------------	---------	-----	--------------	----------

+		2%;70% (10.5ML)	N020832	005	Apr 03, 2006	May CAHN
---	--	-----------------	---------	-----	--------------	----------

+		2%;70% (3ML)	N020832	007	Oct 10, 2006	May CAHN
---	--	--------------	---------	-----	--------------	----------

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	May CAHN
---	---------------------	-----------------	---------	-----	--------------	----------

CHLORAPREP SINGLE SWABSTICK

+	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005	May CAHN
---	---------------------	-----------------	---------	-----	--------------	----------

CHLORAPREP TRIPLE SWABSTICK

+	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	May CAHN
---	---------------------	-----------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988	Feb CAHN
---	---------------------	------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND	A090397	001	Nov 22, 2010	Jan CAHN
--	----------------	-----------------------------	---------	-----	--------------	----------

POTASSIUM SALT

FAMOTIDINE

TABLET;ORAL
FAMOTIDINE

AUROBINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016	Apr NEWA
	20MG	A206531	002	Apr 26, 2016	Apr NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
FLUTICASONE PROPIONATE

>A>	APOTEX INC	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Jul CAHN
>D>	APOTEX TECHNOLOGIES	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Jul CAHN
		0.05MG/SPRAY	A208150	001	Feb 29, 2016	Feb NEWA
	ROXANE	0.05MG/SPRAY	A207957	001	May 26, 2016	May NEWA

IBUPROFEN

CAPSULE;ORAL
IBUPROFEN

BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
PURACAP PHARM LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016	Jun NEWA

MIDOL LIQUID GELS

+ BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002	Jan CAHN
------------------	-------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011	May CAHN
	200MG	A091355	001	Apr 04, 2011	May CAHN
@ SUN PHARM INDS	200MG	A070493	001	Dec 24, 1985	Mar CAHN
@	200MG	A070908	001	Sep 26, 1986	Mar CAHN
@	200MG	A071462	001	Oct 02, 1986	Mar CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016	May NEWA
------------------	------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016	Jun NEWA
---------------	------	---------	-----	--------------	----------

LEVONORGESTREL

TABLET;ORAL
HER STYLE

NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016	Feb NEWA
-----------------	-------	---------	-----	--------------	----------

LEVONORGESTREL

GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016	Mar NEWA
---------------------	-------	---------	-----	--------------	----------

+ PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Apr CRLD
-------------------	--------	---------	-----	--------------	----------

@ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009	Apr DISC
---------------	--------	---------	-----	--------------	----------

PLAN B

@ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	Apr DISC
----------------------	--------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005	Jan CAHN
----------------	-----	---------	-----	--------------	----------

+	2MG	N021855	002	Aug 04, 2005	Jan CAHN
---	-----	---------	-----	--------------	----------

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996	Mar CMS1
--------------------	----------	---------	-----	--------------	----------

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar CAHN
------------------	---------------	---------	-----	--------------	----------

TABLET;ORAL

NAPROXEN SODIUM

AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016	Mar NEWA
----------------------	---------------	---------	-----	--------------	----------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 2MG BASE
EQ 4MG BASE

A204794 001 May 10, 2016 Apr NEWA
A204833 001 Feb 26, 2016 Feb NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>A>
>A> ACTAVIS ELIZABETH 20MG;1.1GM
>A> PAR PHARM 20MG;1.1GM
>A> PERRIGO R AND D 20MG;1.1GM

A204137 001 Jul 15, 2016 Jul NEWA
A201946 001 Jul 15, 2016 Jul NEWA
A201361 001 Jul 15, 2016 Jul NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA EQ 75MG BASE

A201745 001 Feb 29, 2012 May CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2016

NO JULY 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP		PED	Jan 11, 2017
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	>A> 9399012	Sep 11, 2031	U-1882			
	>A> 9399012*PED	Mar 11, 2032				
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 001					>A> RTO	Jul 08, 2019
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
	>A> 9381179	Mar 12, 2023	U-1078			
	>A> 9387187	Mar 12, 2023	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	001				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	002				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	001				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	002				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	003				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	004				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	005				M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	006				M-177	Apr 05, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081	001				NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	001	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	002	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	003	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	004	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	005	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	006	8709491	Jun 28, 2032	DP		
		8840924	Jun 05, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	>A> 9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	>A> 9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	>A> 9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	>A> 9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005	>A> 9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
>A>	9387182	Dec 25, 2023	U-1529			
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001						

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156 004					>A> PC	Nov 28, 2016
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
	9351984	Dec 19, 2021	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023	U-644			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	>A> 7736665	Apr 25, 2024	U-1878		NP	May 26, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	>A> 8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					I-735	May 20, 2019
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	8129346	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	>A> 9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	>A> 9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	>A> 9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	>A> 9402805	Sep 13, 2022	DP U-1578			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	>A> 9402805	Sep 13, 2022	DP U-1578			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	9375410	Nov 14, 2023	U-1088			
	>A> 9399025	Nov 14, 2023	DP U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	>A> 9375410	Nov 14, 2023	U-1088			
	>A> 9399025	Nov 14, 2023	DP U-979			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161	Feb 05, 2019
					D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002					D-161	Feb 05, 2019
					D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002 >A>	9138456	Nov 23, 2030	DP			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001					>A> NCE	Dec 19, 2019
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805		>A> NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		>A> NPP	Jul 08, 2019
					>A> NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805		>A> NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		>A> NPP	Jul 08, 2019
					>A> NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001 >A>	6328994	May 17, 2019	DP			
	>A> 6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003					PC	Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431	005				PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	007	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP U-918		
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	008	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP U-918		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	9302009	Oct 24, 2030	DP		
<u>ELBASVIR; GRAZOPREVR - ZEPATIER</u>						
N 208261	001	7973040	Jul 24, 2029	DS DP U-1813	NCE	Jan 28, 2021
		8871759	May 04, 2031	DS DP U-1813		
<u>ELUXADOLINE - VIBERZI</u>						
N 206940	001	9364489	Jul 07, 2028	U-1709		
<u>ELUXADOLINE - VIBERZI</u>						
N 206940	002	9364489	Jul 07, 2028	U-1709		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629	001	>A> 8551957	Oct 14, 2029	DP U-1651	M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629	002	>A> 8551957	Oct 14, 2029	DP U-1651	M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	001	7407955	May 02, 2025	DS DP		
		>A> 8551957	Oct 14, 2029	DP U-1651		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073	002	7407955	May 02, 2025	DS DP		
		>A> 8551957	Oct 14, 2029	DP U-1651		
		8673927	May 04, 2027	DP U-1652		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	001				>A> M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	002				>A> M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	003				>A> M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111	004				>A> M-174	Mar 18, 2019
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351	001	5814639	Sep 29, 2015	DS DP	NCE	Nov 05, 2020
		5814639*PED	Mar 29, 2016			
		5914331	Jul 02, 2017	DS		
		5914331*PED	Jan 02, 2018			
		6642245	Nov 04, 2020	U-257		
		6642245*PED	May 04, 2021			
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Aug 09, 2022	DS DP		U-257	
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022			U-257	
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP		U-257	
	9296769	Aug 15, 2032	DS DP		U-257	
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020			U-257	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022			U-257	
	8754065	Aug 15, 2032	DS DP		U-257	
	9296769	Aug 15, 2032	DS DP		U-257	
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017			U-248	
	6043230	Jul 25, 2017			U-541	
	6043230	Jul 25, 2017			U-1170	
	6043230	Jul 25, 2017			U-1259	
	6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS		U-248	
	5922695	Jul 25, 2017	DS		U-541	
	5922695	Jul 25, 2017	DS		U-1170	
	5922695	Jul 25, 2017	DS		U-1259	
	5935946	Jul 25, 2017	DS DP		U-248	
	5935946	Jul 25, 2017	DS DP		U-541	
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946	Jul 25, 2017	DS DP		U-1259	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-248	
	5977089	Jul 25, 2017	DS DP		U-541	
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089	Jul 25, 2017	DS DP		U-1259	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017			U-248	
	6043230	Jul 25, 2017			U-541	
	6043230	Jul 25, 2017			U-1170	
	6043230	Jul 25, 2017			U-1259	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-248	
	6642245	Nov 04, 2020			U-541	
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-1259	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS		U-248	
	5922695	Jul 25, 2017	DS		U-541	
	5922695	Jul 25, 2017	DS		U-1170	
	5922695	Jul 25, 2017	DS		U-1259	
	5935946	Jul 25, 2017	DS DP		U-248	
	5935946	Jul 25, 2017	DS DP		U-541	
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946	Jul 25, 2017	DS DP		U-1259	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-248	
	5977089	Jul 25, 2017	DS DP		U-541	
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089	Jul 25, 2017	DS DP		U-1259	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017			U-248	
	6043230	Jul 25, 2017			U-541	
	6043230	Jul 25, 2017			U-1170	
	6043230	Jul 25, 2017			U-1259	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-248	
	6642245	Nov 04, 2020			U-541	
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-1259	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS		U-248	
	5922695	Jul 25, 2017	DS		U-541	
	5922695	Jul 25, 2017	DS		U-1170	
	5922695	Jul 25, 2017	DS		U-1259	
	5935946	Jul 25, 2017	DS DP		U-248	
	5935946	Jul 25, 2017	DS DP		U-541	
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946	Jul 25, 2017	DS DP		U-1259	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-248	
	5977089	Jul 25, 2017	DS DP		U-541	
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089	Jul 25, 2017	DS DP		U-1259	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017			U-248	
	6043230	Jul 25, 2017			U-541	
	6043230	Jul 25, 2017			U-1170	
	6043230	Jul 25, 2017			U-1259	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-248	
	6642245	Nov 04, 2020			U-541	
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-1259	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
				>A>	M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
				>A>	M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
				>A>	M-181	Jun 01, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021	DP			
	6528540*PED	Jul 12, 2021				
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6310094*PED	Jul 12, 2021				
	6528540	Jan 12, 2021	DP			
	6528540*PED	Jul 12, 2021				
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	>A> 6369085	May 25, 2018	DS DP U-1509			
	>A> 6369085	May 25, 2018	DS DP U-1875			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1509			
	>A> 6428810	Nov 03, 2019	DP U-1874			
	>A> 6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031		U-1781		
	9345695	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9345695	May 31, 2022	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP	Y		
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP	Y		
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001 >A>	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001 >A>	9387191	Jul 21, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2016	DS		NCE	May 27, 2021
>A>	9387266	Nov 28, 2026	U-1879			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003 >A>	9402874	Aug 19, 2030	U-441			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP			
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165 I-729 I-736 I-737 ODE ODE	May 06, 2019 Mar 04, 2019 May 06, 2019 May 06, 2019 Mar 04, 2023 May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932 RE43932*PED	Jul 16, 2018 Jan 16, 2019	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	>A> 6958335	Dec 19, 2021	U-791			
	>A> 6958335	Dec 19, 2021	U-1883			
	>A> 6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	>A> 6958335	Dec 19, 2021	U-791			
	>A> 6958335	Dec 19, 2021	U-1883			
	>A> 6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	>A> 9393372	Jul 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
>A>	9393372	Jul 04, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
>A>	9393372	Jul 04, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
>A>	9393372	Jul 04, 2029	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
>A>	9399040	Jul 30, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	9339504	Jul 02, 2028	DP U-1596			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158 D-159 D-160	Feb 12, 2019 Feb 12, 2019 Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	9216179	Aug 02, 2030		U-1806		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP U-1850			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9339489	Mar 14, 2034	DP U-1850			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9339489	Mar 14, 2034	DP U-1850			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	9358338	Apr 27, 2035		U-1870		
	9370622	Sep 28, 2035		U-1870		
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	>A> 7314938	Mar 10, 2025	DS DP		>A> NCE	Jul 11, 2021
	>A> 7745460	Nov 05, 2024	DS DP U-1880			
	>A> 7790743	Nov 05, 2024	U-1880			
	>A> 7928122	Nov 05, 2024	DS DP			
	>A> 8084047	May 17, 2026	DS DP			
	>A> 8168655	May 09, 2029		U-1880		
	>A> 8367701	Apr 15, 2029	DP U-1880			
	>A> 8592450	May 17, 2026	U-1880			
	>A> 8927574	Nov 12, 2030	DP			
	>A> 9085553	Jul 25, 2033	DP			
	>A> 9216174	Nov 05, 2024	DP			
	>A> 9353088	Oct 21, 2030	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	>A> 8475414	Dec 28, 2030	DP U-1881		>A> NCE	Jul 27, 2021
	>A> 8882721	Jun 28, 2031	DP			
	>A> 8915888	Jun 08, 2030	DP U-1881			
	>A> 9072836	Mar 15, 2032	DP			
	>A> 9084853	Oct 05, 2031	DP			
	>A> 9308329	Dec 28, 2030	DP U-1881			
	>A> RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	>A> 8475414	Dec 28, 2030	DP U-1881		>A> NCE	Jul 27, 2021
	>A> 8882721	Jun 28, 2031	DP			
	>A> 8915888	Jun 08, 2030	DP U-1881			
	>A> 9072836	Mar 15, 2032	DP			
	>A> 9084853	Oct 05, 2031	DP			
	>A> 9308329	Dec 28, 2030	DP U-1881			
	>A> RE45313	Jul 12, 2020	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001					>A> NCE	Jun 27, 2017
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9370629	May 20, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	>A> 9382191	Mar 07, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	>A> 9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	>A> 6559158	Nov 03, 2017	U-1185		>A> NP	Jul 19, 2019
	>A> 8420663	Sep 30, 2029	U-1185			
	>A> 8524276	Mar 10, 2031	DP			
	>A> 8956651	Mar 10, 2031	DP			
	>A> 9180125	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	>A> 7438930	Dec 16, 2019	DP		Y	
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	>A> 7438930	Dec 16, 2019	DP		Y	
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	>A> 7438930	Dec 16, 2019	DP		Y	
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	>A> 7438930	Dec 16, 2019	DP		Y	
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	>A> 7438930	Dec 16, 2019	DP		Y	
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	>A> 7438930	Dec 16, 2019	DP		Y	
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	>A> 7438930	Dec 16, 2019	DP		Y	
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	9271975	Sep 09, 2031	U-528			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	9364564	Dec 26, 2027	DP			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	>A> 9301932	Feb 28, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-588	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	>A> 7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	>A> 7771707	Mar 24, 2025	DP			
	>A> 8449909	Mar 24, 2025	DP			
	>A> 8557291	Mar 21, 2025	DP			
	>A> 8758813	Jun 10, 2025	U-1556			
	>A> 8840928	Jul 07, 2023	DP U-1556			
	>A> 9044398	Jul 07, 2023	DP			
	>A> 9248195	Jul 07, 2023	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	>A> 6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	>A> 8580282	Apr 02, 2030	DP U-1876			
	>A> 9308191	Apr 02, 2030	DP U-1876			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	>A> 8658205	Jun 18, 2019	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9296694	Mar 06, 2021	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206	006				PC	Jan 01, 2017
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	001	5288726	Apr 14, 2017	DS DP U-991	>A> M-182	Jul 12, 2019
		5288726*PED	Oct 14, 2017		>A> PED	Jan 12, 2020
		8404703	Jan 02, 2023	U-1381		
		8404703*PED	Jul 02, 2023			
		8569325	Jan 02, 2023	U-1381		
		8569325*PED	Jul 02, 2023			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	002	5288726	Apr 14, 2017	DS DP U-991	>A> M-182	Jul 12, 2019
		5288726*PED	Oct 14, 2017		>A> PED	Jan 12, 2020
		8404703	Jan 02, 2023	U-1381		
		8404703*PED	Jul 02, 2023			
		8569325	Jan 02, 2023	U-1381		
		8569325*PED	Jul 02, 2023			
<u>PROPOFOL - PROPOFOL</u>						
A 205307	001				PC	Feb 24, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001	9289446	Jun 22, 2019	DP U-116		
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324	001				NP	Apr 15, 2019
					ODE	Apr 15, 2023
					>A> ODE	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324	002				NP	Apr 15, 2019
					ODE	Apr 15, 2023
					>A> ODE	Jul 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001	9271968	Feb 27, 2026	DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	9271968	Feb 27, 2026	DP		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	001	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	002	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	7157456	Aug 28, 2024	DS DP U-1301		
		7157456	Aug 28, 2024	DS DP U-1302		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	006	7828787	Oct 18, 2025	DP		
		7857802	Nov 28, 2026	DP		
		8118802	May 18, 2023	DP		
		8162915	May 23, 2024	DP		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	007	7828787	Oct 18, 2025	DP		
		7857802	Nov 28, 2026	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					>A> PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					>A> PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					>A> PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					>A> PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	>A> 7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8575135	Nov 16, 2032	DS DP U-1470			
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8921341	Nov 16, 2032	DS DP U-1470			
	>A> 8940718	Nov 16, 2032	DS DP U-1470			
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	>A> 6525060	Dec 02, 2019	DS DP U-1171			
	>A> 6525060	Dec 02, 2019	DS DP U-1860			
	>A> 6525060	Dec 02, 2019	DS DP U-1862			
	>A> 6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	6956041	Dec 08, 2020	DP			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
>A>	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
>A>	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
>A>	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
>A>	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	RE42353	Jun 27, 2022	DS DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>